タイトル:

出版社:

ISBN:

著者:

キーワード:

カテゴリー:

発行年:

～

検索条件をクリア

書籍詳細

未契約

書籍名	血液凝固 ―止血と血栓・上
出版社	宇宙堂八木書店
発行日	1982-05-10
著者	福武勝博(編集) 山中學(編集)
ISBN
ページ数	313
版刷巻号	第1版
分野	臨床医学：内科血液
閲覧制限	未契約

本書は現代凝血学の総輯的なものとしてその出版はまさに時宜をえたものであろう。上巻は総論的な内容を主として取り上げ、下巻は臨床の実際に直結する内容である。(序より)

目次

表紙
閲覧
分担執筆者
閲覧
序
閲覧
目次
P.1閲覧
1. 血液凝固学説とその歩み
P.1閲覧
- I. 凝血学の始め
- II. 近代学説への展開
- III. 線溶現象
2. 血栓
P.45閲覧
- I. 血栓の発生機序
- II. 血栓症の病理
3. 血液凝固因子
P.105閲覧
- I. 凝固促進因子
- II. 凝固抑制因子
4. 線維素溶解現象
P.161閲覧
- A. 序論
- B. 線溶現象に関係する諸因子
- C. 線溶系と凝固系・キニン系
- D. 線溶現象以外の現象でプラスミンが関係しているとみなされる現象
5. 血小板
P.201閲覧
- I. 血小板の生成, 代謝と機能
- II. 血小板の形態と機能
6. 毛細血管
P.255閲覧
- I. 毛細血管の構造
- II. 血管透過性
索引
P.291閲覧
奥付
閲覧

参考文献

1. 血液凝固学説とその歩み

P.28 掲載の参考文献

1) 安部英, 他:ゲル侶過法によるFgDPとFDPの鑑別. 医用酵素, 1:679, 1976.

2) Addison, W.:London Med. Gaz. [N. S.], 30:144, 1842.

3) Addis, T.:The pathogenesis of hereditary hemophilia. J. Pathol. Bact., 15:427, 1911.

4) Albrechtsen, O. K.:The fibrinolytic activity of human tissues. Brit. J. Haemat., 3:284, 1957.
pubmed

5) Aldrich, R. A., Steinberg, A. G. and Campbell, D. C.:Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea. Pediatrics, 13:133, 1954.
pubmed

6) Alexander, B. and Goldstein, R.:Dual hemostatic defect pseudohemophilia. J. Clin. Invest., 32:551, 1953.

7) Alkjaersig, N., Fletcher, A. P. and Sherry, S.:E-Aminocaproic acid. an inhibitor of plasminogen activation. J. Biol, Chem., 234:832, 1959.

8) Almquist, H. J. and Klose, A. A,:Synthetic and natural antihemorrhagic compounds. J. Am. Chem. Soc., 61:2557, 1939.

9) Ambrus, C. M. and Markus, G.:Plasmin-antiplasmin complex as a reservoir of fibrinolytic enzyme. Am. J. Physiol., 199:491, 1960.
pubmed

10) Andersen, B. R. and Terry, W. D.:Gamma G4-globulin antibody causing inhibition of clotting factor VIII. Nature (London), 213:174, 1968.

11) Apitz, K.:Uber Profibrin. I. Die Entstehung und Bedeutung des Profibrins in Gerinnungs-verlauf. Z. Ges. Exp. Med., 101:552, 1937.

12) Aronson, J.:Handbook of Hemophilia Part I by Brinkhous & Hemker, Amsterdam:Excerpta Medica, 1975. p. 243.

13) Arthus, N. M. and Pages, C.:Nouvelle theorie chimique de la coagulation du sang. Arch. de Physiol. Norm. Pathol., 2:739, 1890.

14) Astrup, T. and Darling, S.:Antithrombin and heparin. Acta Physiol. Scand., 5:13, 1943.

15) Astrup, T. and Stage, A.:Isolation of a soluble fibrinolytic activator from animal tissue. Nature, London, 170:929, 1952.
pubmed

16) Austin, J. H. and Pepper, D. H. P,:Experimental observations on the coagulation of oxalated plasma with the study of some cases of purpura. Arch. Intern. Med., 11:305, 1913.

17) Bachmann, F., Duckert, F. and Koller, F.:The Stuart-Prower factor assay and its clinical significance. Thromb. Diath. Haemorrh., 2:24, 1958.
pubmed

18) Bailey, K. and Sanger, F.:The chemistry of amino acid and proteins. Ann. Rev. Biochem., 20:118, 1951.

19) Baldini, M. G.:Nature of the platelet defect in the Wiskott-Aldrich syndrome. Ann. N. Y. Acad. Sci., 201:437, 1972.
pubmed

20) Bang, N. U. and Chang, M. L.:Soluble fibrin complexes. Seminars Thromb. Hemost., 1:91, 1974.

21) Barber, A. J. and Jamieson, G. A.:Platelet collagen adhesion characterization of collagen glucosyltransferase of plasma membranes of human blood platelets. Biochim. Biophys. Acta, 252:533, 1971.
pubmed

22) Bennett, E.:Abnormality of separate subunits of factor VIII. Lancet, i:885, 1973.
pubmed

23) Bernard, J. and Soulier, J. P.:Sur une nouvelle variete de dystrophie thrombocytaire hemorragipare congenitale. Sem. Hop. Paris, 24:3217, 1948.

24) Bernik, M. B. and Kwaan, H. C.:Origin of fibrinolytic activity in cultures of the human kidney. J. Lab. & Clin. Med., 70:650, 1967.

25) Bessis, M:Technique permettant la compression des petites cellules pour lexamen en contraste de phase. C. R. Soc. Biol, 142:1498, 1948. (Blood, 5:1803, 1950.)

26) Bettex-Galland, M. and Luscher, E. F.:Thrombasthenin-a contractile protein from thrombocytes. Extraction from human blood platelets and some of its properties. Biochim. Biophys. Acta, 49:539, 1961.

27) Bidwell, E., Denson, K. W. E., Dike, G. W. R., Augustin, R. and Lloyd, G. M.:Antibody nature of the inhibitor to antihaemophilic globulin (factor VIII). Nature (London), 210:746, 1966.

28) Bidwell, E.:Acquired inhibitors of coagulants. Ann. Rev. Med., 20:63, 1969.
pubmed

29) Biggs, R., Douglas, A. S., Macfarlane, R., Dacie, J. V., Pitney, W. and Merskey, C.:Christmas disease; condition previously mistaken. Br. Med. J., 11:1378, 1952.

30) Biggs, R. and Douglas, A. S.:The thromboplastin generation test. J. Clin. Pathol., 6:23, 1953.

31) Biggs, R. and Denson, K. W. E,:The mode of action of a coagulation inhibitor in the blood of two patients with disseminated lupus erythematosus (DLE). Brit. J. Haemat., 10:198, 1964.

32) Biggs, R., Denson, K. W. E., Akman, N., Borrett, R. and Hadden, M. E.:Antithrombin III, antifactor Xa and heparin. Brit. J. Haemat., 19:283, 1970.

33) Binkley, S. B., Cheney, L C., Holcomb, W. F., McKee, R. W., Thayer, S. A., MacCorquodale, D. W. and Doisy, E. A.:Constitution and synthesis of vitamin K1. J. Am. Chem. Soc., 61:2558, 1939.

34) Binkley, S. B., McKee, R. W., Thayer, S. A. and Doisy, E. A.:The constitution of vitamin K2. J. Biol. Chem., 133:721, 1940.

35) Bizzozero, J.:Uber einen neuen Formbestandteil des Blutes und dessen Rolle bei der Thrombose und der Blutgerinnung. Virchows Arch. Pathol. Anat. Physiol., 90:261, 1882.

36) Blomback, B. and Blomback, M.:Purification of human and bovine fibrinogen. Arkiv. fur Kemi., 10:415, 1956.

37) Blomback, B.:Studies on action of thrombic enzymes on bovine fibrinogen as measured by N-terminal analysis. Arkiv. fur Kemi., 12:321, 1958.

38) Bohn, H. and Schwick, H. G.:Isolierung und Charakterisierung eines fibrinstabilisierenden Faktors aus menschlichen Placenten. Arzneimittel-Forsch., 21:10, 1970.

39) Borelli, G.:De Motu Animatium. Prop CX) XII p. Op Posth. pars alt. Rome, 1681.

40) Born, G. V. R.:The break-down of adenosine triphosphate in the blood platelets during clotting. J. Physiol (London), 133:619, 1956.

41) Bounameaux, S.:Thrombin et agglutination plaquettaire. Arch. Int. Physiol., 63:243, 1955.

42) Bowie, E. J. W. and Owen, C. A.:Thrombopathy. Seminars Hemat., 5:73, 1968.

43) Braunsteiner, H. and Pakesch, F.:Thrombocytoasthenia and thrombocytopathia. Old names and new diseases. Blood, 11:965, 1956.
pubmed

44) Breckenridge, R. T. and Ratnoff, O. D.:The site of action of a circulating anticoagulant in disseminated lupus erythematosus. Am. J. Med., 35:813, 1963.
pubmed

45) Brinkhous, K. M., Smith, H. P., Warner, E. D. and Seegers, W. H.:The inhibition of blood clotting:An unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin to thrombin. Am. J. Physiol., 125:683, 1939.

46) Brown, P. E., Hougie, C. and Roberts, H. R.:The genetic heterogeneity of hemophilia B. New Engl. J. Med., 283:61, 1970.

47) Budtz-Olsen, O. E.:Clot Retraction. Springfield:Thomas, 1951.

48) Butler, W. T. and Cunningham, L. W.:Evidence for the linkage of a disaccharide to hydroxylysine in tropocollagen. J. Biol. Chem., 241:3882, 1966.
pubmed

49) Call, K. E., Mull, M. M. and Hathaway, W. E.:Platelet function in classic (AHF-deficiency) hemophilia; Report of a case with defective platelet function. Blood, 33:26, 1969.
pubmed

50) Campbell, H. A. and Link, P. K,:Studies on the hemorrhagic sweet clover disease. J. Biol Chem., 138:21, 1941.

51) Castaldi, P. A. and Penny, R.:A macroglobulin with inhibitory activity against coagulation factor VIII. Blood, 35:370, 1970.

52) Cattan, A. D. and Denson, K. W. E.:The interaction of contact factor and factor IX. Thromb. Diath, Haemorrh., 11:155, 1964.

53) Chao, F. C., Tullis, J. L, Kenney, D. M., Shepro, D. and Belamarich, F. A.:In Clot by Tullis, J. L., Springfield:Charles C. Thomas Pub., 1976. p. 58.

54) Chargaff, E., Bancroft, F. W. and Stanley-Brown, M.:Studies on chemistry of blood coagulation; Chemical constituents of blood platelets and their role in blood clotting, with remarks on activation of clotting by lipids, J. Biol Chem., 116:237, 1936.

55) Christensen, L. R.:Streptococcal fibrinolysis; aproteolytic reaction due to a serum enzyme activated by streptococcal fibrinolysis. J. General Physiol, 28:363, 1945.

56) Christensen, L. R. and MacLeod, C. M.:A proteolytic enzyme of serum:characterization, activation and reaction with inhibitors. J. General Physiol., 28:559, 1945.

57) Cochrane, C. G., Revak, S. P. and Wuepper, K. D.:Activation of hageman factor in solid and fluid phases. J. Exp. Med., 138:1564, 1973.

58) Collingswood, B. J. and MacMahon, M. T.:The anticoagulants in blood and serum. J. Physiol., 45:119, 1912.

59) Colman, R. W.:Activation of plasminogen by human kallikrein. Biochem. Biophys. Res. Communications, 35:273, 1969.

60) Colman, R. W., Bagdasarian, A. and Talalno, R. C., et al:Proceedings of the International Conference on Chemistry and Biology of the Kallikrein-kinin system in Health and Disease. Washington, D. C., 1974,

61) Dam H and Schenheyder, F.:Deficiency disease in chicks resembling scurvy. Biochem. J., 28:1355, 1934.

62) Danlos, H.:Un cas de cutis laxa avec tumeurs par contusicn chronique des coudes et des genoux. Bull Soc. France de Dermat. et Syphil, 19:70, 1908.

63) Dastre, A.:Fibrinolyse dans le sang. Arch. de Physiol. Normale et Pathologique, 5:661, 1893.

64) Davie, E.W.and Ratnoff, O. D.:Waterfall sequence for intrinsic blood clotting. Science, 145:1310, 1964.
pubmed

65) Day, H.J. and Molmsen, H.:Platelet adenine nucleotide storage pool deficiency in thrombocytopenic absent radii syndrome. J. A. M. A., 221:1053, 1972.

66) Day, W. C.:The dissociation of bovine factor V and isolation of the activated form. Biochim. Biophys. Acta (Amst.), 386:352, 1975.

67) Delezenne, C. and Pokerski, E.:Action du serum sanguin sur la gealtine en presence du chloroform. Comptes rendus des Seaces de (a Societe de biologie et de ses filiales, 55:327, 1903.

68) Denis de Commercy, P. S.:Memoire sur le Sang. J. B. Bailliere et Fils, Paris, 1859.

69) Denis, P.S.:Essai sur r'application de la chimie a l'etude physiologique du sang de l:homme et a l'etude physiopathologique, hygienique et Therapeutique des moladies de cette humeur. Bechet Paris, 1838.

70) Denson, K. W. E. and Biggs, R., et al.:Two types of haemophilia (A+and A-):A study of 48 cases. Brit. J. Haemat., 17:163, 1969.

71) Denys, J. and de Marbaix, H.:Les peptonisations provoquees par le chloroform. La Cellule, 5:197, 1889.

72) Deutsch, E. and Elsner, P.:The mechanism of fibrinolysis induced by bacterial pyrogens. Thromb. Diath. Haemorrh., 3:286, 1959.

73) De Vries, A., Alexander, B., Goldstein, R. A.:A factor in serum which accelerates the conversion of prothrombin to thrombin. Blood, 4:247, 1949.

74) Donne, A.:De l:origine des globules du sang, de leur mode de formation et de leur fin. C, R. Acad. Sci. (Paris), 14:366, 1842.

75) Doolittle, R. F., Cassman, K. G., Chen, R., Sharp, J. J. and Wooding, G. L.:Correlation of the mode of fibrin polymerization with the pattern of cross-linking. Ann. N. Y. Acad. Sci., 202:114, 1972.

76) Douglas, A S. and McNicol, G. P.:Anticoagulant therapy. In:Human blood coagulation, haemostasis and thrombosis. Oxford, London:Blackwell Sci. Pub., 1976. p. 557,

77) Dubber, A. H. C., McNicol, G. P., Uttley, D. and Douglas, A. S.:In vitro and in vivo studies with Trasylol, an anticoagulant and a fibrinolytic inhibitor. Brit. J. Haemat., 14:31, 1968.

78) Duckert, F., Jung, E. and Shmerling, D. H.:Ahitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb. Diath. Haemorrh., 5:179, 1960.
pubmed

79) Duckert, F.:Le facteur Xm et la proteine Xm. Nouvelle Revue Francaise d'Hematologie, 10:685, 1970.

80) Eberth, J. C. and Schimmelbusch, C.:Experimentelle Untersuchungen uber-Thrombose. Virchows Arch. Pathol. Anat. Physiol., 103:39, 1886.

81) Eegle, H.:Studies on blood coagulation. II. The formation of thrombin and fibrinogen. J. General Physiology, 18:547, 1935.

82) Ehlers, E.:Cutis laxa, Dermat. Ztschr., 8:173, 1901.

83) Ekren, H.:The prothrombin consumption test [Quick] and its importance in differential diagnosis of hemorrhagic diathesis. New Istanbul Contrib. Clin. Sci., 1:449, 1951.

84) Erdogan, G., Ulutin, S. B. and Ulutin, O. N.:Chromosomal aberrations in a case of May-Hegglin anomaly. Proc. Vth. Cong. Asian-Pacific Soc, Hemat. Istanbul, Turkey, 1969. p. 115.

85) Estes, J. W.:Platelet size and function in the heritable disorders of connective tissue. Ann. Intern. Med., 68:1237, 1968.
pubmed

86) Fearnley, G. R., Revill, R. and Tweed, J. M.:Observations on the inactivation of fibrinolytic activity in shed blood. Clinical Science, 11:309, 1952.
pubmed

87) Fieser, L. F.:Synthesis of 2-methyl-3-phythy-1, 4-naphthoquinone. J. Am. Chem. Soc., 61:2561, 1939.

88) Fonio, A. and Schwender, J.:Die Thromozyten des Menschlichen Blutes. Bern:Huber, 1942.

89) Fourcroy, A.:Systeme des Connaissance Chimiques. Paris, 1801.

90) 藤巻道男, 池松正次郎, 大久保明彦:Paracoagulationと臨床. 内科, 34:34, 1974.

91) 藤巻道男, 池松正次郎, 加藤正俊, 小木曾仁:血液凝固における凝血因子抗原性の変化. 臨床病理, 26:298, 1978.
Medical*Online

92) 福武勝博, 小木曾仁, 伊藤多紀, 福島康圭, 田中昭夫, 小野里宗之, 矢野容子, 堀田義弘:Adrenochrome Monoguanylhydrazone Methanesulfanateの止血作用, とくに血小板凝集能に対する影響. 循環器科, 2:81, 1977.

93) 福武勝博, 竹内泉:血小板機能異常症について. 東京医科大学雑誌, 32:825, 1977.

94) Frank, E.:Die essentielle Thrombopenie I und II. Klin. Wschr., 52:454, 1915.

95) Glanzmann, E.:Hereditare hamorrhagische Thrombasthenia. Jahrb. Kindh., 1:88, 1918.

96) Glueck, H. I. and Hong, R.:A circulating anticoagulant in γA-multiple myeloma:its modification by penicillin, J. Clin. Invest., 44:1866, 1965.

97) Graham, J. B., McLester, W. D., Roberts, H. R. and Barrow, E. M.:In the Hemophilia, Ed. Brinkhous, K. M., Univ. North Calo. Press, 1964. p. 263.

98) Gray, G. R., Teasdale, J. M. and Thomas, J. W.:Hemophilia BM. Can. Med. Assoc. J., 98:552, 1968.

99) Green, D.:Spontaneous inhibitors of factor VIII. Brit. J. Haemat., 15:57, 1968.

100) Greig, H, B. and Cornelius, E. M.:The proactivator activity of platelets. South African J. Med. Sci., 26:101, 1961.

101) Grette, K.:The mechanism of thrombin catalyzed hemostatic reaction in blood platelets. Acta Physiol. Scand., 56 suppl., 195:9, 1962.

102) Gross, R. and Holemans, R.:Differenzierung des Einflusses der Blutplattchen auf die Fibrinolyse. Klin. Wochscht., 38:999, 1966.

103) Grottum, K. A., Hovig, T., Holmsen, H., Abrahamsen, A. F., Jeremic, M. and Seip, M.:Wiskott-Aldrich syndrome:Qualitative platelet defects and short platelet survival. Brit. J. Haemat., 17:373, 1969.
pubmed

104) Gulliver, G.:Introduction to the life and works of William Hewson. London:The Sydenham Society, 1846. p. 25.

105) Habal, F. M. and Movat, H. Z.:Kininogens of human plasma. Seminars Thromb. Hemost., 3:27, 1976.

106) Hammarstein, O,:weitere Beitrage zur Kenntniss der Fibrjnbildung. Hoppe-seylers zeitschrift fdr physiologische Chemie, 28:98, 1899.

107) Hardisty, R. M.:The reaction of blood coagulation factors with brain extract. Brit. J. Haemat., 1:323, 1955.
pubmed

108) Hardisty, R. M. and Hutton, R. A.:The kaolin clotting time of platelet-rich plasma:A test of platelet factor-3 availability. Brit. J. Haemat., 11:258, 1965.
pubmed

109) Hardisty, R. M. and Mills, D. C. B.:The platelet defect associated with albinism. Ann. N. Y. Acad. Sci., 201:429, 1972.

110) Harvey, W.:De Generatione Animalium. London, 1651. p. 159.

111) Hathaway, W. E., Belhasen, L. P. and Hathaway, H. S.:Evidence for a new plasma thromboplastin factor. 1. Case report, coagulation studies and physicochemical properties. Blood, 26:521, 1965.

112) Hayem, G.:Sur La formation de la fibrine du sang, 6tudice au microscope. C. R. Acad. Sci., 86:58, 1878.

113) Hayem, G.:Recherches sur l:evolution des hematies dans le sang de l'homme et des vertebres. Arch. Physiol. Norm. Pathol. Ser. 2, 5:692, 1878.

114) Hayem, G.:Du caillot non retractille:suppression de la formation du-serum sanguin dans quelques etats pathologiques. C. R. Acad. Sci., 123:894, 1896.

115) Hedin, S. G.:On the presence of a proteolytic enzyme in the normal serum of the ox. J. Physiol., 30:195, 1903.
pubmed

116) Hegglin, R.:Uber eine besondere form gleichzeitiger konstitutioneller Veranderungen der Neutrophilen und thrombozyten (Konstitutionelle polyplule Reifungsstorung). Arch. Klaus. Stift. Vererbungsforsch., 20:1, 1945.

117) Hellem, A. J.:The adhesiveness of human blood platelets in vitro. Scand. J. Clin. Lab. Invest., 12 Suppl.:51, 1960.

118) Hemker, H. C.:The thrombotest dilution curve and its diagnostic significance. In:Human blood coagulation. Leiden Univ. Press, 1969. p. 365.

119) Hemker, H. C,:Interaction of coagulation factors. In Handbook of Hemophilia. ed Brinkhous and Hemker. Amsterdam:Excerpta Medica, 1975. p. 31.

120) Hermansky, F. and Pudlak, P.:Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow:Report of two cases with histochemical studies. Blood, 14:162, 1959.
pubmed

121) Hess, A. F.:The blood and blood vessels in hemophilia and other homorrhagic diseases. Arch. Intern. Med., 17:203, 1916.

122) Hewson, W.:Experimental inquiries into the properties of blood. London, 1771.

123) Holmsen, H., Day, H. J. and Stormorken, H.:The blood platelet release reaction. Scand. J. Haemat., suppl. 8:3, 1969.

124) Holmsen, H., Day, H. J. and Storm, E.:Adenine nucleotide metabolism of blood platelets. VI. Biochkm. Biophys. Acta, 186:254, 1969.
pubmed

125) Holmsen, H. and Weiss, H. J.:Hereditary defect in the platelet release reaction caused by adeficiency in the storage pool of platelet adenine nucleotides. Brit. J. Haemat., 19:643, 1970.

126) Hopff, F.:Ober die Haemophilie oder die erbiche Anlage zu todlichen Blutungen. Inaugural Abhandlung. ed. Becker, C. W., Wtirzburg, 1828.

127) Horowitz, H. I. and Fujimoto, M. M.:Acquired haemophilia due to a circulating anticoagulant. Am. J. Med., 33:507, 1962. .

128) Hougie, C.:Effect of Russel:s viper venom (Stypven) on Stuart clotting defect. Proc. Soc. Exp. Biol Med., 93:570, 1956.

129) Hougie, C. and Twomey, J. J.:Haemophilia BM:a new type of factor-IX deficiency. Lancet, i:698, 1967.
pubmed

130) Hougie, C., Denson, K. W. E. and Biggs, R.:Astudy on the reaction product of factor VIII and factor IX by gel filtration, Thromb. Diath. Haemarrh., 18:211, 1967,

131) Howard, M. A. and Firkin, B. G.:Ristocetin-a new tool in the investigation of platelet aggregation. Thromb. Diath. Haemorrh., 26:362, 1971.
pubmed

132) Howell, H. H. and Holt, E.:Two new factors in blood coagulation, heparin and proantithrombin. Am. J. Physiol., 47:328, 1918.

133) Hoyer, L W. and Rick, M. E.:Implication of immunologic method for measuring antihemophilic factor (factor VIII). Ann. N. Y. Acad. Sci., 240:97, 1975.
pubmed

134) Hunter, J.:Atreatise on the blood, inflamation and gun-shot wounds. Nicol. London, 1794. P. 87.

135) Hustin, A.:Note sur une nouvelle methode de transfusion. Bull. Soc. Sci. Roy. Med. Nat. Brux., 72:104, 1914.

136) 今岡眞義, 神前五郎, 井下勝男, 小川睦子, 石井啓子:Macroglobulin分画に含まれるactivated factor X inhibitor (M-Xa I) 変動の意義. 医用酵素, 2:53, 1976.

137) Imperato di C. and Dettori, A. G.:Ipofibrinogenemia congenita confibrinoastenia. Helv. Paediat. Acta, 13:380, 1958.

138) Inceman, S., Unugur, A. and Aran, M.:Essential athrombia. Thromb. Diath. Haemorrh. (Stuttg.), 8:502, 1962.

139) Jacques, L B.:Spontaneous hemorrhage with anticoagulants. Circulation, 25:130, 1962.

140) Johnson, S. A., Smathers, W. M. and Schneider, C. L.:Platelets and the plasma cofactor activity in the activation of purified prothrombin. Am. J. Physiol., 170:631, 1952.
pubmed

141) Johnson, S. A. and Schneider, C. L.:The existence of antifibrinolysin activity in platelets. Science, 117:229, 1953,
pubmed

142) Johnson, S. A.:In The Circulating Platelets. ed. Johnson, S. A., New York:Acad. Press, 1971. p. 283.

143) Jurgens, R. and Forsium, H.:Untersuchunger Uber die<konstitutionelle thrombopathie (v. Willebrand JUrgens) >auf den Alandsinseln. Schweiz. Med. Wochenschr., 81:1248, 1951.

144) Karrer, P., Geiger, A., Legler, R., Ruegger, A. and Salomon, H,:Ueber die Isolierung des a-Phyllochinons (Vitamin K aus afalfa) sowie ueber dessen Eutdeckungscpeschichte. Helv. Chim. Acta, 22:1464, 1939.

145) Kisiel, W. and Hanahan, D. J.:The action of factor Xa, thrombin and trypsin on human factor H. Biochim. Biophys. Acta (Amst.), 329:221, 1973.

146) Koller, F ., Krusi, G. a n d Luchsinger, G.:Uber eine besondere Form hamorrhagischer Diathese. Schweiz. Med. Wochenscht., 80:1101, 1950.

147) Korst, D. R. and Kratochvil, C. H.:"Cryofibrinogen" in:acase of lung neoplasm associated with. thrombophlebitis migrans. Blood, 10:945, 1955.

148) Kopec, M., et al.:Studies on the "Double D" fragment from stabilized bovine fibrin. Thromb. Res., 2:283, 1973.

149) Kowalski, E., Kopec, M., Wegrzynowicz, Z.:Influence of fibrinogen degradation products (FDP) on platelet aggregation. Thromb. Diath. Haemorrh., 10:406, 1964.
pubmed

150) Krauss, E.:Uber Purpura. Heidelberg:Inaugural Dissertation, 1883.

151) Kunzer, W. and Haberhausen, A.:Fibrinolytic activity of human erythrocytes. Nature (London), 198:396, 1963.
pubmed

152) Lacombe, Marie-Jose, Varet, B. and Levy, Jean-Paul:A hitherto undescribed plasma factor acting at the contact phase of blood coagulation (Flaujeac factor):case report and coagulation studies. Blood, 46:761, 1975.

153) Laki, K. and Lorand, L,:On the solubility of fibrin clots. Science, 108:280, 1948.
pubmed

154) Legaz, M. F.:Isolation subunit structure and proteolytic modification of bovine factor VIII. Ann. N. Y. Acad. Sci., 240:43, 1975.

155) Leitner, A., Bidwell, E. and Dike, G. W. R.:An antihemophilic globulin (factor VIII) inhibitor:Purification, characterization and reaction kinetics. Brit, J. Haemat., 9:245, 1963.

156) Lewis, J. H., Tagnon, H. J. and Davidson, C. S., et al.:The relation of certain fraction of the plasma globulins to the coagulation defect in hemophilia. Blood, 1:166, 1946.

157) Lewis, J. H. and Ferguson, J. H.:Studies on a proteolytic enzyme system of the blood. Proc. Soc. Exper. Biol & Med., 78:184, 1951.

158) Lewisohn, R.:Anew and greatly simplified method of blood transfusion. A preliminary report. Med. Rec. (N. Y.), 87:141, 1915.

159) Lorand, L,:Fibrin clots. Nature, 167:992, 1951.
pubmed

160) Luscher, E. F.:Retraction Activity of the Platelets:Biochemical background and physiological significance. Blood Platelets, Little Brown, 1960. p. 445.

161) Lutz, B. R., Fulton, G. P. and Akers, R. P.:White thromboembolism in the hamster cheek pouch after trauma, infection and neoplasia. Circulation, 3:339, 1951.
pubmed

162) Lyttleton, J. W.:The antithrombin activity of human plasma. Biochemical J., 58:8, 1954.

163) MacCorquodale, D. W., Thayer, S. A. and Doisy, E. A.:The isolation of vitamins Kl and K2. Am. Chem. Soc., 61:1295, 1939.

164) Macfarlane, R. G.:Fibrinolysis following operation. Lancet, i:10, 1937.

165) Macfarlane, R. G. and Pilling, J.:Fibrinolytic activity of normal urine. Nature (London), 159:779, 1947.
pubmed

166) Macfarlane, R. G., Biggs, R. and Bidwell, E.:Bovine antihemophilic globulin in the treatment of hemophilia. Lancet, ii:985, 1954.

167) Macfarlane, R. G.:The coagulant action of Russelrs viper venom; The use of antlvenom ln defining its reaction with a serum factor. Br. J. Haematol., 7:496, 1961.

168) Macfarlane, R. G.:An enzyme cascade in the blood clotting mechanism, and its function as abiochemical amplifier. Nature, 202:498, 1964.

169) Magnusson, S., Sottrup-Jensen, L, Elleback-Petersen, T. and Claeys, H.:The primary structure of prothrombin, the role of vitamin K in blood coagulation and a thrombin-catalyzed " negative feed-back" control mechanism for limiting the activation of prothrombin. In Proc. Boerhaave Course on Prothrombin. Leiden:Leiden Univ. Press, 1975.

170) Malpighi, M.:De Viscerum Sturctura, accedit Dissertatio de Polyps Cordis. 1666. p. 156.

171) Mammen, E. F.:Congenital abnormalities of the fibrinogen molecule. Seminars Thromb. Hemost., 1:184, 1974.

172) Mann, F. D. and Hurn, M. M.:Intermediate reactions in blood coagulation. Am. J. Physiol., 175:65, 1953.
pubmed

173) Marcus, A. J. and Spaet, T. H.:Platelet phosphatides, their separation, identification and clotting activity. J. Clin. Invest., 37:1836, 1958
pubmed

174) Marder, V. J., et al.:High molecular weight derivertives of human fibrinogen produced by plasmin (m). J. Biol. Chem., 247:4775, 1972.

175) Marquis, N. R. and Becker, J. A.:Platelet aggregation. III. An epinephrine induced decrease in cyclic AMP synthesis. Biochem. Biophys. Res. Commun., 39:783, 1970.

176) Marx, R.:Uber das relative Haufige vorkommen von konstitutioneller Thromopathie von Willebrand-Jurgens in Mtinchen und Umgebung. Verh. Deutsch. Ges. Inn. Med., 60:923, 1954.

177) Maurer, H. M., Wolf, J. A., Buckingham, S. and Spielvogel, A. R.:"lmpotent" platelets in albinos with prolonged bleeding times. Blood, 39:490, 1972.

178) May, R.:Leukocyteneinschlusse. Deutsch. Arch. Klin. Med., 96:1, 1909.

179) McKee, P. A., et al.:Molecular structural studies of human factor VIII. Ann. N. Y. Acad. Sci., 240:8, 1975.
pubmed

180) McKee, R. W., Binkley, S. B., Thayer, S. A., MacCorcodale, D. W. and Doisy, E. A.:Isolation of vitamin K2. J. Biol. Chem., 131:327, 1939.

181) McLean, J.:The thromboplastic action of cephalin. Am. J. Physiol., 41:250, 1916.

182) Mellanby, J.:Thrombase-its preparation and properties. Proc. Royal Society, Series B, Biological Sciences, 113:93, 1933.

183) Mellanby, J.:Heparin and blood coagulation. Proc. Royal Soc. London, B. 116:1, 1935.

184) Milstone, J. H.:A factor in normal human blood which participates in streptococcal fibrinolysis. J. Immunol., 42:109, 1941.

185) Minot, G. R.:Familial hemorrhagic condition associated with prolongation of bleeding time. Am. J. Med. Sci., 175:301, 1928.

186) Mitchell, J. R. A. and Sharp, A. A.:Platelet clumping in vitro. Brit. J. Haemat., 10:78, 1964.

187) Morawitz, P.:Beitrage zur Kenntnis der Blutgerinnung. Beitr. Chem. Physiol. Pathol., 5:133, 1904.

188) Morawitz, P.:Die Chemie der Blutgerinnung. Ergeb. Physiol, 4:307, 1905.

189) Morawitz, P.:Uber einige postmortale Blutverandenungen. Beitrtige Zur Chemischen Physiologie und Pathologie, 8:1, 1906.

190) Moroi, M. and Aoki, N.:Inhibition of plasminogen binding to fibrin by a2-plasmin inhibitor. Thromb. Res., 10:851, 1977.

191) 村上元孝:新らしい線溶測定法-FibrinおよびFibrinogenのBreakdown Productsの免疫学的定量化のこころみ. 日血会誌, 28:341, 1965.

192) Niewiarowski, S. and Kowalski, E,:Formation of an antithrombin-like anticoagulant during proteolysis of fibrinogen. Bull. Acad. Pol. Sci. Classe II, 5:169, 1957.

193) Nilehn, J. E. and Ganrot, P. O.:Plasmin, plasmin inhibitors and degradation products of fibrinogen in human serum during and after intravenous infusion of streptokinase. Scan. J. Clin. & Lab. Invest., 20:113, 1967.

194) Nilson, I. M., Blomback, M. and Von Franken, I.:On an inherited autosomal hemorrhagic diathesis with antihemophilic globulin (AHG) deficiency and prolonged bleeding time. Acta Med. Scand., 159:35, 1957.

195) Nilsson, I.M. and Ockerman, P. A.:The bleeding disorder in hepatomegalic forms of glycogen storage disease. Acta Paediat, Scand., 59:127, 1970.
pubmed

196) Nolf, P.:Contribution a l'etude de la coagulation du sang. V. La fibrinolyse. Arch. Internationales de Physiologie, 6:306, 1908.

197) Norman, P. S. and Hill, B. M.:Studies of the plasmin system. IH. Physical properties of the two plasmin inhibitors in plasma. J. Exp. Med., 108:639, 1958.

198) Nossel, H. L. and Niemetz, J.:A normal inhibitor of the blood coagulation contact reaction product. Blood, 25:712, 1965.
pubmed

199) O'Brien, J. R.:Platelets:A Portsmouth syndrome? Lancet, ii:258, 1967.

200) Ogston, D., Bennett, N. B., Ogston, C. M. and Ratnoff, 0. D.:The assay of a plasma component necessary for the generation of a plasminogen activator in the presence of Hageman factor (Hageman factor co-factor). Brit. J. Haemat., 20:209, 1971.

201) 岡本彰佑, 塚田裕三, 高橋幸一郎:アレルギーの物質的基礎. 生物化学, 2:55, 1950.

202) Okamoto, S. and Okamoto, U.:Amino-methyl-cyclohexane-carboxylic acid, a new potent inhibitor of the fibrinolysis. Keio J. Med., 11:105, 1962.

203) Oncley, J. L., Scatchard, G. and Brown, A.:Physical-chemical characteristics of the proteins of normal human plasma. J. Phys. Colloid Chem., 51:184, 1947.

204) Onel, P., Ulutin, S. B. and Ulutin, O. N.:Platelet defect in a case of Ehlers-Danlos syndrome. Acta Haemat., 50:238, 1973.

205) Otto, J. C.:An account of an haemorrhagic disposition existing in certain families. Med. Repository, 6:1, 1803.

206) Osler, W.:An account of certain organisms occurring in the liquor sanguinis. Proc. Roy. Soc. (London), 22:391, 1874.

207) Owen, C. A., Bowie, E. J. W., Didisheim, P. and Thompson, J. H.:The diagnosis of bleeding disorders. Boston:Little, Brown, 1969. p. 161.

208) Owren, P. A.:Parahemophilia, Hemorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet, i:447, 1947.

209) Owren, P, A. and Bollman:; J. L.:Prothrombin convertion of dicumarol plasma. Proc. Soc. Exp. Biol. Med., 67:231, 1948.

210) Owren, P. A.:Prothrombin and accessory factors. Clinical significance. Am. J. Med., 14:201, 1953.
pubmed

211) Owren, P. A.:Control of anticoagulant therapy. Arch. Intern. Med., 111:248, 1963.
pubmed

212) Patek, A. J. and Taylor, F. H.:Hemophilia. II. Some properties of a substance obtained from normal human plasma effective in accelerating coagulation of hemophilic blood. J. Clin. Invest., 16:113, 1937.

213) Pavlovsky, A.:Contribution to the pathogenesis of hemophilia. Blood, 2:185, 1947.

214) Pizzo, S. V., et al.:The effect of plasmin on the subunit structure of human fibrinogen. J. Biol. Chem., 247:636, 1972.
pubmed

215) Pizzo, S. V., et al.:The effect of plasmin on the subunit structure of human fibrin. J. Biol. Chem., 248:4574, 1973. 1.

216) Plow, E. and Edgington, T. S.:Molecular events responsible for modulation of neoantigenetic expression:The cleavage-associated neoantigen of fibrinogen. Proc. Natl. Acad. Sci. U. S. A., 69:208, 1972.
pubmed

217) Pool, J. G., Hershgold, E. J. and Pappenhagen, A, R.:High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature (London), 203:312, 1964.

218) Prentice, C. R. M.:In:Human blood coagulation, haemostasis and thrombosis. Oxford London:Blackwell Sci. Pub., 1976. p. 571

219) Prydz, H.:Vitamin K-dependent clotting factors. Seminars thromb. Hemost., 4:1, 1977.

220) Quick, A, J., Stanley-Brown, M. and Bancroft, F. W.:Astudy of the coagulation defect in hemophilia and jaundice. Am. J. Med. Sci., 190:501, 1935.

221) Quick, A. J.:Coagulation defect in sweet clover disease and in the hemorrhagic chick disease of dietary origin. Am. J. Physiol., 118:260, 1937.

222) Quick, A, J.:The normal antithrombin of the blood and its relation to heparin. Am. J. Physiol, 123:712, 1938.

223) Quick, A. J.:Congenital hypoprothrombinemia and pseudohypoprothrombinemia. Lancet, ii:379, 1947.

224) Quick, A. J.:Studies on the enigma of the hemostatic dysfunction of hemophilia. Am. J. Med. Sci., 214:272, 1947.
pubmed

225) Rabe, F. and Salomon, E.:Uber Faserstoffmangel im Blut bei einem Falle von Haemophilie. Deutsch. Arch. Klin. Med., 132:240, 1920.

226) Rapaport, S. I., Hjort, P. F. and Patch, M. J.:Further evidence that thrombin-activation of factor VIII is an essential step in intrinsic clotting. Scand. J. Clin. Lab. Invest., 17:Suppl. 84:88, 1965.

227) Ratnoff, O. D. and Colopy, J. E.:A familial hemorrhagic trait associated with a deficiency of aclot-promoting fraction of plasma. J. Clin. Invest., 34:602, 1955.
pubmed

228) Ratnoff, O. D. and Zimmerman, S.:Detection of carriers of classic hemophilia using an immunologic assay for antihemophilic factor. J. Clin. Invest., 50:255, 1971.

229) Ratnoff, O. D. and Saito, H.:Bleeding in von Willebrand:s disease. New Engl. J. Med., 290:1089, 1974.
pubmed

230) Revak, S. D., et al.:Structural changes accompanying enzymatic activation of human Hageman factor. J. Clin, Invest., 54:619, 1974.
pubmed

231) Robbins, K. C.:Astudy on the conversion of fibrinogen to fibrin. Am. J. Physiol., 142:581, 1944.

232) Robbins, K. C., et al.:The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J. Biol Chem., 242:2333, 1967.
pubmed

233) Roberts, H. R., Grizzle, J. E., McLester, W.D., et al.:Genetic variants of hemophilia B:Detection by means of a specific PTC inhibitor. J. Clin. Invest., 47:360, 1968.
pubmed

234) Robertson, O, H.:Transfusion with preserved red blood cells. Brit. Med. J., 1:691, 1918.
pubmed

235) Robinson, D. S. and French, J. E.:The role of albumin in the interaction of chyle and plasma in the rat. Quart. J. Exper. Physiol., 38:233, 1953.

236) Rosenthal, R. L., Dreskin, O. O. and Rosenthal, N.:New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc. Soc. Exp. Biol Med., 82:171, 1953.

237) Sahli, W.:Uber das Vorkommen von Pepsin und Rypsin in normalen menschilen Harn. Pflugers Archiv fur die Gesamte Physiologie des Menschen und der Tiere, 36:209, 1885.

238) Saito, H., Ratnoff, O. D., Waldmann, R, et al.:Impaired Hageman factor (Factor XII)-mediated reactions in Fitzgerald trait. Blood, 44:934, 1974.

239) Salzman, E. W.:Measurement of platelet adhesiveness a simple in vitro technique demonstrating an abnormality in von Willebrand:s disease for hemophilia. J. Lab. Clin. Med., 62:724, 1963.

240) Salzman, E. W., Chambers, D. A. and Neri, L. L:Possible mechanism of aggregation of blood platelets by adenosine diphosphate. Nature, 210:167, 1966.
pubmed

241) Salzman, E. W., Lindon, J., Brier, D. and Merrill, E. W.:Surface-induced platelet adhesion, aggregation and release. Ann. N. Y. Acad. Sci., 283:114, 1977.

242) Schmidt, A.:Uber der Faserstoff gerinnung. Pflugers a Archiv fur die Gesamte Physiologie des Menschen und der Tiere, 6:413, 1872.

243) Schmidt, A.:Zur Blutlehre. Leipzig:Vogel, 1892.

244) Schmidt, A.:Zur BIutlehre. Leipzig, 1893; Weitere Beitrage zur Blutlehre Bergmann, Wiesbaden, 1895.

245) Schreiber, A. D., Kaplan, A. P. and Austen, K. F.:Plasma inhibitors of the components of the fibrinolytic pathway in man. J. Clin. Invest., 52:1394, 1973.

246) Schreiber, A. D.:Plasma inhibitors of the Hageman factor dependent pathways. Seminars Thromb. Hemost., 3:43, 1976.

247) Schultz, M.:Ein Heizzarer Objecttisch und sein Verwendung bei Untersuchungen des Blutes. Arch. Mikrosk. Anat., 1:1, 1865.

248) Schwartz, M. L., Pizzo, S. V., Hill, R. L. and MaKee, P. A.:The subunit structures of human plasma and platelet factor Xm (Fibrin stabilizing factor). J. Biol. Chem., 246:5851, 1971.

249) Seegers, W. H., Brinkhous, K. M., Smith, H. P. and Warner, E. D.:The purification of thrombin. J. Biol. Chem., 126:91, 1938.

250) Seegers, W. H.:Purification of prothrombin and thrombin. J. Biol. Chem., 136:103, 1940.

251) Seegers, W. H., Nieft, M. L. and Loomis, E. C.:Note on the adsorption of thrombin on fibrin. Science, 101:520, 1945.

252) Seegers, W. H.:Prothrombin. Harvard University Press, 1962.

253) Seegers, W. H.:Enzymes in blood clotting. J. Med. Enzymol., 2:328, 1977.

254) Shainoff, J. R. and Page, I. H.:Cofibrins and fibrin intermediates as indicators of thrombin activity in vivo, Circ. Res., 8:1013, 1960.

255) Shepro, D., Belamarich, F. A., Robblee, L. and Chao, F. C.:Antimotility effect of cytochalasin B observed in mammalian clot retraction. J. Cell Biol., 47:544, 1970.
pubmed

256) Sherry, S. and Troll, O.:The action of thrombin on synthetic substrates, J. Biol Chem., 208:95, 1954.

257) Sherry, S., Fletcher, A. P. and Alkjaersig, N.:Fibrinolysis and fibrinolytic activity in man. Physiological Reviews, 39:343, 1959.
pubmed

258) Shinowara, G. Y.:Thromboplastic cell component. The lipoprotein of erythrocytes and platelets. J. Biol. Chem., 225:1, 1957.
pubmed

259) Sobel, G. W., Mohler, S. R., Jones, N. W., Dowdy, A. B. and Guest, M. M.:Urokinase:an activator of plasma profibrinolysin extracted from urine. Am. J. Physiol., 171:768, 1952.

260) Soulier, J. P. and Prou-Wartelle, O.:Nouvelles dounees sur les facteurs Hageman et P. T. A., et sur le:contact. Revue frangaise d:etudes cliniques et biologiques, 4:932, 1959.

261) Soulier, J. P. and Prou-Wartelle, O.:Etude comparative des taux de cofacteur de la staphylocoagulase (C. R. F.) et des taux de facteur H dans diverses conditions. Nouvelle revue frangaise d:hematologie, 6:623, 1966.

262) Spaet, T. H.:Analytical review:Vascular factors in the pathogenesis of hemorrhagic syndromes. Blood, 7:641, 1952.

263) Spaet, T. H. and Cintron, J.:Pathways to blood coagulation product I formation. Blood, 21:745, 1963.
pubmed

264) Spaet, T. H.:The platelet in hemostasis. Ann. N. Y. Acad. Sci., 115:31, 1964.
pubmed

265) Spaet, T. H. and Cintson, J.:Studies on platelet factor-3 availability. Brit. J. Haemat., 11:269, 1965.
pubmed

266) Steichele, D. F. and Herschlein, H. J.:Zur antifibrinolytischen Wirkung der Trypsin-Kallikrein-Inactivators. Medizinische Welt, 42:2170, 1961.

267) Stemerman, M. B., Baumgartner, H. R. and Spaet, T. H.:The subendotherial microfibril and platelet adhesion. Lab. Invest., 24:179, 1971.

268) Straub, W. and Duckert, F.:The formation of the extrinsic prothrombin activator. Thromb. Diath. Haemorrh., 5:402, 1961.

269) Sussman, L. N., Wald, N. and Rosenthal, R.:A haemorrhagic diathesis due to a qualitative platelet defect. Blood, 7:1100, 1952

270) Svendsen, L., Blomback, M. and Olsson P. I.:Synthetic chromogenic substratess for determination of trypsin, thrombin and thrombin-like enzymes. Thrombosis Res., 1:267, 1972.

271) Telfer, T. P., et al:A 'new' coagulation defect. Brit. J. haemat., 2:308, 1956.
pubmed

272) Tillett, W. S, and Garner, R. L.:The fibrinolytic activity of hemolytic streptococci. J. Exp. Med., 58:485, 1933.
pubmed

273) Todd, A. S.:Localisation of fibrinolytic activity in tissue. Brit. Med. Bull., 20:210, 1964.
pubmed

274) Triantaphyllopoulos, D. C. Anticoagulant effect of incubated fibrinogen. Canadian J. Biochem. Physiol., 36:249, 1958.

275) Tullis, J. L.:Clot. Springfield:C. C. Thomas Pub., 1976. p. 25.

276) 浮田実, 三上俊衛, 三上恵子, 北原武, 加藤正俊, 可児卓朗:第XIII因子欠乏症とその周辺. 臨床病理, 24:281, 1976.
Medical*Online

277) Ulutin, O. N. and Karaca, M.:Trombopatilerin TGT ile tetkiki ve bu hususta yeni musahedeler. Turk. Tip. Cem. Mec., 22:473, 1956

278) Ulutin, O. N.:The platelet secretion mechanism in normal and in pathological conditions. J. Med. Enzymol:346, 1977.

279) van Creveld, S. and Paulssen, M. M. P.:Significance of clotting factors and blood platelets in normal and pathologic conditions. Lancet, ii:242, 1951.

280) Veltkamp, J, J., Meilof, J., Remmelts, H. G., et al.:Another genetic variant of haemophilia B:Haemophilia B Leyden. Scand. J. Haemat., 7:82, 1970
pubmed

281) Virchow, chow, R.:Zur pathologischen Physiologie des Blutes. Arch. Pathol. Anat., Physiol. Virchow 1:547, 1847.

282) Virchow, R.:Die Bluterkrankheit (Blutsucht, Haemophilia, Haemorrhaphilia). In Handbuchder speziellen Pathologieund Therapie. 1:263, 1854.

283) von Kaulla, K. N.:Fibrinolysis, past and future. Hemostase, 3:211, 1963.

284) von Mourick, J. A., Bouma, B. N. and Mochtar, I. A.:Biochemistry of factor VIII. Handbook. of Hemophilla ed Brinkhous, H, C., Am. Elsevier Pub., 1975

285) von Willebrand, E. A.:Hereditary pseudohemofilia; description; previously observed cases. Finska Lak-Sallsk Hanal., 68:87, 1925.

286) von Willebrand, E. F. and Jurgens, R.:Uber eine neue Bluterkrankheit, die konstituelle Thrombopathie. Klin. Wschr., 12:444, 1933.

287) Waldman, R. and Abraham, J. P.:Fitzgerald factor:aheretofore unrecognized coagulation factor. Blood, 44:934, 1974.

288) Walsh, P. N.:The effects of collagen and kaolin on the intrinsic coagulant activity of platelets. Evidence for an alternative pathway in intrinsic coagulation not requiring factor XII. Brit. J. Haemat., 22:393, 1972.

289) Ware, A. G. and Seegers, W. H.:Plasma accelerator globulin, partial purification, quantitative determination and properties. J. Biol Chem., 172:609, 1948.

290) Warner, E. D., Brinkhous, K. M. and Smith, H. P.:The titration of prothrombin in certain plasmas. Arch. Pathol., 18:587, 1934.

291) 渡辺清明, 安藤泰彦:免疫グロブリンと凝固. 臨床病理, 25 (補):16, 1977.

292) Weiss, H. J.:Platelet aggregation, adhesion and adenosine diphosphate release in thrombopathia (platelet factor 3 deficiency). Am. J. Med., 43:570, 1967.
pubmed

293) Weiss, H. J. and Aledort, L. M.:Impaired platelet/connective-tissue reaction in man after aspirin ingestion. Lancet, ii:495, 1967.

294) Weiss, H. J., Rogers, J. and Brand, H.:Properties of the platelet retention (von Willebrand) factor and its similarity to the antihemophilic factor AHF. Blood, 41:809, 1973.

295) Werlhoff, P. G,:Opera Medica. ed Wichman, J. A., 1775. p. 748.

296) White, J. G. and Krivit, W.:The ultrastructural localization and release of platelet lipids. Blood, 27:167, 1966.
pubmed

297) White, J. G. and Krivit, W.:Changes in platelet microtubules and granules during early clot development. Thromb. Diath. Haemorrh., 26 (Suppl.):29, 1967.
pubmed

298) White, S. G., Aggeler, P. M., Glendening, M. B., Page, E. W., Leake, T. B. and Bates, G.:Plasma thromboplastin component (PTC) deficiency:Anew disease resembling hemophilia. Proc. Soc. Exp. Biol. Med., 79:692, 1952.

299) Williams, J. R. B.:The fibrinolytic activity of urine, Brit. J. Exp. Pathol., 32:530, 1951.

300) Woods, M. C., Gamble, F. N., Furth, J. and Bigelow, R. R.:Control of the postirradiation hemorrhagic state by platelet transfusions. Blood, 8:545, 1953.
pubmed

301) Wright, A. E.:On a method of determining the condition of blood coagulability for clinical and experimental purperses and on the effect of the administration of calcium salts in haemophilia and actual or treatened haemorrhage. Brit. Med. J., 2:223, 1893.
pubmed

302) Wright, J. H.:Origin and nature of the blood patelets. Boston, Massachusetts, 1906.

303) Wright, J. H.:The histogenesis of the blood platelets. J. Morphol., 21:263, 1910.

304) 矢野容子, 加藤正俊, 山口巌, 藤巻道男, 福武勝博:アプロチニンの接触因子活性化に対する影響. 日血会誌, 40:757, 1977.

305) 安永幸二郎:von Willebrand病と遺伝性血小板異常症, 内科-小児科疾患,の遺伝. 柴田進, 北川, 照男編, 東京:医学書院, 1977. p. 125.

306) Zuker-Frank (in, D., Nachman, R. L. and Marcus, A. J.:Ultrastructure of thrombosthenin, the contractile protein of human blood platelets. Science, 157:945, 1967.

307) Zucker, M. B. and Borrelli, J.:Platelet clumping Proudced by connective tissue suspensions and by collagen. Proc. Soc. Exper. Biol. Med., 109:779, 1962.

308) Zucker, M. B. and Peterson, J.:Inhibition of adenosin diphosphate induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion. Proc. Soc. Exper. Biol. Med., 127:547, 1968.

309) Aoki, N., Moroi M., Sakata, Y., Yoshida, N. and Matsuda, M.:Abnormal plasminogen. J. Clin. Invest., 61:1186, 1978.
pubmed

310) Aoki, N., Moroi, M. and Tachiyo, K.:Effects of a2-plasmin inhibitor on fibrin clot lysls. Its comparison with a2-macroglobulin. Thrombos. Haemosta., 39:22, 1978.

311) Bordet, J. and Gengon, O.:Recherches sur la coagulation du Sang. Ann. de l'Inst. Pasteur. Par., 17:822, 1903.

312) Cliffton, E. E. and Downie, G. R.:Variations in proteolytic activity of serum of animals including man. Proc. Soc. Experi. Biol & Med., 73:559, 1950.

313) Davie, E. W., Fujikawa, K., Kurachi, K. and Kisiel, W.:The role of serine proteases in the blood coagulation cascade. Adv. Enzymol., 48:277, 1979.
pubmed

314) Denson, K. W. E.:Abnormal clotting factors. Human Blood Coagulation, Haemostasis and Thrombosis (Biggs, R., ed.), London:Blackwell Sci., Pub., 1976. p 202.

315) Discipio, R. G., Hermodson, M. A., Yates, S. G. and Davie, E. W.:Acomparision of human prothrombin, factor D ((Christmas factor), factor X (Stuart factor) and protein S. Biochemistry, 10:698, 1977.

316) Fujii, S., et al:Inhibitory effects ofω-guanidino acid esters on trypsin, plasmin, plasma kallikrein and thrombin. Biochim. Biophys. Acta, 268:221, 1972.

317) Fujikawa, K., Kurachi, K., Davie., E. W.:Characterization of bovine factor XIIa (activated Hageman factor). Biochemistry, 16:4182, 1977.
pubmed

318) 福武勝博, 池. 松正次郎, 他:FgDPとFDPの鑑別のための臨床検査. 医用酵素, 1:670, 1975.

319) 緇荘和子, 福武勝博, 他:SDSアガロースゲルを用いた二次元免疫電気泳動法によるFgDPとFDP の鑑別について. 血液と脈管, 投稿中 (第4回日本血栓止血学会発表, 大阪, 1981.)

320) Gaffney, P. J. and Balkuv-Ulutin, S.:Fibrinolysis, current fundamental and clinical concepts. London, New York, San Fransisco:Academic Press, 1978.

321) Gonzalez-Gronew, M., Siefring, G. E., Castellino, F. J.:Mechanism of activation of human plasminogen by the activator complex, streptokinase-plasmin. J. Blol Chem., 253:1090, 1978.

322) Hayashi, H., Koya, H., Kitajima, K. and Kimura, I.:Coagulation factor deficiency apparently related to the Fitzgerald trait:The first cases in Japan. Acta Med. Okayama, 32:81, 1978.

323) Ikematsu, S.:An approach to the metabolism of factor XIII. Acta Haematol. Jap., 44:1499, 1981.

324) Jackson, G. M. and Nemerson, Y.:Blood coagulation. Ann. Rev. Biochem., 49:765, 1980.

325) Johnson, A. J., Newman, J., Howell, M. B. and Puszkin, S.:Two large-scale procedures for purification of human antihemophilic factor (AHF). Blood, 28:1011, 1966.

326) 可児卓朗:FgDPのX分画から成るフィブリン様凝塊paraclotの溶解性について. 東京医大誌, 38:177, 1980.

327) Kisiel, W., Fujikawa, K. and Davie, E. W.:Activation of bovine factor VII (proconvertin) by factor XIIa (activated Hageman factor). Biochem., 16:4189, 1977.

328) 近藤元治, 吉川敏一:補体系からみたDIC. DIC (前川正ら編), 東京:テクノ, 1981. p 73.

329) Laake, K. and Osterud, B.:Activation of puri fied plasma factor VII by human plasmin, plasma kallikrein, and activated components of the human intrinsic blood coagulation system. Throm. Res., 5:759, 1974.

330) 前川正:抗血小板剤と抗血栓療法. Biomedical Sciences, 12:1, 1981.

331) Miletich, J. P, Jackson, C. M., Majerus, P. W.:Properties of the factor Xa binding site on human platelets. J. Biol. Chem., 253:6908, 1978.
pubmed

332) Moncada, S., Gryglewski, R, Bunting, S. and Vane, J. R.:An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature, 263:663, 1976.

333) Mosher, D. F., Shad, P. E. and Kleinman, H. K.:Inhibition of blood coagulation factor XIII a mediated cross.linking between fibronectin and collagen by polyamines. J. Supramolec. Struct., 11:227, 1979.

334) 中村克己, 鹿取信, 他:Tachibana Trait:Fitzgerald欠損症-本邦2家系図. 日血会誌, 44:393, 1981.

335) Nyman, D. F. and Duckert, F.:Factor XIII, fibrin and collagen. Thromb. Diath. Haemorrh., 34:551, 1975.

336) Okamoto, S., Hijikata, A., Kikumoto, R. and Tamao, Y.:Asynthetic thrombin inhibitor taking extremely active stereostructure. Thromb. Haemat., 42:205, 1979.

337) Radcliffe, R., Nemerson, Y.:Activation and control of factor VII by activated factor X and thrombin. Isolation and characterization of a single chain form of factor VII. J. Biol. Chem., 250:388, 1975.
pubmed

338) Rosenberg, R. D.:The coagulation-fibrinolytic mechanism and the action of heparin. Adv. Exp. Med. Biol. (Heparin), 52:217, 1975.
pubmed

339) Saito, H., Ratnoff, O. D.:Alteration of factor VIII activity by a activated Fletcher factor (a plasma Kallikrein):Apotential link between the intrinsic and extrinsic blood clotting systems. J. Lab. Clin. Med., 85:405, 1975.

340) Shanberge, J. N. and Gore, I.:Studies on the immunologic and physiologic activities of antihemophilic factor (AHF). J. Lab. Clin. Med., 50:954, 1957.

341) Stenflo, J.:Anew vitamin-dependent protein. J. Biol Chem., 251:355, 1976.

342) Senflo, J., Ganrot, P.:Vitamin K and the biosynthesis of prothrombin I. Identification and purification of a dicumarol-induced abnormal prothrombin from bovine plasma. J. Biol Chem., 247:8160, 1972.
pubmed

343) 高松純樹, 岩永貞昭:フィブリノーゲンの分子異常. 代謝, 17:1027, 1980.

344) Troll, W., Sherry, S.:The activation of human plasminogen by streptokinase. J. Biol. Chem., 213:881, 1955.
pubmed

345) Violand, B. M. and Castellino, F. J.:Mechanism of the urokinase-catalyzed activation of human plasminogen. J. Biol. Chem., 251:3906, 1976.

346) White, J. G. and Gerrard, J. M.:Platelet morphology and the ultrastructure of regulatory mechanisms involved in platelet activation. Platelets:amultidisciplinary approach (de,:Gaetano, G., Garattini, S., ed.), New York:Raven Press, 1978. p. 17-34.

347) White, W. F., Barlow. G. H. Mozen, M. M.:The isolation and characterization of plasminogen activators (Urokinase) from:human urine. Biochemistry, 5:2160, 1966.
pubmed

2. 血栓

P.62 掲載の参考文献

1) Mcfarlane, R. G.:Haemostasis:Introduction. Brit. Medical Bulletin, 33:183, 1977.

2) Baumgartner, H. R.:The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc. Research, 5:167, 1973.

3) Ashford, T. D., Freiman, D. G.:Platelet aggregation at site of minimal endotheliat injury. An electron microscopic study. Am. J. Pathol., 53:599, 1967.

4) Barnhart, M. I., Baechler, C. A.:第16回国際血液学会 (京都), 1976. 9.

5) Wallen, P.:Activation of plasminogen with urokinase and tissue activator. Thrombosis and Urokinase (Paoletti. R., Sherry. C., eds.), London:Academic Press, 1977. p. 91-102.

6) Bettex-Galland, M., Ltischer, E. F.:Thrombosthenin, the contractile protein from blood platelet and its relation to other contractile proteins. Advances Protein Chem., 20:1, 1965.

7) 松岡松三:接触因子 (Contact factor) について. 日内会誌, 54:844, 1965.

8) Baumgartner, H. R.:Platelet interaction with vascular structures. Thromb. Diathes. Haemorrh. Suppl. 51:161, 1972.

9) Mustard, J. F., Packham, M. A.:Factors influencing platelet function:Adhesion, release and aggregation. Pharmacol Rev., 22:97, 1970.
pubmed

10) Jamieson, G. A., Urban, C. L., Barber, A. J.:Enzyme basis for platelet:Collagen adhesion as the primary step in hemostasis. Nature (New Biology), 334:5, 1971.

11) Jaffe, E. A., Hoyer, L. W., Nachman, R. L.:J. Ctin. Invest., 52:2757, 1973.

12) Nemerson, Y., Pitlick, F. A.:Purification and characterization of the protein component of tissue factor. Biochemistry, 9:5100, 1970.
pubmed

13) Murray, M.:Vasculokinase, a clotting substance from arteries. Am. J. Clin. Pathol., 36:500, 1961.
pubmed

14) 大石正晃:動脈凝固線溶能に関する研究, 第1編Vasculokinse様物質について. 日内会誌, 58:605, 1969.

15) Astrup, T.:Tissue activators of plasminogen. Fed. Proc., 25:42, 1966.
pubmed

16) 青木延雄:血管壁と凝固線溶-血管壁の止血-血栓における役割-. 内科, 34:11, 1974.

17) Bang, N. U., Beller, K. F., Deutsch, E.:Thrombosis and Bleeding Disorders. Stuttgart:Georg Thieme Verlag, New York, London:Academic Press, 1971. p. 496.

18) Egeberg, O., Owren, P. A.:Oral contraception and blood coagulability. Brit. Med. J., 1:220, 1963.
pubmed

19) 松岡松三:血液病と分娩. 日産婦誌, 21:330, 1969.

20) Gaston, L. W.:Studies on a family with an elevated plasma level of factor V (proaccelerin) and a tendency to thrombosis. J. Pediat., 68:367, 1966.

21) Penick, G. O., Dejanov, I. I., Roberts, H. R., et al:Elevation of factor VIII in hypercoagulable state. Thromb. Diathes. Haemorrh. Suppl., 20:39, 1966.

22) 松岡松三, 渡部透:急性前骨髄球性白血病の30例について. 臨床血液, 15:1, 1974.

23) 安藤泰彦, 渡辺清明:急性前骨髄球性白血病におけるDICの原因と病態生理. 臨床血液, 17:389, 1976.

24) Kosewski, J. B., Vahabzadeh, H.:Hypercoagulability syndrome due to heparin cofactor deficiency, A case report and review of literature. Thromb. Diathes. Haemorrh., 11:485, 1964.

25) Egeberg, O.:Inherited antithrombin deficiency causing thrombophilia. Thromb. Diathes. Haemorrh., 13:516, 1965.

26) McDonald, L.:Coagulability of blood in ischemic heart disease. Lancet, ii:457, 1957.

27) Zahvi, J., Dreyfuss, F.:An abnormal pattern of adenosine diphosphate induced platelet aggregation in acute myocardial infarction. Thromb. Diathes. Haemorrh., 21:76, 1969.

28) Fabizewski, R., Niewiarowski, S., Worowski, K., Lipinski, B.:Release of platelet factor 4 in vivo during intravascular coagulationui and in thombotic state. Thromb. Diathes. Haemorrh., 19:578, 1968.

29) Chimielewski, J., Farbizewski, R.:Platelet factor 4 (pf 4) release during human platelet aggregation in dibetic patients. Thromb. Diathes. Haemorrh., 24:203, 1970.

30) Nestel, P. J.:Fibrinolytic activity of the blood in intermittent claudication. Lancet, ii:378, 1969.

31) Chakrabarti, R., Hocking, Z. O.:Fibrinolytic activity and coronary artery disease. Lancet, i:987, 1968.

32) 松岡松三:血液凝固学20年の歩み (会長講演). 日血会誌, 35:577, 1972.

33) Conner, E. W., Hoak, J. C., Warner, E. D.:Massive thrombosis produced by fatty acid infusion. J. Clin. Invest., 42:860, 1963.

34) 松岡松三:血液凝固とRheology. 日内会誌, 58:1344, 1969.

35) Zahn, W.:Virchows Arch. Pathol. Anat. Physiol, 62:81, 1875.

36) Bizzozero, G.:Uber einen neuen Formbestandteil des Blubes und dessen Rolle bei der Thrombose und der Blutgerinnung. Virchows Arch. Pathol Anat. Physiol., 90:267, 1882.

37) Eberth, J. C., Schimmelbusch. C.:Virchows Arch. Pathol Anat. Physiol, 103:331, 1886.

38) Shulz, H.:Thrombocyten und Thrombose in elecktronmikroskopischen Bild. Berlin:Springer, 1968.

39) Dietrich, A.:Pathologie und Klinik in Einzeldarstellungen IV. Berlin:Springer, 1932.

40) Studer, A.:Thromb. Diathes. Haemorrh., Suppl. 21:109, 1966.

41) French, J. E.:Blood platelet. Morpho|ogical studies on their properties and lifecycle. Brit. J. Haematol., 13:595, 1967.

42) Hattori, A., Jimbo, C., Iizumi, T., Ito, M., Matsuoka, M.:Ascanning electron microscope study on haemostatic reaction, Early plug formation and effect of aspirin. Arch. Histolog. Jap., 37:343, 1975.

43) Hattori, A., Tokunaga, J., Fujita, T., Matsuoka, M.:Scanning electron microscopic observations on human blood platelets and their alterations induced by thrombin. Arch. Histolog. Jap., 31:37, 1969.

44) Matsuoka, M., Hattori, A., Mizushina, T., Jimbo, C.:The ultrastracture of the cryofibrinogen in acute promyelocytic leukemia displaying the defibrination syndrome and fibrillar inclusions in promyelocytes. Acta Med. et Biol. (Niigata), 17:49, 1969.

45) White, J. G., Krivit, W., Vernier, R. L.:The platelet-fibrin relationship in human blood clots:An ultrastructural study utilizing ferritin conjugated anti-human fibrinogen antibody. Blood, 25:241, 1965.
pubmed

46) Bull, B. S., Kuhn, I. N.:The production of schistocytes by fibrin strands (A scanning electron microscope study). Blood, 35:104, 1970.
pubmed

48) Bjφrklid, E., Giercksky, K. E., Prydz, H.:An immunoradiometric assay for factor m (tissue thromboplastin). Brit. J. Haematol., 39:445, 1978.

49) 松岡松三:血液凝固検査-進め方と測定法-. 改訂第3版, 金原出版, 1978. p. 75, 155.

50) Packham, M. A., Kinlough Rathbone, R. L., Reimes, H-J., Scott, S., Mustard, J. F.:Mechanisms of platelet aggregation independent of adenosine diphosphate. Prostaglandin in Haematology (Silver, M. J., Smith, J. B., Kocsis, J. J., eds.), New York:Spectrum Publication, 1977. p. 247.

51) O:Brien, J. R., Heywood, J. B., Heady, J. A.:The quantitation of platelet aggregation induced by four compounds:Astudy in relation myocardial infarction. Thromb. Diathes. Haemorrh., 16:752, 1966.

52) Yamazaki, H., Takahashi, T., Sano, T.:Hyperaggregability of platelets in thromboembolic disorders. Thromb. Diathes. Haemorrh., 34:94, 1975.

53) Swank, R. L.:The screen filtration pressure method in platelet research. Significance and interpretation. Series Haematologica, 1:2, 146, 1968.

54) Kobayashi, I., Fujita, T., Yamazaki, H.:Platelet aggregability measured by screen filtration method in cerebrovascular disease. Stroke, 7:406, 1976.
pubmed

55) 佐野忠弘, 山崎博男:血小板機能検査法の進歩と血栓予知. 日本臨牀, 36:3836, 1978.
Medical*Online

56) Hornstra, G., Ten Hoor, F.:The filtragometer:A new device for measuring platelet aggregation in venous blood of man. Thromb. Diathes. Haemorrh., 34:531, 1975.

57) Wu, K. K., Hoak, J. C.:A new method for the quantitative detection of platelet aggregates in patients with arterial insu伍ciency. Lancet, ii:924, 1974.

58) Wu, K. K., Hoak, J. C.:Increased platelet aggregates in patients with transient ischemic attacks. Stroke, 6:521, 1975.
pubmed

59) Packham, M. A.:Method for detection of hypersensitive platelets. Thrombos. Haemostas., 40:175, 1978.

60) Spaet, T. H.:Studies on the in vivo behavior of blood coagulation product I in rats. A Thromb. Diathes. Haemorrh., 8:276, 1962.

61) Spaet, T. H., Horowitz, H. T., Zucker-Franklin. D., Citron, J., Biezenski, J.:Reticuloendothelial clearance of blood thromboplastin by rats. Blood, 17:196, 1961.

62) Yin, E. T., Wessler, S., Stoll, J. P.:Identity of plasma-activated factor X inhibitor with antithrombin HI and heparin cofactor. J. Biol. Chem., 246:3712, 1971.

63) Damus, P. S., Hicks, M., Rosenberg, R. D.:Anticoagulant action of heparin. Nature, 246:355, 1973.
pubmed

64) Rosenberg, R. D., Damus, P. S.:The purification and mechanism of action of human antithrombin-heparin cofactor. J. Biol. Chem., 248:6490, 1973.
pubmed

65) 櫻川信男, 高橋薫, 星山直理, 松岡松三:血管内凝固亢進亢進症候群と阻害因子-Antithrombin III, Platelet factor 4およびheparinとの関連と血管内凝固亢進症候群での変動-. 日血会誌, 40:218, 1977.

66) Ashford, T. P., Freiman, D. G., Weinstein, M. C.:The role of intrinsic fibrinolytic system in the prevention of stasis thrombosis in small veins. Am. J. Pathol, 52:1117, 1968.
pubmed

67) Triantaphyllopoulos, D. C., Triantaphyllopoulos, E., Chandra, S.:Effect of fibrin (ogen) degradation product on coagulation. Thromb. Diathes. Haemorrh., Suppl., 47 (thrombolytic therapy):121, 1971.

47 Warren, B. A., Kahn, S., Vales, O.:Thromb. Diathes. Haemorrh., Suppl., 56:35, 1973.

P.98 掲載の参考文献

1) Alkjaersig, N., Fletcher, A. P., Sherry, S.:The mechanism of clot dissolution by plasmin. J. Clin. Invest., 38:1086-1095, 1959.
pubmed

2) Ambrus, C. M., Markus, G.:Plasmin-antiplasmin complex as a reservoir of fibrinolytic enzyme. Am. J. Physiol., 199:491-494, 1960.
pubmed

3) Ambrus, C. M., Ambrus, J. L:On the mechanism of thrombolysis by plasmin. Circul. Res., 10:161-165, 1962.

4) Anderson, M. C., Shields, T. W.:An evaluation of factors which influence the incidence and extent of venous thrombosis. Surgery, 51:347-350, 1962.
pubmed

5) Aoki, N.:Preparation of plasminogen activator from bascular trees of human cadavers. Its comparison with urokinase. J. Biochem., 75:731-741, 1974.

6) Astrup, T.:The biological significance of fibrinolysis. Lancet, ii:565-568, 1956.

7) Astrup, T., Albrechtsen, O. K., Classen, M., et al.:Thromboplastic and fibrinolytic activity of the human aorta. Circul. Res., 7:969-976, 1959.

8) Astrup, T.:Role of blood coagulation and fibrinolysis in the pathogenesis of arteriosclerosis. Connective Tissue, Thrombosis and Atherosclerosis (Page, 1., ed.), New York:Academic Press, 1959. p. 223-237.

9) Astrup, T., Coccheri, S.:Thromboplastic and fibrinolytic activity of the arteriosclerotic human aorta. Nature, 193:182-183, 1962.
pubmed

10) Ashford, T. P., Freiman, D. G.:The role of endothelium in initial phases of thrombosis:Electron microscopic study. Am. J. Path., 50:257-273, 1967.

11) Ashford, T. P., Freiman, D. G.:Platelet aggregation at sites of minimal endothelial injury. Am. J. Path., 53:599-607, 1968.
pubmed

12) Back, N., Hiramoto, R., Ambrus, J. I,:Immunohistochemical study of thrombolytic mechanisms. Blood, 25:1028-1036, 1965.

13) Barnhart, M. I., Riddle, J. M.:Cellular locarization of profibrinolysin (plasminogen). Blood, 21:306-321, 1963.
pubmed

14) Baumgartner, H. R.:The role of blood fiow in platelet adhesion, fibrin deposition and formation of mural thrombi, Microvasc. Res., 5:167-179, 1973.

15) Baumgartner, H. R.:The subendothelial surface and thrombosis. Thromb. Diath. Haemorrh., Suppl. 59:91-105, 1974.

16) Blomback, B.:Fibrinogen to fibrin transformation. Blood Clotting Enzymology (Seegers, W. H., ed.), New York:Academic Press, 1967. p. 143.

17) Campbell, R. S. F.:Early atherosclerosis in the pig, a histological and histochemical study. J, Atheroscler. Res., 5:483-496, 1965.

18) Casley-Smith, J. R., Ardlie, N. G., Schwartz, C. J.:Electron microscopical observations on the organization of artificial thrombi in the rabbit pulmonary artery. Br. J. Exp. Pathol., 48:501-506, 1967.
pubmed

19) Chakrabarti, R., Evans, J. F., Fearnley, G. R.:Effects on platelet stickiness and fibrinotysis of phenformin combined with ethyloestrenol or stanozolol. Lancet, i:591-593, 1970.
pubmed

20) Chakrabarti, R., Fearnley, G. R.:Phenformin plus ethyloestrenol in survivors of myocardial infarction. Lancet, ii:556-559, 1972.

21) Chesney, C. McI., Harper, E., Colman, R. W.:Critical role of the carbohydrate side chains of collagen in platelet aggregation. J. Clin. Invest., 51:2693-2701, 1972.

22) Chesterman, C. N., Allington, M. J., Sharp, A. A.:Relationship of plasminogen activator to fibrin. Nature New Biology, 238:15-17, 1972.
pubmed

23) Constantinides, P.:Plaque fissures in human coronary thrombosis. (Abstract) Fed. Proc., 23:443, 1964.

24) Copley, A. L.:Fibrinolysis and atherosclerosis. Lancet, i:102-103, 1957.

25) Copley, A. L.:Flow properties of blood and other biological systems. New York:Pergamon Press, 1960.

26) Crawford, T., Levene, C. I.:The incorporation of fibrin in the aortic intima. J. Path. Bact., 64:523-528, 1952.
pubmed

27) Davidson, J. F., Lochhead, M., McDonald, G. A., McNicol, G. P.:Fibrinolytic enhancement by stanozolol:Adouble blind trial. Br. J. Haematol., 22:543-559, 1972.

28) Deykin, D.:Thrombogenesis. New Engl. J. Med., 276:622-628, 1967.
pubmed

29) Duguid, J. B.:Thrombosis as a factor in the pathogenesis of coronary atherosclerosis, J. Pathol. Bact., 58:207-212, 1946.

30) Duguid, J. B.:Thrombosis as a factor in the pathogenesis of aortic atherosclerosis. J. Pathol Bact., 60:57-61, 1948.

31) Egeberg, O.:Blood factor XI after fat-rich meals. Thromb. Diath. Haemorrh., 15:390-402, 1966.
pubmed

32) Fletcher, A. D., Alkjaersig, N., Sherry, S.:Fibrinolytic mechanisms and the development of thrombolytic therapy. Am. J. Med., 33:738-752, 1962.

33) Freiman, A. H., Bang, N. U., Grossi, C. E., et al:Factors affecting the formation and dissolution of experimental thrombi. Am. J. Cardiol, 6:426-431, 1960.
pubmed

34) Freiman, D. C., Wessier, S., Lertzman, M.:Experimental pulmonary embolism with serum induced thrombi aged in vivo. Am. J. Path., 39:95-102, 1961.

35) Fry, D. L:Certain histological and chemical responses of the vascular interface to acutely induced mechanical stress in the aorta of the dog. Circ. Res., 24:93-108, 1969.
pubmed

36) Fujinami, T., Gore, I.:Fibrinolytic activity of the endothelium. Jap. Circ. J., 31:267-273, 1967.

37) Goldsmith, H. L.:Motion of particles in a flowing system. Thromb. Diath. Haemorrh., Suppl. 40:91, 1970.

38) Goldsmith, H. L:The flow of model particles and blood cells and its relation to thrombogenesis. Progress in Hemostasis and Thrombosis, 1. (Spaet, T. H., ed.), New York:Grune and Stratton. 1972. P. 97.

39) Gore, I., Tanaka, K., Larkey, B. J.:Hypercholesteremia and pulmonary arterial lesions produced by thromboplastin. Am. J. Path., 42:345-356, 1962.

40) Gore, I., Tanaka, K., Nakashima, T., Larkey, B. J.:Pulmonary vascular lesions following the repeated intravascular administration of thromboplastin. Am. J. Path., 41:77-93, 1962.
pubmed

41) Gottlob, R., BIUmel, G.:Studies on thrombolysis with streptokinase. 1. On the penetration of streptokinase into thrombi. Thromb. Diath. Haemorrh., 19:94-98, 1968.

42) Gottlob, R., BIUmel, G., Piza, F., et al:Studies on thrombolysis with streptokinase. II. The influence of changes due to age in thrombi and whole blood clots. Thromb. Diath. Haemorrh., 19:516-525, 1968.

43) Gottlob, R., Stockinger, L., Potting, U., et al:Studies on thrombolysis with streptokinase. III. Morphological examinations of thrombi-thrombus retraction and secondary swelling and the termination of lysibility because of organization. Thromb. Diath, Haemorrh., 25:354-378, 1971.

44) Gottlob, R., El Nashef, B., Donas, P., et al.:Studies on thrombolysis with streptokinase. IV, Immunofluorescent investigations on the fibrin pattern and the content of plasminogen and of plasma plasmin-inhibitors in clots and thrombi of various age, Thromb. Diath, Haemorrh., 29:393-407, 1973.
pubmed

45) Greig, H. B. W., Runde, I. A.:Studies on the inhibition of fibrinolysis by lipids. Lancet, ii:461-463, 1957.

46) Grette, K.:Studies on the mechanism of thrombincatalyzed hemostatic reactions in blood platelets. Acta Physiol. Scand., Suppl. 56:195, 1962.

47) Hand, R. A, Chandler, A. B.:Atherosclerotic metamorphosis of autologous pulmonary thromboemboli in the rabbits. Am. J. Pathol., 40:469-486, 1962.
pubmed

48) Harrison, C. V.:Experimental pulmonary arteriosclerosis. J. Pathol Bact., 60:289-293, 1948.

49) Heard, B. E.:Mural thrombosis in the renal artery and its relation to atherosclerosis. J. Pathol. Bact., 61:635-637, 1949.

50) Hellen, A. J.:Platelet adhesiveness. Series Haematol., 1:99, 1968.

51) Henry, R. L:Leukocytes and thrombosis. Thromb. Diath. Haemorrh., 13:35-46, 1965.
pubmed

52) 久野修資, 川井法子, 田中健蔵:血栓融解機序に関する実験的研究. 第3回血栓および止血に関する討議会発表, 1974.

53) Holmsen, H., Day, HJ., Stormorken, H.:The blood platelet release reaction. Scand. J. Haematol., Suppl. 8:3-26, 1969.
pubmed

54) Honour, A. J.:Ultrastructure and behaviour of platelet thrombi in injured arteries. Brit. J. Exp. Pathol., 52:482-4941971.

55) 堀江昭夫, 黒住武史, 森松稔, 田中健蔵:血栓-特に動脈壁の微細構造との相関-. 血液と脈管, 1:497-09, 1970.

56) Hovig, T., Jφrgensen, L, Packham, M. A., et al.:Platelet adherence to fibrin and collagen. J. Lab. Clin. Med., 71:29-40, 1968.

57) Hovig, T., Mckenzie, F. N., Arfors, K-E.:Measurement of the platelet response to laserinduced microvascular injury-ultrastructural studies. Thromb. Diath. Haemorrh., 32:695-703, 1974.

58) Jevons, S., Barton, P. G.:Biochemistry of blood platelets. Interaction of activated factor X with platelets. Biochemistry, 10:428-434, 1971.
pubmed

59) Johnson, A. J.:Recent advances in experimental thrombogenesis. Fed. Proc., 24:827-834, 1965.
pubmed

60) Johnson, S. A., Wojcik, A. J., Webber, A. J., et al.:Dynamics of thrombus formation and dissolution (Johnson, S. A. and Guest, M. M., eds.), Philadelphia:Lippincott, 1969. p. 72.

61) Jφrgensen, L., Rowsell, H. C., Hovig, T., et al.:Adenosine diphosphate-induced platelet aggregation and myocardial infarction in swine. Lab. Invest., 17:616-644, 1967.

62) Jφrgensen, L., Hovig, T., Gowsell, H. C., et al.:Adenosine diphosphate-induced platelet aggregation and vascular injury in swine and rabbits. Amer. J. Pathol, 61:161-176, 1970.

63) Kao, V. C. Y., Wissler, R. W.:Astudy of the immunohistochemical localization on serum lipoproteins and other plasma proteins in human atherosclerotic lesion. Exp. Molec. Pathol., 4:465-479, 1965.

64) Kay, A. B., Pepper, D. S., Ewart, M. R.:Generation of chemosactic activity for leukocytes by the action of thrombin on human fibrinogen. Nature New Biol., 243:56, 1973.
pubmed

65) Kocsis, J, J., Hernandovich, J., Silver, M. J., et al.:Duration of inhibition of platelet prostaglandin formation and aggregation by ingested aspirin or indomethacin. Prostaglandins, 3:141-144, 1973.

66) 古賀通義:家兎肺動脈における血栓の融解, 器質化に関する研究. 福岡医誌, 62:525-540, 1971.

67) 古賀通義:実験的家兎肺動脈血栓ならびに実験的コレステロール性動脈硬化に対するデキストラン硫酸の経口投与の影響に関する研究. 医学研究, 41:502-520, 1971.

68) Kwaan, H. C., Astrup, T.:Fibrinolytic activity in thrombosed veins. Circulation, 17:477-483, 1965.

69) Leonard, E. F.:The role of flow in thrombogenesis. Bull N. Y. Acad, Med., 48:273-280, 1972.
pubmed

70) Lieberman, J., Kellogg, F.:Fibrinolytic activity of arterial tissues. Circ. Res., 9:515-521, 1961.
pubmed

71) Lttscher, E, F.:Biochemistry of blood platelets and thrombus formation. In:Swed., 15-21 August, 1965. (Theodor Kocher Inst., Univ. Berne, Berne, Switz.) Ser. Haematol., 10:76-82, 111us. 1965.

72) 前川正:血栓症. 現代内科学大系年刊補遺1966b. 東京:中山書店, 1966:p. 49-69.

73) 前川正:血栓症の成因-血液の面より-. 血液と脈管, 1:473-484, 1970.

74) 松田保:Hypercoagulabilityと血栓. 血液と脈管, 1:485-495, 1970.

75) 松岡松三, 渡辺浩:血管内凝固症候群-内科領域を主として-. 血液と脈管, 1:149-170, 1970.

76) McDonald, R. A., Robbins, S. L.:The significance of nonbacteriat thrombotic endocarditis:An autopsy and clinical study of 78 cases. Ann. Int. Med., 46:255-273, 1957.

77) Miller, S., Sanchez-Avalos, J., Stefanski, T., et al.:Coagulation disorders in cancer I. Clinical and laboratory studies. Cancer, 20:1452-1465, 1967.
pubmed

78) Moe, N., Jergensen, L.:Fibrin deposits on the syncytium of the normal human placenta:Evidence of their thrombogenic origin. Acta Path. Microbiol. Scand., 72:519-541, 1968.

79) Mole, R. H.:Fibrinolysin and the fluidity of the blood post mortem. J. Pathol. Bact., 60:413-427, 1948.

80) Morgan, A. D.:The pathogenesis of coronary occlusion, Oxford:Blackwell, 1956. p. 171.

81) Morgan, A. D.:The thrombogenic hypothesis in coronary atherosclerosis. Cardiologia, 40:77-96, 1962.
pubmed

82) Movet, H. Z., et al:The morphologic elements in the early lesions of arteriosclerosis. Am. J. Pathol., 35:93-97, 1959.

83) Muggli, R., Baumgartner, H. R.:Collagen induced platelet aggregation:Requirement for tropocollagen aggregates. Abstracts., IV International Congress on Thrombosis and Haemostasis, Vienna, Austria. 1973. p. 86.

84) Muir, H. M., Mustard, J. F.:Enhancement of Platelet Aggregation by Glycosaminglycans (Mucopolysaccharides). Le role de la Paroi Arterielle dans L:atherogenes. Collq. Int. Centre Nat. Rech. Sci., 169:589, 1968.

85) 村上元孝:血栓の動脈硬化の成り立ちに占める役割. 日内会誌, 51:843-849, 1962.

86) Mustard, J. F., Murphy, E. A., Rowsell, H. C., et al:Platelets and atherosclerosis. J. Atheroscler. Res., 4:1-28, 1964.
pubmed

87) Mustard, J. F., Movat, H. Z., Macmorine, D. R. L., et al:Release of permeability factors from the blood platelet. Proc. Soc. Exp. Biol Med., 119:988-991, 1965.

88) Mustard, J. F., Kinlough. Rathbone, R. L., Packham, M. A.:Recent status of research in the pathogenesis of thrombosis. Thromb. Diath. Haemorrh., Suppl. 59:157-188, 1974.

89) Mustard, J. F., Packham, M. A.:The role of blood and platelets in atherosclerosis and the complications of atheroscierosis. Thromb. Diathes. Haemorrh., 33:444-456, 1975.

90) Niewiarowski, S., Regoeczi, E., Mustard, J.F.:Platelet interaction with fibrinogen and fibrin:Comparison of the interaction of platelets with that of fibroblasts, leukocytes and erythrocytes. Ann. N. Y. Acad. Sci., 201:72-83, 1972.
pubmed

91) Niewiarowski, S., Rogoeczi, E., Stewart, G. L., et al.:PIatelet interaction with polymerizing fibrin. J, Clin. Invest., 51:685-700, 1972.

92) Niewiarowski, S., Senyi, A. F., Gillies, P.:Plasmin-induced platelet aggregation and platelet release reaction. Effects on hemostasis. J. CIin. Invest., 52:1647-1659, 1973.

93) Nilson, I. M., Pandom, M.:Fibrinolytic response of the vascular wall. Thromb. Diath. Haemorrh., Suppl. 40:231, 1970.

94) Nitzberg, S. I., Peyman, M. A., Goldstein, R., Proger, S.:Studies of blood coagulation and fibrinolysis in patients with idiopathic hyperlipemia and primary hypercholesteremia before and after a fatty meal Circulation, 19:676-690, 1959.

95) Ogston, C. M., Ogston, D., Fullerton, H. W.:Observations on the lysis of artificial thrombi by urokinase. Thromb. Diath. Haemorrh., Suppl. 19:107-116, 1968.

96) Ohta, G.:Morphology of the vascular endothelium. An investigation of the morphogenesis of incipient thrombosis. Acta Path. Jap., 10:377-394, 1960.

97) Oiwin, J. A., Oiwin, V. I., Baluda, V. P.:Permanent fibrin film on the intima of the vessels. Nature, 194:686-687, 1962.

98) O:Neal, R. M., Thomas, W. A.:The role of pulmonary hypertension and thromboembolism in the production of pulmonary arteriosclerosis. Circulation, 12:370-382, 1955.
pubmed

99) Onoyama, K., Tanaka, K.:Fibrinolytic activity of the arterial wall. Thromb. Diath. Haemorrh., 21:1-11, 1969.
pubmed

100) Prentice, C. R. M., McNicol, G. P., Douglas, A. S.:Effect of blood coagulation, fibrinolysis, and platelet aggregation of normal and atheromatous aortic tissue. J. ain. Pathol., 19:154-158, 1966.

101) Prokowicz, J., Stormorken, H.:Fibrinolytic activity of leucocytes in smear of bone marrow and peripheral blood. Scand. J. Haemat., 5:129-137, 1968.
pubmed

102) Riddle, J. M., Barnhart, M. I.:Ultrastructural study of fibrin dissolution via emigrated polymorphonuclear neutrophils. Am. J. Path., 45:805-823, 1964,
pubmed

103) Riddle, J. M., Barnhart, M. I.:The eosinophil as a source for profibrinolysin in acute inflammation. Blood, 25:776-794, 1965.
pubmed

104) Rohner, R. F., Prior, J. T., Sipple, J. H.:Mucinous malignancies venous thrombosis and terminal endocarditis with emboli. Cancer, 19:1805-1812, 1966.

105) Sarker, N.:Reduced fibrinolytic activity of atherosclerotic sera caused by an increase in low-density lipoproteins in blood. Nature, 189:929-931, 1961.

106) Sawyer, W. D., Alkjaersig, N., Fletcher, A. P., et al.:Thrombolytic therapy. Arch. Int. Med., 107:274-289, 1961.

107) Sherry, S., Fletcher, A. P., Alkjaersig, N.:Fibrinolysis and fibrinolytic activity in man. Physiol. Rew., 39:343-382, 1959.

108) Studer, A.:Thrombosis and Atherogenesis. Atherosclerosis:Proceedings of the 2 nd International Symposium on Atherosclerosis. (Jones, R. J., ed.), Berlin:Springer Verlag, 1970.

109) 住吉昭信, 田中健蔵, 吉田喜美男, 他:腸間膜血管閉塞症-わが国における剖検例の文献的考察並びにその発生要因について-. 最新医学, 20:951-958, 1965.

110) 住占昭信, 田中健蔵, Gore, I., Hirst, A. E.:心筋硬塞症と血栓症-九大剖検例におけるそれらの頻度, 時代的推移並びに血栓原性動脈硬化発生に関する考察-. 福岡医誌, 56:571-589, 1965.

111) Sumiyoshi, A., et al.:Aortic fibrofatty type atherosclerosis from thrombus in normolipidemic rabbits. Atherosclerosis, 18:43-57, 1973.
pubmed

112) 住吉昭信:実験的動脈硬化と血栓. 動脈硬化, 3 (4):407-413, 1976.

113) 田中健蔵:」血栓形成, 血液凝固と動脈硬化. 日病会誌, 54:340-353, 1965.

114) Tanaka, K.:Thrombus and coagulation factors in the genesis of arteriosclerosis. Acta Path. Jap., 18 (1):91-106, 1968.
pubmed

115) 田中健蔵:血栓症. 福岡医誌, 59:337-361, 1968.

116) 田中健蔵:癌と線溶 (招待講演要旨). 第29回東京医大癌, 第12回フラスミン合同研究会, 東京医大 1; ε, 26 (3, 4):571-576, 1968.

117) 田中健蔵, 岩田康:血管壁の組織線溶活性-その血栓溶解並びに動脈硬化の発生進展における意義-. 脈管学, 10 (5):227-235, 1970.

118) 田中健蔵:血栓症 (凝固尤進状態). 第18回日本医学会総会シンポジウム記録, 第18回日本医学会会誌, 717-720, 1971.

119) 田中健蔵日吉雄一, 福島武雄:冠状動脈および脳動脈の血栓症. 血液と脈管, 3 (12):1495, 1972.

120) 田中健蔵:出血と血栓の病理. 日本臨牀, 31 (4):743-754, 1973.
Medical*Online

121) 田中健蔵:血栓形成の機作. 代謝, 10:108-117, 1973.

122) 田中健蔵:動脈硬化症の病理. 興和医報, 18 (3):2-12, 1974.

123) 田中健蔵:血栓症の病理, 総論. 興和医報, 19 (1):3-15, 1975.

124) 田中健蔵:血栓融解の病理, 総論. 興和医報, 19 (2):2-9, 1975.

125) 田中健蔵:血栓と動脈硬化. 内科シリーズ, No. 20:39-49, 1975.

126) Todd, A. S.:The blood vessel wall and fibrinolytic activity. Dynamics of thrombus formation and dissolution. Philadelphia and Toronto:Lippincott Co., 1969. p. 321-339.

127) Ts:ao, C. E., Glagov, S.:Platelet adhesion to subendothelial components in experimental aortic injury, Role of fine fibrils and basement membrane, Br. J. Exp. Pathol., 51:423-427, 1970.

128) Warren, B. A.:Tumor metastasis and thrombosis. Thromb. Diath. Haemorrh., Suppl. 59:139-156, 1974.

129) Warren, B. A., Khan, S.:The ultrastructure of the lysis of fibrin by endothelium in vitro. Br. J. Exp. Path., 55:138-148, 1974.

130) 渡辺照男:血管壁凝固線溶活性に関する研究. 福岡医誌, 61:682-694, 1970.

131) Wilner, G. D., Nossel, H. L., LeRoy, E. C.:Activation of hageman factor by collagen. J. Clin. Invest., 47:2608-2615, 1968.
pubmed

132) Woolf, N., Carstairs, K. C.:In丘ltration and thrombosis in atherogenesis. A study using immunofluorescent techniques. Am. J. Pathol., 51:373-381, 1967.

133) Zucker, M. B,:ADP and collagen.induced platelet aggregation in vivo and in vitro. Thromb. Diath. Haemorrh., Suppl, 26:175-184, 1967.
pubmed

3. 血液凝固因子

P.136 掲載の参考文献

1) Ratnoff, O. D., Colopy, J. E.:Afamilial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J. Clin. Invest., 34:602-613, 1955.

2) Ratnoff, O. D., Rosenblum, J. M.:Role of Hageman factor in the initiation of clotting by glass. Am. J. Med., 25:160-168, 1958.

3) Didisheim, P., et al.:Hematologic and coagulation studies in various animal species. J. Lab. Clin. Med., 53:866-875, 1959.
pubmed

4) Ratnoff, O. D., Davie, E. W.:The purification of activated Hageman factor (activated factor XII). Biochemistry, 1:967-975, 1962.
pubmed

5) Schoenmakers, J. G. G., et al:Purification of activated bovine Hageman factor. Thromb. Diath. Haemorrh., 9:546-556, 1963.

6) Speer, R. J., et a:Activated human Hageman factor (XII). Thromb. Diath. Haemorrh., 14:1-11, 1965.

7) Weiss, A. S., et al:Fletcher factor deficiency, a diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. J. Clin. Invest., 53:622-633, 1974.
pubmed

8) Cochrane, C. G., et al.:Activation of Hageman factor in sollid and fluid phases. J. Exp. Med., 138:1564-1583, 1973.

9) Fujikawa, K., et al.:Characterization of bovine factor XIIa (activated Hageman factor). Biochemistry, 16:4182-4188, 1977.
pubmed

10) Donaldson, V. H., Ratnoff, O. D.:Hageman factor:Alterations in physical properties during activation. Science, 150:754-756, 1965.
pubmed

11) Movat, H. Z., Ozge-Anwar, A. H.:The contact phase of blood coagulation; clotting factors XI and XII, their isolation and interaction. J. Lab. Clin. Med., 84:861-877, 1974.

12) Revak, S. D., et al:Structural changes accompanying enzymatic activation of human Hagemall factor. J. Clin. Invest., 54:619-627, 1974.

13) Bordet, J., Gengou, O.:Researches sur la coagulation du sang. Annales de l, Institut Pasteur, 17:822, 1903.

14) Ratnoff, O. D.:The biology and pathology of the initial stages of blood coagulation. Progress in Hematology, 5 (Moore, C. V. and Brown, E., eds.), New York:Grune and Stratton, 1966. p. 204.

15) Niemetz, J., Nossel, H. L.:Activated coagulation factors; in-vivo and in-vitro studies. Brit. J. Haemat., 15:337-343, 1969.

16) Nossel, H. L.:The contact phase of blood coagulation. Philadelphia:Davis, 1964. p. 24.

17) 倉地幸徳, 藤川和雄:血液凝固反応の開始機構. 蛋白質.核酸.酵素, 25:95-111, 1980.

18) Morrison, D. C., Cochrane, C. G.:Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxines). J. Exp. Med., 140:797-811, 1974.

19) Astrup, T., Rosa, A. T.:Aplasminogen proactivator.activator system in human blood effective in absence of Hageman factor. Thromb. Res., 4:609-613, 1974.
pubmed

20) Kluft, C.:Determination of prekallikrein in human plasma; optimal conditions for activating prekallikrein. J. Lab. Clin. Med., 91:83-95, 1978.
pubmed

21) Kaplan, A. P., Austen, K. F.:Aprealbumin activator of prekallikrein II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J. Exp. Med., 133:696-712, 1971.
pubmed

22) Revak, S. D., et al.:The relationship of structure and function in human Hageman factor. J. Clin. Invest., 57:852-860, 1976.
pubmed

23) Revak, S. D., et al.:The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasma deficient in factor XI, prekallikrein, or high molecular weight kininogen. J. Clin. Invest., 59:1167-1175, 1977.
pubmed

24) Liu, C. Y., et al:Potentiation of the function of Hageman factor fragments by high molecular weight kininogen. J. Clin. Invest., 60:7-17, 1977.
pubmed

25) Meier, H. L, et al.:Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein. J. Clin. Invest., 60:18-31, 1977.
pubmed

26) Wiggins, R. C. . et al.:Role of high-molecular weight kininogen in surface-binding and activation of coagulation factor XI and prekallikrein. Proc. Natl Acad. Sci. USA, 74:4636-4640, 1977.
pubmed

27) Gri th n, J. H.:Role of surface in surface-dependent activation of Hageman factor (blood coagula. tion factor XII). Proc. Natl. Acad. Sci. USA, 75:1998-2002, 1978.

28) Griflfin, J. H., Cochrane, C. G.:Mechanisms for the involvement of high molecular weight kininogen in surface.dependent reactions of Hageman factor. Proc. Natl Acad. Sci. USA, 73:2554-2558, 1976.

29) Kaplan, A. P., et al.:The Hageman factor dependent pathways of coagulation, fibrinolysis, and kinin.generation. Seminars Thromb. Hemost., 3:1-26, 1976.

30) Forbes, C. D., et al:Inhibition of activated Hageman factor and activated plasma thromboplas. tin antecedent by purified CI inactivator. J. Lab. Clin. Med., 76:809-815, 1970.

31) Habal, F. M., Movat, H. Z.:Kininogens of human plasma. Seminars Thromb. Hemost., 3:27-42, 1976.

32) Schreiber, A. D.:Plasma inhibitors of the Hegeman factor dependent pathways. Seminars Thromb. Hemost., 3:43-51, 1976.

33) Hathaway, W. E., et al.:Evidence of a new plasma thromboplastin factor, I. Case report, coagulation studies and physicochemical properties. Blood, 26:521-532, 1965.
pubmed

34) Ablidgaard, C. F., Harrison, J.:Fletcher factor deficiency:Family study and detection. Blood, 43:641-644, 1974.

35) Wuepper, K. D.:Biochemistry and biology of components of the plasma kinin-forming system. The Inflammation:Mechanisms and Control (Lepow, I. H. & Ward, P. A., eds.), New York:Academic Press Inc., 1972. p. 93.

36) Kaplan, A. P., et al.:The fibrinolytic pathway of human plasma. II. Generation of chemotactic activity by activation of plasminogen proactivator. J. Clin. Invest., 52:2591-2595, 1973.
pubmed

37) Mandle, R. Jr., Kaplan, A. P.:Hageman factor substrates. Human plasma prekallikrein:mechanism of activation by Hageman factor and participation in Hageman factor.dependent fibrinolysis. J. Biol Chem., 252:6097-6104, 1977.
pubmed

38) Damus, P. S., et al.:Anticoagulant action of heparin. Nature, 246:355, 1973.
pubmed

39) Saito, H., Ratnoff, O. D.:Alteration of factor VII activity by activated Fletcher factor (a plasma kallikrein):apotential link between the intrinsic and extrinsic blood-clotting systems. J. Lab. Clin. Med., 85:405-415, 1975.

40) Muller-Eberhard, H. J., G6tze, O.:C3 proactivator convertase and its mode of action. J. Exp. Med., 135:1003-1008, 1972.

41) Saito, H., et al.:Fitzgerald trait:deficiencey of a hitherto unrecognized agent, Fitzgerald factor, participating in surface mediated reactions of clotting, fibrinolysis, generation of kinins, and the property of diluted plasma enhanncing vascular permeability (PF/Dil). J. CIin. Invest., 55:1082-1089, 1975.

42) Nakayasu, T., Nagasawa, S.:Studies on human kininogen. I. Isolation, characterization, and cleavage by plasma kallikrein of high molecular weight (HMW).kininogen. J. Biochemistry (Tokyo), 85:249-258, 1979.

43) Kerbiriou, D. M., Griffin, J. H.:Human high molecular weight kininogen. Studies of structure. function relationships and of proteolysis of the molecule occuring during contact activation of plasma. J. Biol Chem., 254:12020-12027, 1979.
pubmed

44) Nagasawa, S., Nakayasu, T.:Human plasma prekallikrein as a protein complex. J. Biochemistry (Tokyo), 74:401-403, 1973.

45) Mandle, R. Jr., et al:Identification of prekallikrein and high.molecular-weight kiniogen as a complex in human plasma. Proc. Natl. Acad. Sci. USA, 73:4179-4183, 1976.

46) Thompson, R. E., et al:Association of factor XI and high molecular weight kininogen in human plasma. J. Clin. Invest., 60:1376-1380, 1977.
pubmed

47) Donaldson, V. H., et al.:Prekallikrein deficiency in a kindred with kininogen deficiency and Fitzgerald trait clotting defect. Evidence that high molecular weight kininogen and prekalli. krein exist as a complex in normal human plasma. J. Clin. Invest., 60:571-583, 1977.

48) Rosenthal, R. L.:New hemophilia.1ike disease caused by deficinecy of a third plasma thromb plastin factor. Proc. Exp. Biol, 82:171-174, 1953.

49) Ratnoff, O. D., Davie, E. W.:The activation of Christmas factor (factor DO by activated plasma thromboplastin antecedent (activated factor XI). Biochemistry, 1:677-685, 1962.

50) Heck, L. W., Kaplan, A. P.:Substrates of Hageman factor I. Isolation and characterization of human factor XI (PTA) and inhibition of the activated enzyme by al.antitrypsin. J. Exp. Med., 140:1615-1630, 1974.

51) Kurachi, K, Davie, E. W.:Activation of human factor XI (plasma thromboplastin antecedent) by faetsr XIIa (activated Hageman factor). Biochemistry, 16:5831-5839, 1977.
pubmed

52) Bouma, B. N., Griffin, J. H.:Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J. Biol. Chem., 252:6432-6437, 1977.
pubmed

53) Lowenhaupt, R. W.:Human platelet chemotaxis:Requirement for plasma factor (s) and the role of collagen. Am. J. Physiol., 235:H23-28, 1978.

54) Walsh, P. N.:The effects of collagen and kaolin on the intrinsic coagulant activity of platelets. Evidence for an alternative pathway in intrinsic coagulation not requiring factor XL Brit. J. Haematol, 22:393-405, 1972.
pubmed

55) Aggeler, P. M., et al.:Plasma thromboplastin component (PTC) deficiency. A new disease resembling hemophilia. Proc. Soc. Exp. Biol. Med., 79:692-694, 1952.
pubmed

56) Biggs, R., et al:Christmas disease, a condition previously mistaken for hemophilia. Brit. Med. J., 2:1378-1382, 1952.
pubmed

57) Fujikawa, K., et al.:Isolation and characterization of bovine factor IX (Christmas factor). Biochemistry, 12:4938-4945, 1973.
pubmed

58) Anderson, L-O., et al.:Purification and characterization of human factor IX. Thromb. Res., 7:451-459, 1975.

59) Discipio, R. G., et al.:Acomparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. Biochemistry, 16:698-706, 1977.

60) DiScipio, R. G., et al.:Activation of human factor IX (Christmas factor). J. Clin. Invest., 61:1528-1538, 1978.

61) Fryklund, L, et al:Amino-terminal sequence of human factor IX:presence of γ.carboxy glutamic acid residues, FEBS Lett., 65:187-189, 1976.

62) φsterud, B., et al:Mechanism of activation of human factor IX by activated human factor XI. Thromb. Haemostasis, 38:14, 1977.

63) Lindguist, P. A., et al:Activation of bovine factor IX (Christmas factor) by factor XIa (activated plasma thromboplastin antecedent) and a protease from Russel:s viper venom. J. Biol Chem., 253:1902-1909, 1978.

64) φsterud, B., Rapaport, S. I.:Abypass mechanism for activating human factor IX with human factor VII and thromboplastin. Thromb. Haemostasis, 38:179, 1977.

65) Kalousek, F., et al.:Activation of factor D (by activated factor X:Alink between the extrinsic and intrinsic coagulation systems. FEBS Lett., 50:382-385, 1975.

66) Ratnoff, O. D., et al:Studies of the purification of antihemophilic factor (factor VIII). II. Separation of partially purified antihemophilic factor by gel filtration of plasma. J. Clin. Invest., 48:957-962, 1969.
pubmed

67) Hershgold, E. J., et al.:Isolation and some chemical properties of human factor VIII (antihemo:philic factor). J. Lab. Clin. Med., 77:185-205, 1971.

68) Hershgold, E. J., et al:Human factor VIII (antihemophilic factor):Activation and inactivation by phospholipases. J. Lab. Clin. Med., 77:206-218, 1971.

69) McKee, P. A., et al.:Molecular structural studies of human factor W. Ann. N. Y. Acad. Sci., 240:8-33, 1975.

70) Switzer, M. E., et al.:Studies on human antihemophilic factor. J. Clin. Invest., 57:925-937, 1976.
pubmed

71) Weiss, H. J., et al.:von Willebrand factor:Dissociation from antihemophilic factor procoagu. lant activity. Science, 182:1149-1151, 1973.

72) Cooper, H. A., et al:Factor VIII recombination after dissociation by CaC12, Proc. Natl Acad. Sci. USA, 70:2326-2329, 1973.

73) Rick, M. E., Hoyer, L. W.:Immunologic studies of antihemophilic factor (AHF, Factor VIII). V. Immunologic properties of AHF subunits produced by salt dissociation. Blood, 42:737-747, 1973.
pubmed

74) Ratnoff, O. D.:Antihemophilic factor. The Year in Hematology (Gordon, A. S., et al, eds.), N. Y.:Plenum Med., 1977. p. 399.

75) 01son, J. D., et al.:Purification of porcine and human ristocetin.Willebrand factor. J. Lab. Clin. Med., 89:1278-1294, 1977.

76) Counts, R. B., et al.:Disulfide bonds and the quaternary structure of factor VIII/von Willebrand factor. J. Clin. Invest., 62:702-708, 1978.
pubmed

77) Marchesi, S. L, et al.:Studies on the purification and characterization of human factor VIII. J. Clin. Invest., 51:2151-2161, 1972.
pubmed

78) Shapiro, G. A., et al.:The subunit structure of normal and hemophilic factor VIII. J. Clin. Invest., 52:2198-2210, 1973.
pubmed

79) Legaz, M. E., et al.:Isolation and characterization of human factor VIII (antihemophilic factor). J. Biol Chem., 248:3946-3955, 1973.
pubmed

80) Sodetz, J. M., et al.:Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J. Biol Chem., 252:5538-5546, 1977.

81) Sodetz, J. M., et al.:Carbohydrate on human factor W/von Willebrand factor:Impairement of function by removal of specific galactose residues. J. Biol Chem., 253:7202-7206, 1978.

82) Gralnick, H. R.:Factor VIII/von Willebrard factor protein. Galactose, a cryptic determinant of von Willebrand factor activity. J. Clin. Invest., 62:496-499, 1978.
pubmed

83) Zimmerman, T. S., et al.:Factor.W.related antigen:Multiple molecular forms in human p|asma. Proc. Natl. Acad. Sci. USA, 72:5121-5125, 1975.

84) Fass, D. N., et al.:Porcine Willebrand factor:A population of multimers. J. Lab. Clin. Med., 91:307-320, 1978.
pubmed

85) Hoyer, L. W., et al.:Factor-W.related protein circulates in normal human plasma as high molecular weight multimers. Blood, 55:1056-1059, 1980.

86) Bloom, A. L.:The von Willebrand syndrome. Semin. Hematol., 17:215-227, 1980.

87) Abildgaard, C. F., et al.:Serial studies in von Willebrand:s disease:Variability versus "variants". Blood, 56:712-716, 1980.
pubmed

88) Zimmerman, T. S., et al.:The factor VIII abnormality in severe von Willebrand's disease. N. Engl. J. Med., 301:1307-1310, 1979.
pubmed

89) Kernoff, P. B. A., et al:Avariant of factor VIII related antigen. Br. J. Haematol, 26:435-440, 1974.

90) Peake, I. R., et al.:Inherited variants of factor VIII-related protein in von Willebrand:s disease. N. Engl. J. Med., 291:113-117, 1974.
pubmed

91) Meyer, D., et al.:Mutimeric structure of factor W/von Willebrand factor in von Willebrand:s disease. J. Lab. Clin. Med., 95:590-602, 1980.

92) Vehar, G. A., Davie, E. W.:Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry, 19:401-410, 1980.

93) Hoyer, L. W.:The effect of thrombin on human factor VIII cleavage of the factor VIII proco. agulant protein during activation. J. Lab. Clin. Med., 97:50-64, 1981.

94) Austen, D. E. G.:Thiol groups in the blood clotting action of factor VIII. Br. J. Haematol., 19:447-484, 1970.

95) Hoyer, L W., et al.:Antihemophilic factor antigen. Localization in endothelial cells by immuno. fluorescent microscopy. J. Clin. Invest., 52:2737-2744, 1973.

96) Bloom, A. L, et al:Factor VIII on the vascular intima:Possible importance in haemostasis and thrombosis. Nature (New Biol.), 241:217-219, 1973.
pubmed

97) Jaffe, E. A., et al.:Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J. Clin Invest., 52:2757-2764, 1973.
pubmed

98) Webster, W. P., et al.:Plasma factor VIII synthesis and control as revealed by canine organ transplantation. Am. J. Physiol., 220:1147-1154,, 1971.
pubmed

99) Owen, C. A. Jr., et al.:Generation of factor VIII coagulant activity by isolated, Perfused neonatal pig livers and adult rat livers. Br. J. Haematol., 43:307-315, 1979.
pubmed

100) Shaw, E., et al:Synthesis of procoagulant factor W, factor VIII related antigen and other coagulation factors by the isolated perfused rat liver. Br. J. Haematol., 41:585-596, 1979.

101) Bloon, A. L.:The biosynthesis of factor VIII. Clin. Haematol., 8:53-77, 1979.

102) Hugie, C.:Effect of Russel:s viper venom (Stypven) on Stuart clotting defect. Proc. Soc. Exp. Biol Med., 93:570-573, 1956.

103) Tefler, T. P., et al:Anew coagulation defect. Brit. J. Haematol., 2:308-316, 1956.

104) Seegers, W. H., et al:Further observations on the purification and properties of autoprothrombin III (factor X). Thromb. Res., 1:209-220, 1972.

105) Fujikawa, K., et al:Bovine faetor XI and X2 (Stuart factor). Isolation and characterization. Biochemistry, 11:4882-4891, 1972.

106) Morita, T., Jackson, C. M.:Eight Steenbock Symposium on Vitamin K Metabolism and Vitamin K.dependent Proteins, June 11-13, Madison, Wisconsin, 1979.

107) Mizuochi, T., et al:The structures of the carbohydrate moieties of bovine blood coagulatjon factor X. J. Biol. Chem., 255:3526-3531, 1980.
pubmed

108) Jackson, C. M., et al.:Studies on bovine factor X. I Large scale purification of the bovine plasma protein possesing factor X activity. Biochemistry, 7:4492-4505, 1968.

109) Biggs, R., et al.:Antithrombin III and antifactor Xa. Brit. J. Haematol., 19:283-305, 1970.

110) Imaoka, S., et al:Significance of the decrease of activated factor X inhibitor in macroglobulin fraction. J. Med. Enzymol., 2:53-59, 1976.

111) Fujikawa, K., et al.:The mechanism of activation of bovine factor X (Stuart factor) by intrinsic and extrinsic pathways. Biochemistry, 13:5290-5299, 1974.
pubmed

112) Jesty, J., et al:The activation of coagulation factor X. Identity of cleavage sites in the alternative activation pathways and characterization of the COOH.terminal peptide. J. Biol. Chem., 250:4497-4504, 1975.
pubmed

113) Fujikawa, K., et al:Activation of bovine factor X (Stuart factor):Conversion of factor Xa a to factor Xaβ, Proc. Natl. Acad. Sci. USA, 72:3359-3363, 1975.

114) Fujikawa, K., et al.:Bovine factor X1 (Stuart factor), Mechanism of activation by a protein from Russell:sviper venom. Biochemistry, 11:4892-4899, 1972.

115) Esmon, C. T., et at.:A plausible mechanism for prothrombin activation by factor Xa, factor Va, phospholipid, and calcium ions. J. Biol. Chem., 249:8045-8047, 1974.

116) Stenn, K. S., Blout, E. R.:Mechanism of bovine prothrombin activation by an insoluble preparation of bovine factor Xa (thrombokinase). Biochemistry, 11:4502-4515, 1972.
pubmed

117) Esmon, C. T., et al:The conversion of prothrombin to thrombin. II. Differentiation between thrombin and factor Xa.catalyzed proteolysis. J. Biol. Chem., 249:606-611, 1974.
pubmed

118) Kisiel, W., Hanahan, D. J.:Proteolysis of human factor H by factor Xa in the presence of hirudin. Biochem. Biophys. Res. Commun., 59:570-577, 1974.

119) Rosenberg, J. S., et al:Activation of human prothrombin by highly purified human factors Vand Xa in the presence of human antithrombin. J. Biol Chem., 250:1607-1617. 1975.

120) Downing, M. R., et al:Human prothrombin activation. J. Biol. Chem., 250:8897-8906, 1975.
pubmed

121) Radcliffe, R., Nemerson, Y.:Activation and control of factor VIII by activated factor X and thrombin. Isolation and characterization of a single chain form of factor Nll. J. Biol. Chem., 250:388-395, 1975.

122) Radcliffe, R., Nemerson, Y.:Mechanism of activation of bovine factor VIII. Products of cleavage by factor Xa. J. Biol. Chem., 251:4797-4802, 1976.

123) McDonagh, J., McDonagh, R. P.:Alternative pathways for the activation of factor XIII. Brit. J. Haematol., 30:465-477, 1975.

124) Aurell, L., et al:A new sensitive and highly specific chromogenic peptide substrate for factor Xa. Thromb. Res., 11:595-609, 1977.
pubmed

125) Morita, T., et al.:A new fluorogenic substrates fora-thrombin, factor Xa, kallikreins, and urokinase. J. Biochem., 82:1495-1498, 1977.

126) Smith, C. M., Hanahan, D. J.:The activation of factor V by factor Xa or a.chymotrypsin and comparison with thrombin and RVV action. An improved factor V isolation procedure. Biochemistry, 15:1830-1838, 1976.

127) Davie, E. W., et al.:Proteases and Biological Control (Reich, E., et al. eds.), N. Y.:Cold Spring Harbor Lab., 1975. p. 65.

128) Howell, W. H.:The nature and action of the thromboplastic (zymoplastic) substance of the tissue. Amer. J. Physiol., 31:1, 1912.

129) Gonmori, H., Takeda, Y.:Properties of human tissue thromboplastins from brain, 1ung, arteries and placenta. Thromb. Haemostas., 36:90-103, 1976.

130) Maekawa, T., et al.:Tissue thromboplastin in leukocytes from various leukemias and its localization by immunoperoxydase staining method. (Abstr). Thromb. Haemostas., 38:151, 1977.

131) Maynard, J., et al.:Tissue-factor coagulant activity of cultured human endothelial and smooth musc[e cells and fibroblasts. Blood, 50:387-396, 1977.

132) Nemerson, Y., Pitlick, F. A.:Extrinsic clotting pathways, Progress in Haenostasis and Thrombosis Vol. 1, N. Y.:Grune & Stratton, 1972. p. 1-38.

133) Nemerson, Y., Pitlick, F. A.:Purification and characterization of the protein component of tissue factor. Biochemistry, 9:5100-5105, 1970.
pubmed

134) Bjφrklid, E., Storm, E.:Purification and some properties of the protein component of tissue thromboplastin from human brain. Biochem. J., 165:89-96, 1977.

135) Liu, D. T. H., McCoy, L. E.:Tissue extract thromboplastin-quantitation, fractionation and characterization of protein components. Thromb. Res., 7:199-211, 1975.

136) Nemerson, Y.:The phospholipid requirement of tissue factor in blood coagulation. J. Clin. Invest., 47:72-80, 1968.
pubmed

137) Pitlick, F. A.:Concanavalin A inhibits tissue factor coagulaut activity. J. Clin. Invest., 55:175-179, 1975.
pubmed

138) Williams, W. J.:The activity of human placenta microsomes and brain, pariticles in blood coagulation. J. Biol. Chem., 241:1840-1846, 1966.

139) Kisiel, W., Davie, E. W.:Isolation and characterization of bovine factor VII. Biochemistry, 14:4928-4934, 1975.
pubmed

140) Broze, GJ., Majerus, P. W.:Purification and properties of human coagulation factor VIII. J. Biol, Chem., 255:1242-1247, 1980.

141) Zur, M. Nemerson, Y.:The esterase activity of coagulation factol VII. Evidence for intrinsic activity of the zymogen. J. Biol. Chem., 253:2203-2209, 1978.
pubmed

142) Kisiel, W., et al.:Activation of bovine factor VIII (proconvertin) by factor XIIa (activated Hageman factor). Biochemistry, 16:4189-4194, 1977.

143) Ingwall, J. S., Scheraga, H. A.:Purification and properties of bovine prothrombin. Biochemistry, 8:1860-1868, 1963.

144) Mann, K. G.:Prothrombin. Methods in Enzymology, 45:123-156, 1976.
pubmed

145) Kisiel, W., Hanahan, D. J.:Purification and characterization of human factor II. Biochim. Biophys. Acta, 304:103-113, 1973.
pubmed

146) Suttie, J. W., Jackson, C. M.:Prothronbin structure, activation, and biosynthesis. Physiol. Rev., 57:1-70, 1977.

147) Magnusson, S., et al.:Comolete primary stucture of prothrombin:isolation, structure, and reactivity of ten carboxylated glutamic acid residues and regulation of prothrombin activation by thrombin. Proteases and Biological Control (Reich, E., et al., eds.), Cold Spring Harbor, N. Y.:Cold Spring Harbor Lab., 1975. p. 123-149.

148) Thompson, A. R., et al:Human thrombin partial primary structure. Arch. Biochem. Biophys., 178:356-367, 1977.
pubmed

149) Butkowski, R. J., et al.:The primary structure of human prothrombin 2 and a-thrombin. J. 3 Biol Chem., 252:4942-4957, 1977.

150) Walz, D. A, et al.:Amino acid sequence of human prothrombin fragment 1 and 2. Proc. Natl Acad. Sci. USA, 74:1969-1972, 1977.
pubmed

151) Mizuochi, T., et al.:The carbohydrate of bovine prothrombin. Occurrence of Gal, 81-3GlcNAc grouping in asparagine-1inked sugar chain. J. Biol Chem., 254:6419-6425, 1979.

152) Stenflo, J., et al.:Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc. Natl Acad. Sci. USA, 71:2730-2733, 1974.
pubmed

153) Suttie, J. W., et al.:Relationship between vitamin K-dependent carboxylation and vitamin Kepoxydation. Fed. Proc., 37:2605-2609, 1978.
pubmed

154) Whitlon, D. S., et al.:Mechanism of coumarin action:Significance of vitamin K epoxide reductase inhibition. Biochemistry, 17:1371-1377, 1978.
pubmed

155) Larson, A. E., Suttie, J. W.:Vitamin K-dependent carboxylase:Evidence for a hydroperoxyde intermediate in the reaction. Proc. Natl. Acad. Sci. USA, 75:5413-5416, 1978.

156) Suttie, J. W., et al.:Biosynthesis of prothrombin complex proteins. Ann. N. Y. Acad. Sci., 370:271-280, 1981.
pubmed

157) Sperling, R., et al.:Metal binding properties of γ-carboxyglutamic acid. Implications for the vitamin K-dependent blood coagulation proteins. J. Biol. Chem., 253:3898-3906, 1978.

158) Furie, B. C., et al.:Metal binding sites of γ:carboxyglutamic acid-rich fragment of bovine prothrombin. J. Biol Chem., 254:12521-12530, 1979.

159) Fenton, J. W.:Thrombin specificity. Ann. N. Y. Acad. Sci., 370:468-495, 1981.
pubmed

160) Weinstein, M. J., Doolittle, R. F.:Differential specificities of thrombin, plasmin and trypsin with regard to synthetic and natural substrates and inhibitors. Biochim. Biophys. Acta, 258:577-590, 1972.
pubmed

161) Abildgaard, U.:Purification of two progressive antithrombins of human plasma. Scand. J. Clin. Lab. Invest., 19:190-195, 1967.

162) Rosenberg, R. D., Damus, P. S.:The purification and mechanism of action of antithrombinheparin cofactor. J. Biol Chem., 248:6490-6505, 1973.
pubmed

163) Heimberger, N., et al:Proteinase inhibitors of humn plasma. Proc. Int. Res. Conf. Proteinase Inhibitors (Fritz, H., et al., eds), Berlin:Walter de Gruyter, 1971. p. 1.

164) Bagdy, D., et al:Hirudin. Methods in Enzymol, 45:669, 1976.
pubmed

165) Seegers, W. H., et al.:Relationship of "new" vitamin K-dependent protein C and "old" autoprothrombin II-A. Thromb. Res., 8:543-552, 1976.
pubmed

166) Kisiel, W., et al.:Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry, 16:5824-5831, 1977.
pubmed

167) Hugli, T. C.:Complement factors in inflammation:Effects of a-thrombin on components C3 and C5. Chemistry and Biology of Thrombin (Lundblad, R. L., et al., eds.), Ann. Arbor, Michigan:Ann Arbor Science Pub., 1977.

168) Davie, E. W., Hanahan, D. J.:Blood coagulation proteins. Plasma Proteins (Putnum, F. W., ed.), Vol. III. N. Y., San Francisco & London:Acad. Press, 1977. p. 422-544.

169) Saraswathi, S., et al.:Subunit structure of bovine factor V. Influence of proteo|ysis during blood coagulation. J. Biol. Chem., 253:1024-1029, 1978.

170) Colman, R. W.:Factor V. Progress in Hemostasis and Thrombosis (Spaet, T. H., ed.) Vol 3. NY, San Francisco and London:Grune & Stratton, 1976. p. 109-143.

171) Colman, R. W., Weinberg, R. M.:Factor V. Methods in Enzymology (Lorand, L., ed.), Vol. XLV, Part B, NY, San Francisco and London:Acad. Press, 1976. p. 107-122.

172) Ware, A. G., et al:The function of Acglobulin in blood clotting. Science, 106:618, 1947.
pubmed

173) Esnouf, M. P.:The biochemistry of factor X and factor V. Haemostasis:Biochemistry, and Physiology, Pathology (Ogston, D., et al., eds.), N. Y, London, Sydney & Tronto:John Wiley & Sons, 1977. P. 76-90.

174) Bartlett, S., et al.:Insensitivity of factor V and factor Va to diisopropyl fiuorophosphate and antithrombin IH. Biochim. Biophys. Acta, 524:485-490, 1978.

175) 岩永貞昭, 他:血液中のメイゾフ゜ロテアーゼーその特色, 構造, 機能. 化学と生物, 15:2-12, 1977.

176) Saraswathi, S., Colman, R. W.:Role of galactose in bovine factor V. J. Biol. Chem., 250:8111-8118, 1975.
pubmed

177) Blombtick, B., Blomback, M.:Purification of human and bovine fibrinogen. Arkiv. Kemi., 10:415-443, 1957.

178) Murano, G., et al.:Human fibrinogen; some characteristics of its S-carboxymethyl derivative chains. Thromb. Res,, 1:161-171, 1972.

179) Hall, C. E., Slayter, H. S.:The fibrinogen molecule; its size, shape, and mode of polymerization. J. Biophys. Biochem. Cytol., 5:11-16, 1959.
pubmed

180) 岩永貞昭, 中村伸:フィブリノゲン及びその誘導体について, 臨床科学, 9:605-619, 1973.

181) Doolittle, R. F.:Fibrinogen and fibrin. Sci. Am., 245:1264-1273, 1981.

182) Blomback, B.:Glycoproteins (Gottschalk, ed.), BBA Library vol 5, Amsterdam:Elsevier Publishing Co., 1972. p. 1074.

183) Henschen, A.:Peptide chains S-sulfo-fibrinogen and S-sulfo-fibrin; isolation methods and general properties. Arkiv. Kemi., 22:375-396, 1964.

184) Krajewski, T., et al.:O-phosphoserine as a constituent of polypeptide chains of bovine fibrinogen. Biochim. Biophys. Acta, 271:174-181, 1972.
pubmed

185) 岩永貞昭:フィブリノゲンの構造と機能. 蛋白質・核酸・酵素, 14:175-195, 1969.

186) Doolittle, R. F.:Structure and funtion of fibrinogen. Horizons Biochem. Biophys., 3:164-191, 1977.

187) Lottspeich, F., Henschen, A.:Amino acid sequenuce of human fibrin. Preliminary note on the completion of the γ-chain sequence. Hoppe-Seyler:s Z. Physiol Chem., 358:935-938, 1977.

188) Watt, K. W. K, et al:The amino acid sequence of theβ-chain of human fibrinogens-Biochemistry, 18:68-76, 1979.

189) Doolittle, R. F., et al.:Fibrinogen-A highly regulatory agent for maintaining the integrity of the vertebrate circulatory system. Vessatility of Proteins (Li, C. H., ed.), New York:Acad. Press, 1978. p. 393-411.

190) Heuschen, A., Lottspeich F.:Amino acid sequence of human fibrin. Preliminary note on the completion of the β-chain sequence. Hoppe-Seyler's Z. Physiol Chem., 358:1643-1646, 1977.

191) Iwanaga, S., et al:Amino aeid sequence of the N-terminal part of γ-chain in human fibrinogen. Biochim. Biophys. Acta, 160:280-283, 1968.

192) Blomback, B., et al.:Primary structure of human fibrinogen and fibrin. 1. Cleavage of fibrinogen with cyanogen bromide. Isolation and characterization of NH2-terminal fragments of the a ("A") chain. J. Biol Chem., 247:1496-1512, 1972.

193) Blomback, B., et al:N-terminal disulfide knot of human fiorinogen. Nature, 218:130-134, 1968.
pubmed

194) Mosesson, M. W., et al.:Human fibrinogen heterogeneities. 1. Structural and related studies of plasma fibrinogens which are high solubility catabolic intermediates. J. Biol Chem., 247:5210-5219, 1972.

195) Mosesson, M. W., et al.:Human fibrimogen heterogeneities. III. Identification of γ-chain variants. J. Biol Chem., 247:5223-5227, 1972.

196) Lederer, K.:Small angle X-ray scattering measurements with dilute solutions of bovine fibrinogen. J. Mol. Biol, 63:315-320, 1972.

197) Mosesson, M. W.:Fibrnogen catabolic pathways. Semin. Thromb. Hemost., 1:63-84, 1974.

198) Mosesson, M. W., Finlayson, J. S.:The search for the structure of fibrinogen. Prog. Hemostas. Thromb., 3:61-107, 1976.

199) Blombtick, B., et al.:Human fibrinopeptides isolation, Characterization and structure, Biochim. Biophys. Acta. 115:371-396, 1966.

200) Murano, G.:The molecular structure of fibrinogen. Semin. Thromb. Hemost., 1:1-31, 1974.

201) Gladner, J. A., et al:Nature of peptides released by thrombin. Ann. N. Y. Acad. Sci., 104:47-52, 1963.
pubmed

202) Nossel, H. L., et al:Radioimmunoassay of human fibrinopeptide A. Proc. Natl. Acad. Sci. USA, 68:2350-2353, 1971.
pubmed

203) Budzynski, A. Z., et al.:Reaction of plasmic degradation products of fibrinogen in the radio-immunoassay of human fibrinopeptide A. Blood, 45:757-768, 1975.

204) Chen, R., Doolittle, R. F.:γ-γ cross-linking sites in human and bovine fibrin. Biochemistry, 10:4486-4491, 1971.

205) McKee, P. A., et al.:Subunit structure of human fibrinogen, soluble fibrin, and cross-linked insoluble fibrin. Proc. Natl. Acad. Sci. USA, 66:738-744, 1970.
pubmed

206) Pisano, JJ., et al:ε-(γ-glutamyl) lysine in fibrin:Lack of crosslink formation in factor XIII deficiency. Proc. Natl Acad. Sci., 68:770-772, 1971.

207) Barnhart, M. I., Anderson, G. F.:Intracellular locarization of fibrinogen. Proc. Soc. Exp. Biol. Med., 110:734-737, 1962.
pubmed

208) McFarlane, A. S.:Labelling of plasma proteins with radioactive iodine. Biochem. J., 62:135-143, 1956.
pubmed

209) McFarlane, A. S.:Short term measurement of catabolic rates using iodine-labeled plasma proteins. J:Clin. Invest., 49:1903-1911, 1970.
pubmed

210) Reeve, E. B., Franks, J. J.:Fibrinogen synthesis, distribution and degradation. Semin. Thromb. Hemost., 1:129-183, 1974.

211) Castaidi, P. A., Caen, J.:Platelet fibrinogen. J. Clin. Path., 18:579-585, 1965.

212) Solum, N. O., Lopaciuk, S.:Bovine platelet. proteins. H. Purification of platelet fibrinogen. Thromb. Diath. Haemorrh., 21:419-427, 1969.

213) Robbins, K. C.:Study on conversion of fibrinogen to fibrin. Am. J. Physiol., 142:581-588, 1944.

214) Laki, K., Lorand, L.:On the solubility of fibrin clots. Science, 108:280, 1948.
pubmed

215) Duckert, E., F. et al:A hitherto undescribed congenital hemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb. Diath. Haemorrh., 5:179-186, 1960.

216) Loewy, A. G., et al:Fibrinase:I. Purification of substrate and enzyme. J. Biol Chem., 236:2625-2633, 1961.
pubmed

217) Schwartz, M. L., et al.:The subunit structures of human plasma and platelet factor XIII (fibrin stabilizing factor). J. Biol. Chem., 246:5851-5854, 1971.
pubmed

218) Takagi, T., Konishi, K.:Purification and some properties of fibrin stabilizing factor. Biochim. Biophys. Acta, 271:363-370, 1972.
pubmed

219) McDonagh, J., et al:Affinity chromatography of human plasma and platelet factor XIII on organomercurial agarose. Biochem. Biophys. Acta, 446:345-357, 1976.
pubmed

220) Schwartz, M. L., et al.:Human factor XIII from plasma and platelets. Molecular weights, subunit structure, proteolytic activation, and cross-linking of fibrinogen and fibrin. J. Biol. Chem., 248:1395-1407, 1973.
pubmed

221) Bohn, V. H., et al.:Die molekulare structur der fibrinstabilisierenden Faktoren des Menschen. II. Vergleichende immunologische Untersuchung von Faktur XIII-Mangelplasmen und Normal plasma. Blut, 26:303-311, 1973.

222) Chung, S. I., et al:Relationships of the catalytic properties of human plasma and platelet transglutamlnases (activated blood coagulation factor XIII) to their subunit structures. J. Biol. Chem., 249:940-950, 1974.
pubmed

223) Chen, R., Doolittle, R. F.:γ-γ cross linking sites in human and bovine fibrin. Biochemistry, 10:4487-4491, 1971.

224) Ikematsu, S., et al.:Immunochemical studies of human factor XIII. J. Lab. Clin. Med., 97:662-671, 1981.
pubmed

225) McDonagh, J., et al:Detection and regulation of the subunit proteins of plasma factor XIII. Thromb. Haemostas., 46:241, 1981.

226) Takagi, T., Doolittle, R. F.:Amino acid sequence studies on factor XIII and the peptide released during its activation by thrombin. Biochemistry, 13:750-756, 1974.
pubmed

227) Seeling, G. F., Folk, J. E.:Half-of-the-sites and all-of-the-sites reactivity in human plasma blood coagulation factor XIIIa. J. Biol. Chem., 255:9589-9593, 1980.

228) Curtis, C. G., et al.:Titration and subunit localization of active center cysteine in fibrinoligase (thrombin-activated fibrin stabilizing factor). Biochem Biophys. Res. Commun., 52:51-56, 1973.
pubmed

229) Cooke, R. D., et al:Calcium and thiol reactivity of human plasma clotting factor XIII. Biochem. J., 141:675-682, 1974.
pubmed

230) Cooke, R. D.:Calcium induced dissociation of human factor XIII and the appearance of catalytic activity. Biochem. J., 141:683-691, 1974.
pubmed

231) Cooke, R. D., Holbrook, J. J.:The calcium induced dissociation of human plasma clotting factor XIII. Biochem. J., 141:79-84, 1974.
pubmed

232) Lorand, L, et al.:Dissociation of the subunit structure of fibrin stabilizing factor during activation of the zymogen. Biochem. Biophys. Res. Commun., 56:914-922, 1974.
pubmed

233) Folk, J. E., Finlayson J. S.:The-ε(γ-glutamyl) lysine crosslink and the catalytic role of transglutaminases. Adv. Prot. Chem., 31:1-133, 1977.

234) Lorand, L., et al:Human factor XIII:Fibrin-stabilizing factor. Prog. Hemost. Thromb., 5:245-290, 1980.
pubmed

235) Holbrook, J. J., et al:The amino acid sequence around the reactive cysteine residue in human plasma. Biochem. J., 135:901-903, 1973.
pubmed

236) Holbrook, J. J., et al:Factor XIII:Astudy using polarization of fluorescence of the activation of the enzyme by calcium and by substrate. Biochem. Soc. Trans., 5:1247-1251, 1977.

237) McDonagh, R. P., et al.:Studies of the a-chain crosslinking of human fibrin, XVI Internatl. Cong. Hematol., Kyoto (abstr.), 1976. p. 311.

238) Mosher, D. F.:Cross-linking of cold-insoluble globulin by fibrin-stabilizing factor. J. Biol. Chem., 250:6614-6621, 1975.
pubmed

239) Nyman, D., Duckert, F.:Factor XIII, fibrin and collagen. Thromb. Diath. Haemorrh., 34:551, 1975.
pubmed

240) Mosher, D. F.:Cross.linking of collagen and fibronectin by factor XIIIa. Localization of participating glutamyl residues to a tryptic fragment of fibronectin. J. Biol Chem., 255:1181-1188, 1980.

241) Mui, P. T., Ganguly, P.:Cross-linking of actin and fibrin by fibrin stabilizing factor. Am. J. Physiol., 233:H346-349, 1977.
pubmed

242) Cohen, I., et al:Fibrinoligase-catalysed cross-linking of myosin from platelet and skeletal muscle. Arch. Biochem. Biophys., 192:100-111, 1979.

243) Sakata, Y., Aoki, N.:Cross-linking of a2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J. Clin. Invest., 65:290-297, 1980.

244) Kiesselbach, T. H., Wagner, R. H.:Demonstration of factor XIII in human megakaryocytes by a fluorescent antibody technique. Ann. N. Y. Acad. Sci., 202:318-328, 1972.
pubmed

245) Rider, D. M., et al:Apossible contributory role of the platelet in the formation of plasma factor XIII. Brit. J. Haematol., 39:579-588, 1978.

246) Lee, S. Y., Chung., S. I.:Biosynthesis and degradation of plasma protransglutaminase (factor XIII). Fed. Proc., 35:1486, 1976.

247) Ikematsu, S.:An approach to the metabolism of factor XIII. Acta Haematol. JPN., 44:1499-1505, 1981.

248) Broekman, M. J., et al.:Distribution of fibrinogen and platelet factor 4 and XIII in subcellular fractions of human platelets. Brit. J. Haematol. 31:51-55, 1975.

P.155 掲載の参考文献

1) Fell, C., Ivanovic, N., Johnson, S. A., Seegers, W. H.:Differentiation of plasma antithrombin activities. Proc. Soc. Exp. Biol. Med., 85:199, 1954.
pubmed

2) Verstraete, M.:Antithrombins. Thromb. Diath. Haemorrh. (Suppl.), 20:385, 1966.
pubmed

3) Seegers, W. H.:Multiple protein interactions as exhibited by the blood-clotting mechanism. J. Phys. Colloid. Chem., 51:198, 1947.
pubmed

4) Hensen, A., Loeliger, E. A.:Antithrombin III:Its metabolism and its function in blood coagulation. Thromb. Diath. Haemorrh. (Suppl. 1), 9:1, 1963.

5) Quick, A. J.:Current blood clotting schemes. Thromb. Diath. Haemorrh., 16:318, 1966.
pubmed

6) Howell, W. H., Holt, E.:Two new factors in blood coagulation-heparin and pro-antithrombin. Amer. J. Physiol., 47:328, 1918.

7) B[omback, B.:Studies on the action of thrombic enzymes on bovine fibrinogen as measured by N-terminal analysis. Arkiv. Kemi., 12:321, 1958.

8) Lewis, J. H., Walters, D., Didisheim, P., Merchant, W. R.:Application of continuous flow electrophoresis to the study of the blood coagulation proteins and fibrinolytic enzyme system. I. Normal human materials. J. Clin. Invest., 37:1323, 1958.

9) Lyttleton, J. W.:The antithrombin activity of human plasma. Biochem. J., 58:8, 1954.
pubmed

10) Burstein, M., Guinand, A.:Heparine et consommation de l:antithrombine. Arch. Sci. Physiol. (Paris), 10:129, 1956.

11) Loeb, J.:Le cofacteur plasmatique de l'heparine et les rapports avec l'antithrombine. Arch. Sci. Physiol. (Paris), 10:129, 1956.

12) Abildgaard, V.:Highly purified antithrombin III with heparin cofactor activity prepared by disc electrophoresis. Scand. J. ain. Lab. Invest., 21:89, 1968.

13) Schmer, G., Wasser, E.:The chemical binding of clotting inhibitors to agarose:Its use and significance in laboratory medicine in coagulation current research and clinical applications. (Schmer, G. and Strandjord, P. E., ed.), N. Y.:Academic Press, 1973. p. 227-234.

14) Yin, E. T., Wessler, S., Stoll, P. J.:Biological properties of the naturally occuring plasma inhibitor to activated factor X. J. Biol Chem., 246:3703, 1971.
pubmed

15) Yin, E. T., Wessler, S., Stoll, P. J.:Identity of plasma-activated factor X inhibitor with antithrombin HI and heparin cofactor. J. Biol. Chem., 246:3712, 1971.

16) Rosenberg, R. D., Damus, P. S.:The purification and mechanism of action of human antithrombin-heparin cofactor. J. Biol Chem. 248:6490, 1973.
pubmed

17) Abildgaard, U.:Inhibition of the thrombin-fibrinogen reaction by antithrombin m studied by N-terminal analysis. Thromb. Diath. Haemorrh., 20:207, 1967.

18) Lanchantin, G. F., Plesset, M. L., Friedmann, J. A., Hart, D. W.:Dissociation of esterolytic and clotting activities of thrombin by trypsin-binding macroglobulin. Proc. Soc. Exp. Biol Med., 121:444, 1966.
pubmed

19) Abildgaard, U.:Inhibition of the thrombin fibrinogen reaction by a2-macroglobulin, studied by N-terminal analysis. Thromb. Diath. Haemorrh., 21:173, 1969.

20) Rimon, A., Shamash, Y., Shapiro, B.:The plasmin inhibitor of human plasma. IV:Its action on plasmin, trypsin, chymotrypsin and thrombin. J. Bicl. Chem., 241:5102, 1966.

21) Abildgaard, U.:Purification of two progressive antithrombins of human plasma. Scand. J. Clin. Lab. Invest., 19:190, 1967.

22) Abildgaard, U., Egeberg, O.:Thrombin inhibitory activity of fractions obtained by gel filtration of antithrombin m deficient plasma. Scand. J. Haemat., 5:155, 1968.

23) Monkhouse, F. C., et al.:Studies on the antithrombin and heparin cofactor activities of a fraction adsorbed from plasma by aluminum hydroxide. Cir. Res., 3:397, 1955.

24) Monkhouse, F. C., Milojevic, S.:Studies on the relation between plasma antithrombin and heparin cofactor. Can. J. Physiol Pharmacol, 46:347, 1968.
pubmed

25) Seegers, W. H., Miller, K. D., Andrews, E. B., Mulphy, R. C.:Fundamental interactions and effect of storage, ether, adsorbants and blood clotting on plasma antithrombin activity. Amer. J. Physiol, 169:700, 1952.

26) Astrup, T., Darling, S.:Antithrombin and heparin. Acta Physiol Scand., 5:13, 1943.

27) Monkhouse, F. C.:The influence of inorganic salts on plasma antithrombin activity. Thromb. Diath. Haemorrh., 9:387, 1963.

28) Monkhouse, F. C.:Relationship between antithrombin and thrombin levels in plasma and serum. Amer. J. Physiol., 197:984, 1959.
pubmed

29) Abildgaard, U.:Binding of thrombin to antithrombin m. Scand. J. Clin.Lab.Invest., 24:23, 1969.

30) 青木延雄, 五十嵐紀子:アンチトロンビンの基礎と臨床. 日本血液学会雑誌, 36:472-476, 1973.

31) Highsmith, R. F., Rosenberg, R. D.:The inhibition of human plasmin by human antithrombin. heparin cofactor. J. Biol Chem., 249:4335, 1974.
pubmed

32) Egeberg, O.:On the natural blood coagulation inhibitor system. Investigations of inhibitor factors based on antithrombin deficient blood. Thromb. Diath. Haemorrh., 14:473, 1965.
pubmed

33) Egerberg, O.:On the natural blood coagulation inhibitor system. Investigations of inhibitor factors based on antithrombin deficient blood. Thromb. Diath. Haemorrh., 14:473, 1965.

34) Seegers, W. H., Cole, E. R., Harmison, C. R, Monkhouse, F. C.:Neutralization of autopro. thrombin C activity with antithrombin. Canad. J. Biochem., 42:359, 1964.

35) Biggs, R., Denson, K. W. E., Akman, N., Borrett, R., Hadden, M.:Antithrombin m, Antifactor Xa and Heparin. Brit. J. Haemat., 19:283, 1970.

36) Denny, G. P., Minot, G. R.:The origin of antithrombin. Amer. J. Physiol, 38:233, 1915.

37) Monkhouse, F. C., Miolojevic, S.:Changes in thrombin generation and antithrombin titer following massive bleeding and transfusion in dogs. Canad. J. Biochem. Physiol., 38:475, 1960.

38) Mann, L T., Jensenius, J. C., Simonsen, M.:Antithrombin m. Protection against death after injection of thromboplastin. Science, 166:517, 1969.

39) Eika, C., Abildgaard, V.:Inhibition of thrombin induced aggregation of human platelets by antithrombin III. Scand. J. Haemat., 7:460, 1970.

40) Egeberg, O.:Inherited antithrombin deficiency causing thrombophilia. Thromb. Diath. Haemorrh., 13:516, 1965.
pubmed

41) Van der Meer, J., Stoepman-Van Dalen, E. A., Jansen, J. M. S.:Antithrombin-m deficiency in a Dutch family. J. Clin. Path., 26:532, 1973.

42) Marciniak, E., Farley, C. H., DeSimone, P. A.:Familial thrombosis due to antithrombin III deficiency. Blood, 43:219, 1974.

43) von Kaulla, E., von Kaulla, K. N.:Deficiency of antithrombin III activity associated with hereditary thrombosis tendency. J. Med., 3:349, 1972. N

44) Sas, G., Blasko, G., Bankegyi, D., Jako, J., Palos, L. A.:Abnormal antithrombin m (Anti. thrombin m Budapest:) as a cause of a familial thrombophilia. Thromb. Diath. Haemorrh., 32:105, 1974.

45) Matsuo, T., et al.:Familial antithrombin III deficiency in a Japanese family. Thromb. Res., 16:815, 1979.

46) Nakagawa, M., et al:Familial antithrombin m deficiency and its clinical significance. 血液と脈管, 11:106, 1980.

47) 村山英樹, 他:先天性低アンチトロンビンIII血症を伴う. 腸間膜静脈血栓症の1例. 日本臨床外科医学会雑誌, 42:812, 1981.

48) 小林祥泰, 他:上矢状静脈洞血栓症を呈した先天性アンチトロンビンIII欠乏症の2家系. 臨床神経学, 20:904, 1980.

49) 中村治雄, 他:慢性肺動脈血:栓症の発症により発見されたアンチトロンビンIII欠乏症の一家系, 臨床血液, 22:2001, 1981.

50) Seegers, W. H., Schroer, H., Kagami, M,:In activation of purified autoprothrombin I with an. tithrombin. Can. J. Biochem., 42:1425, 1964.

51) Monkhouse, F. C., Milojevic, S.:The inactivation of antithrombin by ether:Evidence against the existence of antithrombin W. Can. J. Physiol Pharmacol., 43:819, 1965.

52) Loeliger, A., Hers, J. F. P.:Chronic antithrombinaemia (antithrombin V) with haemorrhagic diathesis in a case of rheumatoid arthritis with hyper gammaglobulinemia. Thromb. Diath. Haemorrh., 1:499, 1957.

53) Verstraete, M., Vermylen, G.:Recherches sur I:antithrombine V dans la maladie de Kahler. Acta Haematol., 22:240, 1959.

54) Vermylen, G., Verstraete, M.:Antithrombin V. Critical evaluation of its assessment and properties. Thromb. Diath. Haemorrh., 5:267, 1960.

55) Niewiarowski, S., Kowalski, E.:Un nouvel anticoagulant derive du fibrinogene. Rev. Hematol., 13:320, 1958.

56) Triantaphyllopoulos, D. C.:Anticoagulant effect of incubated fibrinogen. Canad. J. Biochem. Physiol., 36:249, 1958.
pubmed

57) Schultze, H. E., Heimburger, N., Heide, K., et al:Preparation and characterization of al. trypsin inhibitor and a2-plasmin inhibitor of human serum. Proc. Congr. European Soc. Haematol., 9 th, Lisbon, 1963. p. 1315-1320.

58) Ganrot, P. O., Nilehn, J. E.:Competition between plasmin and thrombin for a2.macroglobulin. Clin. Chim. Acta, 17:511, 1967.

59) Nilehn, J. E., Ganrot, P. O.:Plasmin, plasmin inhibitors and degradation products of fibri. nogen in human serum during and after intravenous infusion of streptokinase. Scand. J. Clin. Lab. Invest., 20:113, 1967.

60) Ganrot, P. O., Schersten, B.:Serum a2.macroglobulin concentration and its variation with age and sex. Clin. Chim. Acta, 15:113, 1967.

61) Aoki, N.:Natural inhibitors of fibrinolysis. Prog. Cardiovasc. Dis., 21:267, 1979.
pubmed

62) Matsuda, M., Yoshida, N., Aoki, N., Wakabayashi, K.:Distribution of cold-insoluble globulin in plasma and tissues. Ann. N. Y. Acad. Sci., 312:74, 1978.
pubmed

63) Aoki, N., Yamanaka, T.:The a2-plasmin inhibitor levels in liver diseases. Clin. Chim. Acta, 84:99, 1978.

64) Harpel, P. C., Rosenberg, R. D.:a2-Macroglobulin and antithrombin.heparin cofactor:Modulators of hemostatic and infiammatory reactions. Progress in Hemostasis and Thrombosis, 3:145, 1976.

65) Yin, E. T., Wessler, S.:Investigation of the apparent thrombogenicity of thrombin. Thromb. Diath. Haemorrh., 20:465, 1968.
pubmed

66) Yin, E. T., Wessler, S.:Evidence for a naturally occuring Plasma inhibitor of activated factor X:its isolation and partial purification. Thromb. Diath. Haemorrh., 21:398, 1969.
pubmed

67) Yin, E. T., Wessler, S., Stoll, P. J.:Rabbit plasma inhibitor of the activated species of blood coagulation factor X. Purification and some properties. J. Biol Chem., 246:3694, 1971.
pubmed

68) Marciniak, E., Tsukamura, S.:Two progressive inhibitors of Factor Xa in human blood:Brit. J. Haemat., 22:341, 1972.
pubmed

69) Wessler, S., Yin, E. T.:On the antithrombotic action of heparin. Thrombos. Diaths. Haemorrh., 32:71, 1974.

70) Marciniak, E.:Factor.Xa inactivation by antithrombin III. Evidence for biological stabili. zation of factor Xa by factor V.phospholipid complex. Brit. J. Haemat., 24:391, 1973.

71) Niemetz, J., Nossel, H. L.:Method of purification and properties of anti.Xla (inhibitor of the contact product). Thromb. Diath. Haemorrh., 17:335, 1967.

72) Forbes, C. D., Pensky, J, Ratnoff, O. D,:Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum CI inactivator. J. Lab. Clin. Med., 76:809, 1970.

73) Schreiber, A. D., Kaplan, A. P., Austen, K. F.:Inhibition by CI INH of Hageman factor frag:ment activation of coagulation, fibrinolysis, and kinin generation. J. Clin. Invest., 52:1402, 1973.

74) Silver, M. J., Turner, D. L., Tocantins, L. M.:Phospholipid antithromboplastin. Assay in vitro and evaluation in vivo of purified fractions. Amer. J. Physiol., 190:8, 1957.
pubmed

75) Hecht, E.:New inhibitors of the first stage of the blood-clotting process. Nature, 167:279, 1951.
pubmed

76) Jorpes, J. E.:Heparin in the treatment of thrombosis. Oxford University Press, 1946.

77) Holmgren, H., Wilandu, O.:Beitrag zur Kenntnis der Chemie und Function der Ehrlichschen Mustzellen. Zeitschrift fur Mikroskopinch.Anatomische Forenschung., 42:242, 1937.

78) Lundblad, R. L., Die, E. W.:The activation of antihemophilic factor (factor III) by activated Christmas factor (activated factor IX). Biochemistry (Wash), 3:1720, 1964.

79) Hemker, H. C., Muller, A. D.:Kinetic aspects of the interaction of blood-clotting enzymes. VI. Localization of the site of blood coagulation inhibiton by the protein induced by vitamin Kabsence (PIVKA). Thromb. Diath. Haemorrh., 20:78, 1968.

80) Marciniak, E.:Functional and steric characteristics of modified thrombin zymogen. Thromb. Diath. Haemorrh., 24:361, 1970.

81) Marciniak, E.:Coagulation inhibitor elicited by thrombin. Science, 170:452, 1970.
pubmed

82) GriMn, J. H., Evatt, B., Zimmerman, T. S., Kleiss, A. J., Wideman, C.:Deficiency of protein Cin congenital thrombotic disease. J. Clin. Invest., 68:1370, 1981.

4. 線維素溶解現象

P.189 掲載の参考文献

1) Soulier, J. P., et al.:Syndrome hemorrhagiques mortels avec incoagulabilite totale par defibrination et avic fibrinolyes I. Au coure des exereses pulmonaires. Rev. Hematol., 7:30-47, 1952.

2) Soulier, J. P., et al.:Syndrome hemorrhagiques mortels avec incoagulabilite totale par defibrination et avic fibrinolyes II. A la suite d:un avartement par injection inra.uterine d:eau de javel:probleme des defibrinations en obstetrique et en gynecologie. Rev. Hematol, 7:48-52, 1952.

3) Ratnoff, O. D.:Studies on the proteolytic enzyme in human plasma VIL A fatal hemorrhagic state associated with excessive plasma proteolytic activity in patients undergoing surgery for carcinoma of the head of the pancreas. J. Clin, Invest., 31:521-528, 1952.

4) Stefanini, M., Dameshek, W.:Idiopathic thrombocytopenic purpura. Lancet, ii:209-212, 1953. 5) Wallen, P., Wiman, B.:Characterization of human plasminogen. I. On the relationship between different molecular forms of plasminogen demonstrated in plasma and found in purified preparations. Biochim. Biophys. Acta, 221:20-30, 1970.

6) Wallen, P., Wiman, B.:Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen. Biochim. Biophys. Acta, 257:122-134, 1972.
pubmed

7) Summaria, L, et al.:Studies on the isolation of the multiple molecular forms of human plas:minogen and plasmin by isoelectric focusing methods. J. Biol. Chem., 247:4691-4702, 1972.

8) Robbins, K. C., et al.:The primary structure of human plasminogen. I. The NH2-terminal sequences of human plasminogen and the S-carboxymethyl heavy (A) and light (B) chain derivatives of plasmin. J. Biol. Chem., 247:6757-6762, 1972.

9) Summaria, L., et al:Characterization of the NH2-terminal glutamic acid and NH2-terminal lysine forms of human plasminogen isolated by affinity chromatography and isoelectric focusing methods. J. Biol. Chem., 248:2984-2991, 1973.

10) Wiman, B.:Primary structure of peptides released during activation of human plasminogen by urokinase. Eur. J. Biochem., 39:1-9, 1973.
pubmed

11) Wiman, B., Wallen, P.:Amino acid sequence around the arginyl.valyl bond in plasminogen which is cleaved during the second step of the activation process. Thrombosis Res., 7:239-243, 1975.

12) Sodetz, J. M., et al.:Multiplicity of rabbit plasminogen. Physical characterization. Bioche. mistry, 11:4451-4458, 1972.

13) Siefring, G. E., Jr., Castellino, F. J.:Metabolic turnover studies on the two major forms of rat and rabbit plasminogen. J. Biol. Chem., 249:1434-1438, 1974.
pubmed

14) Castellino, F. J., et al:Amino terminal amino acid sequences and carbohydrate of the two major forms of rabbit plasminogen. Biochem. Biophys. Res. Commun., 53:845-851, 1973.
pubmed

15) Wallen, P. and Wiman, B.:Characterization of human plasminogen. I. On the rlationship between different molecular forms of plasminogen demonstrated in plasma and found in purified preparation. Biochim. Biophys. Acta, 221:20-30, 1970.

16) Wallen, and P. Wiman, B.:Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen. Biochim. Biophys. Acta, 257:122-134, 1972.

17) Sottrup-Jensen, L., et al:The primary stucture of human plasminogen:Isolation of two lysin-binding fragments and one "mini"-plasminogen (M. W. 38000) by elastase.catalyzed. specific limited proteolysis. Progress in chemical fibrinolysis and thrombosis. 3:191-209, 1978.

18) Rickli, E. E. and Cundert, P. A.:Isolation of plasmin-free human plasminogen with N-terminal glutamic acid. Biochim. Biophys. Acta, 250:447-451, 1971.

19) Violand, B. N. and Castellino, F. J.:Mechanism of the urokinase.catalyzed activation of human plasminogen. J. Biol Chem., 251:3906-3912, 1976.
pubmed

20) Magnusson, S., et al.:Homologous "Kringle" structures common to plasminogen and prothrombin. Substrate specificity of enzymes activating prothrombin and plasminogen. Proteolysis and Physiological Regulation:Miami Winter Symposia (Ribbons, D. W. & Brew, K., eds.), N. Y.:Academic Press, 11:203-238, 1976.

21) Lerch, P. G., et al:Localization of individual lysine-binding regions in human plasminogen and investigations on their complex-forming Properties. Eur. J. Bichem., 107:7-13, 1980.

22) Wiman, B. and Wallen, P.:Structural relationship between "glutamic acid" and "lysine" forms of human plasminogen and their interaction with the NH2.terminal activation peptide as studied by affinity chromatography. Eur. J. Biochem., 50:489-494, 1975.
pubmed

23) Moroi, M. and Aoki, N.:Inhibition of plasminogen binding to fibrin by a2-plasmin inhibitor. Thromb. Res., 10:851-856, 1977.

24) Wiman, B. and Wallen, P.:The specific interaction between plasminogen and fibrin. A physiological role of the lysine-binding site in plasminogen. Thromb. Res., 10:213-222, 1977.
pubmed

25) Moroi, M. and Aoki, N.:Isolation and characterization of a2.plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J. Biol Chem., 251:5956-5965, 1976.

26) Christensen, U. and aemmensen, I.:Kinetic properties of the primary inhibitor of plasmin from human plasma. Biochem. J., 163:389-391, 1977.
pubmed

27) Rakoczil, I., et al:On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin. Biochim. Biophys. Acta, 540:295-300, 1978.
pubmed

28) Juhan.Vague, I., et al.:Binding of 99mTc plasminogen on fibrin. Thrombos. Haemostas., 45:154-157, 1981.

29) Powell, J. R. and Castellino, F. J.:Activation of human neoplasminogen-Val. 442 by urokinase and streptokinase and a kinetic characterization of one.plasmin-Val. 442. J. Biol. Chem., 255:5329-5335, 1980.

30) Moroz, L A.:Mini.plasminogen:A mechanism for leukocyte modulation of plasminogen activation by urokinase. Blood, 58:97-104, 1981.
pubmed

31) Collen, D., et al.:Metabolism of plasminogen in healthy subjects. Effects of tranexamic acid. J. Clin. Invest., 51:1310-1318, 1972.
pubmed

32) Rabiner, S. F., et al:Radioimmunoassay of human plasminogen and plasmin. J. Lab. Clin. Med., 74:265, 1969.
pubmed

33) Mattii, R., et al.:Production of members of the blood coagulation and fibrinolysin system by the isolated perfused liver. Proc. Soc. Exptl. Biol. Med., 116:69-72, 1964.

34) Barnhart, M. I. Riddle, J. M.:Cellular localization of profibrinolysin. Blood, 21:306-321, 1963.
pubmed

35) Highsmith, R. F., Kline, D. L.:Kidney:primary source of plasminogen after acute depletion in the cat. Science, 180:141, 1971.

36) Raum, D., et al.:Synthesis of human plasminogen by the liver. Science, 208:1036-1037, 1980.
pubmed

37) Bohmfalk, J. F. and Fuller, G. M.:Plasminogen is synthesized by primary cultu res of rat hepatocytes. Science, 209:408-410, 1980.

38) Saito, H., et al.:Production and release of plasminogen by isolated perfused rat liver. Proc. Natl. Acad. Sci. USA, 77:6837-6840, 1980.
pubmed

39) Isacson, S., Nillsson, I. M.:The kidneys and the fibrinolytic system in the blood. Thromb. Diath. Haemorrh., 22:211-215, 1969.

40) Siefring, G. E., Castellino, F.:De novo biosynthesis of plasminogen in the anephric rat. J. Applied. Physiology, 38:114-116, 1975.

41) Van den Hamer, C. J. A., et al,:Physical and Chemical studies in ceruloplasmin. IX. The role of galactosyl residues in the clearance of ceruloplasmin from the circulation. J. Biol. Chem., 245:4397-4402, 1970.
pubmed

42) Williams, J. R. B.:Fibrinolytic activity of urine. Brit. J. Exper. Path., 32:530-537, 1951.

43) Astrup, T., Sterndorff, I.:An activator of plasminogen in normal urine. Proc. Soc. Exptl. Biol. Med., 81:675-678, 1952.

44) Sobel, G. W., et al.:Urokinase:an activator of plasma profibrinolysin extracted from urine. Am. J. Physiol., 171:768-769, 1952.

45) Lesuk, A., et al:Crystalline human urokinase:some properties. Nature, 147:880-882, 1965.

46) White, W. F., et al.:The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry, 5:2160-2169, 1966.
pubmed

47) Soberano, M. E., et al.:Purification and characterization of two forms of urokinase. Biochim. Biophys. Acta, 445:763-773, 1976.
pubmed

48) Robbins, K. C., et al.:Plasmin and plasminogen activators:Kinetics, and kinetics of plasminogen activation, Ann. N. Y. Acad. Sci., 370:588-591, 1981.
pubmed

49) Clemmensen, I. and Christesen, F.:Inhibition of urokinase by complex formation with human ai.antirypsin. Biochim. Biophys. Acta, 429:591-599, 1976.

50) Clemmensen, I.:Inhibition of urokinase by complex formation with human antithrombin III in presence and absence of heparin. Thrombos. Haemostas., 39:616-623, 1978.

51) Vahtera, E. and Hamberg, U.:Interaction of urokinase with a2.macroglobulin investigated by isoelectric focusing:evidence for nonspecific dissociable binding. Biochem. J., 171:767-770, 1978.

52) Barlow, G. H and Lager, L.:Characterization of the plasminogen activator isolated from human embryo kidney cells:comparison with urokinase. Thromb. Res., 1:201-2081972.

53) Nolan, C., et al.:Plasminogen activators from humanembryonic kidney cell cultures. Biochim. Biophys. Acta, 496:384-400, 1977.

54) Rijken, D. C., et al.:Immunological characterization of plasminogen activator activity in human tissue and body fluid. J. Lab. Clin. Med., 97:477-486, 1981.
pubmed

55) Bernik, M B., et al.:Production by human tissue in culture of immunologically distinct, multiple molecular weight forms of plasminogen-.activators. Ann. N. Y. Acad. Sci., 370:592-608, 1981.
pubmed

56) VuKovich, Th., et al.:Different forms of urokinase. Vth Congress of the International Society on Thrombosis and Hemostasis. Abstruct, 92, 1975.

57) Aoki, N., Von Kaulla, K. N.:Dissimilarity of human vascular plasminogen activator and human urokinase. J. Lab. Clin. Med., 78:354-362, 1971.
pubmed

58) Aoki, N.:Preparation of plasminogen activator from vascular trees of human cadavers. Its comparison with urokinase. J. Biochem., 75:731-741, 1974.
pubmed

59) Rickli, E. E., Otavsky, W. I.:Release of an N.terminal peptide from human plasminogen during activation with urokinase. Biochim. Biophys. Acta, 295:381-384, 1973.

60) Walther, P. J., et al:Activation of human plasminogen by urokinase. Partial characteriza. tion of a pre.activation peptide. J. Biol. Chem., 249:1173-1181, 1974.

61) Robbins, K. C., et al:Physical and chemical properties of the NH2-terminal glutamic acid and lysine forms of human plasminogen and their derived plasmins with an NH2-terminal lysine heavy (A) chain. J. Biol Chem., 250:4044-4047, 1975.

62) Sodetz, J. M., Castellino, F. J.:The mechanism of activation of rabbit plasminogen by urokinase. J. Biol Chem., 250:3041-3049, 1975.
pubmed

63) Summaria, L., et al:The activation of plasminogen to plasm in by urokinase in the presence of the plasmin inhibitor trasylol. The preparation of plasmin with the same NH2.terminal heavy (A) chain sequence as the parent zymogen. J. Biol. Chem., 250:3988-3995, 1975.

64) Walther, P. J., et al.:The importance of the preactivation peptide in the two-stage mechanism of human p|asminogen activation. J. Biol Chem., 250:5926-5933, 1975.

65) Tillett, W, S., Garner, R. L.:The fibrinolytic activity of hemolytic streptococci. J. Exptl. Med., 58:485-502, 1933.

66) De Renzo, E. C., et al:Preparation and certain properties of highly purified streptokinase. J. Biol. Chem., 242:533-542, 1967.
pubmed

67) Summaria, L, et al.:The interaction of streptokinase with human, cat, dog, and rabbit plasminogens. The fragmentation of streptokinase in the equimolar plasminogen.streptokinase complex. J. Biol. Chem., 249:4760-4769, 1974.
pubmed

68) Davies, M. C., et al:Interaction of streptokinase and human plasminogen. I. Combining of streptokinase and plasminogen observed in the ultracentrifuge under a variety of experimental conditions. J. Biol Chem., 239:2651-2656, 1964.

69) Blatt, W. F., et al.:Purification of streptokinase and human plasmin and their interaction. Thromb. Diath. Haemorrh., 11:393-403, 1964.
pubmed

70) McClintock, D. K., et al.:Two distinct pathways of the streptokinase.mediated activation of highly purified human plasminogen. Biochemistry, 13:5334-5344, 1974.
pubmed

71) Reddy, K. N. N., Markus, G.:Esterase activities in the zymogen moiety of the streptokinase-plasminogen complex. J. Biol. Chem., 249:4851-4857, 1974.

72) Reddy, K. N. N., Markus, G.:Mechanism of activation of human plasminogen by strepto. kinase. Presence of active center in streptokinase.plasminogen complex. J. Biol. Chem., 247:1683-1691, 1972.

73) Chesterman, C. N., et al:The degradation of streptokinase during the production of plas. minogen activator. Thrombosis Res., 5:413-419, 1974.

74) Taylor, F. B., Jr., Beisswenger, J. G.:Identification of modified streptokinase as the activator of bovine and human plasminogen. J. Biol. Chem., 248:1127-1134, 1973.
pubmed

75) McClintock, D. K., Bell, P. H.:The mechanism of activation of human plasminogen by streptokinase. Biochem. Biophys. Res. Commun., 43:694-702, 1971.
pubmed

76) Buck, F. F., Boggiano, E.:Interaction of streptokinase and human plasminogen. VI. Function of the streptokinase moiety in the activator complex. J. Biol. Chem., 246:2091-2096, 1971.
pubmed

77) Buck, F. F., et al,:Interaction of streptokinase and human plasminogen V. Studies on the nature and mechanism of formation of the enzymatic site of the activator complex. J. Biol. Chem., 243:3648-3654, 1968.
pubmed

78) Chesterman, C. N., et al.:The degradation of streptokinase during the production of plasminogen activator. Thrombosis Res., 5:413-419, 1974.

79) Greig, H. B. W., Cornelius, E. M.:Isolation of a proactivator from human plasma fraction III. Biochim. Biophys. Acta, 57:617-619, 1962.

80) Cederholm.Williams, S. A., et al.:Kinetics of the reactions between streptokinase, plasmin and a2 antiplasmin. Eur. J. Biochem., 100:125-132, 1979.

81) Wiman, B.:On the reaction of plasmin or plasminogen.streptokinase complex with aprotinin or a2 antiplasmin. Thromb. Res., 17:143-152, 1980.

82) Cederholm-Williams, S. A.:The effect of streptokinase on the fibrin binding site of plasmin. (ogen). Thromb. Res., 21:649-654, 1981.
pubmed

83) Okamoto, S., et al:Asuppressing effect of ε.aminocaproic acid on the bleeding of dogs pro. duced with the activation of plasmin in the circulatory blood. Keio J. Med., 8:247-266, 1959.

84) Okamoto, S., et al.:Synthetic inhibitors of fibrinolysis:in vitro and in vivo mode of action. Ann. N. Y. Acad. Sci., 146:414-429, 1968.
pubmed

85) Todd, A. S.:The histological localization of fibrinolysin activator. J. Pathol. Bacteriol., 78:281-283, 1959.
pubmed

86) Loskutoff, D. J. and Edgington, T. S.:Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc. Natl. Acad. Sci. USA, 74:3903-3907, 1976.

87) Aoki, N. and von Kaulla, K. N.:The extraction of vascular plasminogen activator from human cadavers and a description of some of its properties. Am. J. CIin. Path., 55:171-179, 1971. 88) Highsmith, R. F.:Isolation and properties of a plasminogen activator derived from canine vascular tissue. J. Biol. Chem., 256:6788-6795, 1981.

89) Izaki, S. and Kitaguchi, H.:Calcium dependent and independent release of plasminogen activator from the vascular wall. Thrombos. Res., 10:765-770, 1977.

90) Kitaguchi, H., et al:Effect of thrombin on plasminogen activator release from isolated per. fused dog leg. Thrombos. Res., 16:407-420, 1979.

91) Hirata, M., et al.:A futher study on plasminogen activator release by vasoactive agents in the isolated perfused dog leg. Kobe J. Med. Sci., 26:101-108, 1980.

92) Hijikata, A., et al.:Effect of proteases on plasminogen activator release from isolated perfused dog leg. Thrombos. Res., 20:521-531, 1980.

93) Bachmann, F., et al.:Partial purification and properties of the plasminogen activator from pig heart. Biochemistry, 3:1578-1585, 1964.
pubmed

94) Ali, S. J. and Evans, L.:Purification of rabbit kidney cytokinase and comparison of its properties with human urokinase. Biochem. J., 107:293-503, 1968.

95) Kok, P. and Astrup, T.:Isolation and purification of a tissue plasminogen activator and its comparison with urokinase. Biochemistry, 8:79-86, 1969.
pubmed

96) Rickli, E. E. and Zaugg, H.:Isolation and purification of highly enriched tissue plasminogen activator from pig heart. Thromb. Diath. Haemorrh., 23:64-76, 1970.
pubmed

97) Hijikata, A., et al:Some properties of the tissue plasminogen activator from the pig heart. Thrombos. Res., 4:731-740, 1974.

98) Cole, E. R. and Bachmann, F. W.:Purification and properties of a plasminogen activator from pig heart. J. Biol. Chem., 252:3729-3737, 1977.

99) Rijken, D. C., et al:Purification and partial characterization of plasminogen activator from human uterino tissue. Biochem. Biophys. Acta, 580:140-153, 1979.

100) Rijken, D. C., et al.:Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thrombos. Res., 18:815-830, 1980.

101) 船原芳範. 他:エールリッヒ腹水癌細胞接種マウス腹水, 癌細胞等の線溶動態:プラスミノーゲン.アクチベーターの産生.放出について. 第19回プラスミン研究会報告集, 22-32, 1979.

102) Okamoto, U. and Takada, Y.:Prolonged hyperplasminaemia with mitomycin C in rabitts:Reversible disappearance of tissue activator in parenchyma of kidney. Keio J. Med., 13:165-172, 1964.

103) Kira, S., et al.:The experimental hyperfibrinolysis of joint fluid in dogs produced by injection of an iodine compound:Immediate releasing of tissue activator of synovial membrane. Kobe J. Med. Sci., 11:89-95, 1965.
pubmed

104) Oshiba, S., et al:A plasminogen activator in mammalian bile. Jap. J. Physiol., 19:212-219, 1969.

105) Oshiba, S., Ariga, T.:Purification and characterization of bilokinase, a biliary plasminogen activator. Vth Congress of the International Society on Thrombosis and Haemostasis. Abstracts, 20, 1975.

106) Zaneveld, L. J. D., et al:The proteolytic enzyme systems of mammalian genital truct secretions and spermatozon. Proteases and biological control. Cold Spring Harbor Conferences on Cell Proliferation (Reich, E., Rifkin, D. B. and Shaw, E. eds.) Vol.2, 1975. p. 691.

107) Astrup, T. and Sterndorff, I.:A fibrinolytic system in human milk. Proc. Soc. Exp. Biol Med., 84:605, 1953.
pubmed

108) 岡本歌子, 他:人乳におけるplasminogen活性化系の研究. I.人乳中のplasminogen activatorおよびproactivatorの分離とその分子量. 日血会誌, 37:121, 1974.

109) Robbins, K. C., et al.:The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J. Biol Chem., 242:2333-2342, 1967.
pubmed

110) Groskopf, W. R., et al.:Studies on the active center of human plasmin. The serine and histi. dine residues. J. Biol Chem., 244:359-365, 1969.

111) Robbins, K. C., et al:NH2.terminal sequence of mammalian plasminogens and plasmin S. carboxymethyl heavy (A) and light (B) chain derivatives. A re.evaluation of the mechanism of activation of plasminogen. J. Biol. Chem., 248:7242-7246, 1973.

112) Groskoff, W. R., et al.:Studies on the active center of human plasmin. Partial amino acid sequence of a peptide containing the active center serine residue. J. Biol. Chem., 244:3590-3597, 1969.

113) Robbins, K. C., et al.:The primary structure of human plasminogen. II. The histidine loop of human plasmin light (B) chain active center histidine sequence. J. Biol Chem., 248:1631-1633, 1973.

114) Murano, G., et al:Human fibrinogen:Some characteristics of its S-carboxymethyl derivative chains. Thrombosis, Res., 1:161-172, 1972.

115) Pizzo, S. V., et al.:The effect of plasmin on the subunit structure of human fibrinogen. J. Biol Chem., 247:636-645, 1972.
pubmed

116) Furlan, M., et al.:Plasmic degradation of human fibrinogen. III. Molecular model of the plasmin.resistant disulfide knot in monomeric fragment D. Biochim. Biophys. Acta, 400:95-111, 1975.
pubmed

117) Furlan, M., et al.:Plasmic degradation of human fibrinogen. IV. Identification of subunit chain remnants in fragment Y. Biochim. Biophys. Acta, 400:112-120, 1975.
pubmed

118) Triantaphylopoulus, D. C.:Anticoagulant effect of incubated fibrinogen. Canad. J. Biochem. Physiol., 36:249-259, 1958.

119) Barnhart, M. I., et al.:Influence of fibrinogen split products on platelets. Thromb. Diath. Haemorrh., 17:78-98, 1967.
pubmed

120) Sherry, S.:Current status of fibrinogen and fibrin degradation products. Thromb. Diath. Haemorrh., Suppl. 39:169-173, 1970.

121) Bocci, V., et al:Factors regulating plasma protein synthesis. IV. Influence of fragment D and E on plasma fibrinogen concentration. Thromb. Diath. Haemorrh., 31:395-402, 1974.

122) Wiman, B.:Primary structure of the β-chain of human plasmin. Eur. J. Biochem., 76:129-137, 1977.

123) Ittyerah, T. R., et al.:Effect of fibrin degradation products and fibrin on fibrinogen synthesis. Br. J. Haematol., 43:661-668, 1979.
pubmed

124) Pizzo, S. V., et al.:The effect of plasmin on the subunit structure of human fibrin. J. Biol. Chem., 248:4574-4583, 1973.
pubmed

125) Pizzo, S. V., et al.:Subunit structure of fragment D from fibrinogen and cross-linked fibrin. J. Biol Chem., 248:4584-4590, 1973.
pubmed

126) Moroi, M. and Aoki, N.:Isolation and characterization of a2.plasmin inhibitor from human plasma. J. Biol. Chem., 251:5956-5965, 1976.

127) Wiman, B. and Collen, D.:On the kinetics of the reaction between human antiplasmin and plasmin. Eur. J. Biochem., 84:573-578, 1978.
pubmed

128) Koren, R. and Hammes, G. G.:Akinetic study of protein-protein interaction. Biochemistry, 15:1165-1171, 1976.

129) Aoki, N., et al.:Effects of a2-plasmin inhibitor on fibrin clot lysis its comparison with a2. macroglobulin. Thrombos. Haemostas. (Stuttg.), 39:22-31, 1978.

130) Sakata, Y. and Aoki, N.:Cross.linking of a2.plasmin inhibitor to fibrin by fibrin-stabilizing factor. J. Clin. Invest., 65:290-297, 1980.

131) Aoki, N. and Sakata, Y.:Influene of a2-plasmin inhibitor on adsorption of plasminogen to fibrin. Thrombos. Res., 19:149-155, 1980.

132) Harpel, P. C.:a2-plasmin inhibitor and a2-macroglobulin.plasmin complex in plasma. J. Clin. Invest., 68:46-55, 1981.

133) Roberts, R. C., et al:Studies on the quaternary structure of human serum a2-macroglobulin. Bayer Symposium "Proteinase Inhibitors" . Springer.Verlag, 1974. p. 63-71.

134) Jones, J. M., et al.:Thiol reduction of human a2-macroglobulin the subunit structure. Bio:chem. J., 127:187-197, 1972.

135) Schultze, H. F. and Heremans, I. F.:Molecularbiology of human proteins with special re. ference to plasma proteins. Vol. 1. Nature and metabolism of extracellular proteins. (Amsterdam):Elsevier Publishing Company, 1966. p. 179.

136) Heimberger, N.:Biochemistry of proteinase inhibitors from human plasma. A review of recent developments. Proteinase Inhibitors, Proc. of the Second Int. Res. Conf. Bayer Symp. (Fritz, V. H., Tschesche, H., Greene, L J. and Truscheit, E., eds.) Springer-Verlag, 1974. p. 14-22.

137) Barret, A. J. and Starkey, P. M.:The interaction of a2.macroglobulin with proteinase. Cha. racteristics and specificity of the reaction; and a hypothesis concerning its molecular mech. anism. Biochem. J., 133:709, 1973.

138) James, K, et al:The effect of a2.macroglobulin in human serum of trypisin, plasmin and thrombin activities. Biochem. Biophys. Acta, 133:374, 1967.

139) Haupt, H., et al:Ein beitrag zur Isolierung und Charakterisierung des C1-Inaktivators aus Humanplasma. Eur. J, Biochem., 17:254-261, 1970.

140) Schreiber, A. D., et al.:Inhibition by CIINH of Hageman factor fragment activation of coagulation, fibrinolysis, and kinin generation. J. Clin. Invest., 52:1402-1409, 1973.

141) Pannell, R.:Isolation and properties of human plasmaa-1-proteinase inhibitor. Biochemistry, 13:5439-5445, 1974.

142) Johnson, D. A., et al.:The molecular stoichiometry of trypsin inhibition by human alpha.1proteinase inhibitor. Biochem. Biophys. Res. Commun., 57:584-589, 1974.

143) Schultze, H. E., Heremans, J. F.:Molecularbiology of human proteins with special reference to plasma proteins. Vol. 1. Nature and Metabolism of Extracellular Proteins. Amsterdam:Elsevier Publishing Company, 1966. p. 179.

144) Crawford, G. P. M, and Ogston, D.:The action of antithrombin III on plasmin and activators of plasminogen. Biochim. Biophys. Acta, 391:189-192, 1975.

145) Miller-Anderson, et al.:Purification of antithrombin III by affinity chromatography. Throm. bosis Res., 5:439-452, 1974.

146) Rosenberg, R. D, and Damus, P. S.:The purification and mechanism of action of human an. tithrombin-heparin cofactor, J. Biol. Chem., 248:6490-6505, 1973.
pubmed

147) Heimburger, N.:Biochemistry of proteinase inhibitors from human plasma:A review of recent development. Bayer.Symposium V "Proteinase Inhibitors", Springer. Verlag, 1974. p. 14-22.

148) Markus, G., et al.:Quantitative determination of the binding of E-aminocaproic acid to native plasminogen. J. Biol. Chem., 253:727-732, 1978.

149) Markus, G., et al:Comparison of some properties of native (Glu) and modified (Lys) human plasminogell. J. Biol. Chem., 253:732-739, 1978.

150) Markus, G., et al.:The binding of tranexamic acid:to native (Glu) and modified (Lys) human plasminogen and its effect on conformation. J. Biol. Chem., 254:1211-1216, 1979.
pubmed

151) Lerch, P. G., et al.:Localization of individual lysine-binding regions in human plasminogen and investigations on their complex-forming properties. Eur. J. Biochem., 107:7-13, 1980.
pubmed

152) Bertelli, A., Fontino, G.:Protection of the skin homografts by ε.acetamide caprioic acid. Nature, 197:510-511, 1963.

153) Gillette, R, W., et al:Prolonged survival of homografts in mice treated with EACA. Transplantation, 1:116-117, 1963.
pubmed

154) Rowinski, W. A., Hager, E. B.:Immunosuppressive effect of epsilon aminocaproic acid (EACA). J. Surg. Res., 6:58-63, 1966.

155) Frank, M. M., et al.:Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. Adouble-blind study. N. Engl. J. Med., 286:808-812, 1973.

156) Pence, H. L., et al.:Prophylactic use of epsilon aminocaproic acid for oral surgery in a patient with hereditary angioneurotic edema. J. Allergy Clin. Immunol., 53:298-302, 1974.

157) Soter, N. A., et al:Inhibition by ε.aminocaproic acid of the activation of the first component of the complement system. J. Immunology, 114:928-932, 1975.

158) Ratnoff, O. D., Colopy, J. E.:Afamilial hemorrhagic trait associated with a deficiency of aclot-promoting fraction of plasma. J, Clin. Invest., 34:602-613, 1955.

159) Niewiarowski, S., Prou.Wartelle, O.:Role du facteur contact (Facteur Hageman) dans la fibrinolys. Thromb. Diath. Haemorrh., 3:535-603, 1959.

160) Iatridis, S. G., Ferguson, J. H.:Active Hageman factor:A plasma lysokinase of the human fibrjnolytic system. J, Clin. Invest., 41:1277-1287, 1962.

161) McDonagh, T. P., Jr., Ferguson, J. H.:Studies on the participation of Hageman factor in fibrinolysis. Thromb. Diath. Haemorrh., 24:1-9, 1970.

162) Nossel, H. L.:The contact phase of blood coagulation. Oxford:Blackwell Scientific Publications, 1964. p. 19-40.

163) Cochrane, C. G., et al:Activation of Hageman factor in solid and fluid phases. J. Exp. Med., 138:1564-1583, 1973.
pubmed

164) Margolis, J.:The mode of action on Hageman factor in the release of plasma kinin. J. Physiol., 151:238-252, 1960. 165) Margolis, J.:Pain-producing substance and blood clotting. Nature, 180:1464-1957.

166) Eisen, V.:Effect of hexadimethrine bromide on plasma kinin formation, hydrolysis of p-tosylarginine methyl ester and fibrinolysis. Brit. J. Pharmacology., 22:87-105, 1964.

167) Ratnoff, O. D., et al.:Studies on the action of Hageman factor. Evidence that activated Hageman factor in turn activate plasma thromboplastin anticedent. J. Clin. Invest., 40:803-819, 1961.

168) Hathaway, W. E., et al.:Evidence for a new plasma thromboplastin factor. I. Case report, Coagulation studies and physicochemical properties. Blood, 26:521-532, 1965.
pubmed

169) Wupper, K. D.:Prekallikrein deficiency in man. J. Exp. Med., 138:1345-1355, 1973.

170) Weiss, A. S., et al.:Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, che. motactic activity and kinin generation. J. Clin. Invest., 53:622-633, 1974.

171) Saito, H., et al:Defective activation of clotting, fibrinolytic and permeability.enhancing systems in human. Circulation Res., 34:641-651, 1974.
pubmed

172) Donaldson, V., et al:Defective esterase and kinin-forming activity in Fletcher trait plasma:afraction rich in kallikrein-1ike activity. Circulation Res., 34:652-662, 1974.

173) Schiffman, S., Lee, P.:Preparation, characterization, and activation of a highly purified factor XI:Evidence that a hitherto unrecognized plasma activity participates in the interaction of factor XI and XII. Brit. J. Haemat., 27:101-114, 1974.
pubmed

174) Schiffman, S., et al:Identity of contact activation cofactor and Fitzgerald factor. Throm. bosis Res., 6:451-454, 1975.

175) Waldmann, R., Abraham, J. P.:Fitzgerald factor:Aheretofore unrecognized coagulation factor. American Society of Hematology, 17th annual meeting, Abstract, 74, 1974.

176) Donaldson, V. H., et al:Kininogen deficiency in Fitzgerald trait:role of high molecular weight kininogen in clotting and fibrinolysis. J. Lab. Clin. Med., 87:327-337, 1976.
pubmed

177) Colman, R. W.:Williams trait:human kininogen dificiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factordependent pathways. J. Clin. Invest., 56:1650-1662, 1975.

178) Wuepper, K. D., et al:Flaujeac trait:deficiency of human plasma kininogen. J. Clin. Invest., 56:1668-1672, 1975.

179) Matheson, R. T., et al.:Flaujeac Factor Deficiency:reconstitution with high purified bovine high molecular weight-kininogen and delineation of a new permeability-inhancing peptide released by plasma kallikrein from bovine high molecular weight.kininogen. J. Clin. Invest., 58:1395-1406, 1976.

180) Saito, H., et al:Fitzgerald trait:Deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface.mediated reactions of clotting, fibrinolysis, generation of kinins and the property of diluted plasma enhancing vascular permeability (PF/dil). J. CIin. Invest., 55:1082-1089, 1975.

181) Heimark, R. L., et al:Surface activation of blood coagulation, fibrinolysis and kinin formation. Nature, 286:456-460, 1980.
pubmed

182) Greengard, J. S. and Griffin, J. H.:Contact activation reaction mechanisms. Prespective in hemostasis (Fareed, J., et al eds.), Revan Press, 1980. p. 21-30.

183) Kaplan, A. P., et al:Mechanisms for Hageman factor activation and role of HMW kininogen as a coagulation cofactor. Ann. N. Y. Acad. Sci., 370:253-260, 1981.
pubmed

184) Goldsmith, G. H., et al.:The activation of plasminogen by Hageman factor (Factor XII) and Hageman factor fragment. J. Clin. Invest., 62:54-60, 1978.
pubmed

185) Mandle, R. J. and Kaplan, A.P.:Hageman factor dependent fibrinolysis:generation of fibrinolytic activity by the interaction of human activated factor XI and plasminogen. Blood, 54:850-862, 1979.
pubmed

186) Mandle, R. J. and Kaplan, A. P.:Hageman factor substrates:Human kallikrein-mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis. J. Biol. Chem., 252:6097-6104, 1977.

187) Gallimore, M. J., et al:The purification of human plasma kallikrein with weak plasminogen activator activity. Thromb. Res., 12:409-420, 1978.
pubmed

188) Ward, P. A.:Aplasmin-split fragment of C:3as a new chemotactic factor.J.Exptl. Med., 126:189-206, 1967.

189) Brade, V., et al.:Formation of the C3.clearing properdin enzyme on zymosan. Demonstration that factor D is replaceable by proteolytic enzymes. J. Immun., 113:1735-1743, 1974.

190) Ratnoff, O. D., et al:The conversion of C:1S to C'1 esterase by plasmin and trypsin.J.Exp. Med., 125:337-358, 1967.

191) Goldberger, G. and Colten, H. R.:Precursor complement protein is (pro-C4) converted in vitro to native C4 by plasmin. Nature, 286:514-516, 1980.
pubmed

192) Mihara, H., et al.:Physiologycal influence of the plasminogen. Activator of ascites tumor cells in mice, Fibrinolysis in Health and Disease with Reference to Haemorrhage, Thrombosis, and Inflammatory Reactions (Okamoto, S., ed) 1971. p. 53-57.

193) Lazarowitz, S. G., et al.:Influenza virus structural and nonstructural proteins in infected cells and their plasma membranes. Virology, 46:830-843, 1971.
pubmed

194) Compans, R. W.:Influenza virus proteins. II. Association with components of the cytoplasm. Virology, 51:56-70, 1973.
pubmed

195) Goldberg, A. R.:Involvement of cell and serum proteases in exposing tumor. specific agglutinin sites. Ann. N. Y. Acad. Sci., 234:348-354, 1974.
pubmed

196) Unkeless, J., et al:Fibrinolysis associated with oncogenic transformation. Partial purification and characterization of the cell factor, a plasminogen activator. J. Biol. Chem., 249:4295-4305, 1974.
pubmed

197) Quigley, J. P., et al.:Plasminogen, the serum proenzyme activated by factors from cells transformed by oncogenic viruses. J. Biol. Chem., 249:4306-4311, 1974.
pubmed

198) Ossowski, L., et al.:Fibrinolysis associated with oncogenic transformation. Morphological correlates. J. Biol. Chem., 249:4312-4320, 1974,
pubmed

199) Goldberg, A. R., Lazarowitz, S, G.:PIasminogen activators of normal and transformed cells. Bayler.Symposium V "Proteinase Inhibitors", Springer.Verlag, 1974. p. 631-648.

200) Wigler, M. and Weinstein, I. B.:Tumor promotor induces plasminogen activator. Nature, 259:232-233, 1976.
pubmed

201) Loskutoff, D. J. and Paul, D.:Intracellular plasminogen activator activity in growing and quiescent cells. J. Cell. Physiol., 97:6-16, 1978.

202) Lewis, J. H., et al.:Thrombin formation; effects of lysin (fibrinolysin, plasmin) on pro. thrombin, Ac-globulin and tissue thromboplastin, J. Clin. Invest., 28:1507-1510, 1949.

203) Wagner, R. H., et al.:Further purification of antihemophilic factor (AHF) from dog plasma. Fed. Proc., 13:445-446, 1954.

204) Pasquini, R., Hershgold, E. J.:Effects of plasmin on human factor VIII (AHF). Blood, 41:105-111, 1973.
pubmed

205) Donaldson, V. H.:Effect of plasmin in vitro on clotting factors in plasma. J. Lab. Clin. Med., 56:644-651, 1960.
pubmed

206) Alagille, D., Soulier, J. P.:Action des enzymes proteolyligues sur le sang total in vivo; modification des facteurs de coagulation et du complement. Segmaine Hop. Paris, 32:355-359, 1956.

207) Seegers, W. H., Loomis, E. C.:Prothrombin and fibrinolysin. Science, 104:461-462, 1946.

208) Mirsky, I. A., et al.:The destruction of glucagon, adrenocorticotropin and somatotropin by human blood plasma. J. CIin. Invest., 38:14-20, 1959.

209) Davie, E. W. and Ratnoff, O. D.:The proteins of blood coagulation. The Protein, 3, N. Y.:Academic Press. 1965. p. 360-443.

5. 血小板

P.205 掲載の参考文献

1) Ebbe, S.:Megakaryocytopoiesis and platelet turnover. Series Haemat., 1:65-98, 1968.

2) Ebbe, S. and Stohlman, F.:Megakaryocytopoiesis in the rat. Blood, 26:20-35, 1965.
pubmed

3) Odell, T. T., Jackson, C. W. and Gosslee, D. G.:Maturation of rat megakaryocytes studied by micro spectrophotometric measurement of DNA. Proc. Soc. Exp. Biol Med., 119:1194-1199, 1965.

4) Penington, D. G and Olsen, T. E.:Megakaryocytes in states of altered platelet production:Cell numbers, size and DNA content. Brit. J. Haemat., 18:447-463, 1970.
pubmed

5) 野村武夫, 小野沢康輔, 長沢俊郎:特発性血小板減少性紫斑病における骨髄巨核球DNA量に関する研究. 厚生省特定疾患, 特発性血小板減少性紫斑病調査研究班. 昭和48年度研究業績報告書 (班長小宮正文), 昭和49年3月.P. 113-122.

6) Hirsh, J. and Doery, J. C. G.:Platelet Function in Health and Disease in Progress in Hema tology. VII. (Brown. E. B., Moore, C. V. eds.), New York:Grune & Stratton, 1971. p. 185-234.

7) Odell, T. T., Jackson, C. W. and Friday, T. J.:Megakaryocytopoiesis in rats with special reference to polyploidy. Blood, 35:775-782, 1970.
pubmed

8) Behnke, O.:An electron microscope study of the megakaryocyte of the rat bone marrow. I. The development of the demarcation membrane system and the platelet surface coat. J. Ultrastruct. Res., 24:412-433, 1968.

9) MacPherson, G. G.:Origin and development of the demarcation system in megakaryocytes of rat bonemarrow. J. Utrastruct. Res., 40:167-177, 1972.

10) Yamada, E.:The fine structure of the megakaryocyte in the mouse spleen. Acta Anat., 29:267-290, 1957.
pubmed

11) Jones, O. P.:Origin of megakaryocyte granules from Golgi vesides. Anat. Rec., 138:105, 1960. 12) MacPherson, G, G.:Synthesis and localization of sulphated mucopolysaccharide in megakaryocytes and platelets of the rat. An analysis by electron microscope autoradiography. J. Cell Sci., 10:705-717, 1972,

13) Tanaka, C., Kuruma, I., Kuramoto, A.:Histochemical demonstration of 5.hydroxytryptamine in platelets and megakaryocytes. Blood, 30:54-61, 1967.
pubmed

14) Silver, M. D., Gardner, H. A.:The very dense granule in rabbit platelets. J. Ultrastruct.Res., 23:366-377, 1968.
pubmed

15) Hoyer, L. W., de los Santos, R. P., Hoyer, J. R.:Antihemophilic factor antigen localization in endothelial cells by immunofluorescent microscopy. J. Clin. Invest., 52:2737-2744, 1973.
pubmed

16) Vazquez, J. J. and Lewis, J. H.:Immunochemical studies on platelets. The demonstration of a common antigen in human platelets and megakaryocytes. Blood, 16:968-974, 1960.

17) Behnke, O., Tinggaard Pederson, N.:Ultrastructural aspects of megakaryocyte maturatlon and platelet release. Platelets Production, Function, Transfusion and Storage. (Baldini, M.G. and Ebbe, S., eds.), New York:Grune & Stratton, 1974. p. 21.

18) Behnke, O.:An electron microscope study of rat megakaryocyte. ll. Some aspects of platelet release and microtubules. J. Ultrastruct. Res., 26:111-129, 1969.

19) Ebbe, S., Stohlman, F., Jr., et al.:Megakaryocyte size in thrombocytopenic and normal rats. Btood, 32:383-392, 1968.
pubmed

20) 山中學, 磯部淳一, 河野康太:新生血小板の粘着能について. 血液と脈管, 2:439-441, 1978.:

21) Odell, T. T., Jr., McDonald, T. P. & Detwiter, T. C.:Stimulation of platelet production by serum of platelet.depleted rats. Proc. Soc. Exp. Biol Med., 108:428-431, 1961.

22) Kelemen, E., Cserhati, I. and Tanas, B.:Demonstration of some properties of human thrombopoietin in thrombocythemic sera. Acta Haemat., 20:350-355, 1958.

23) Evatt, B, L., Levin, J.:Measurement of thrombopoiesis in rabbits using 75 selenomethionine. J. Clin. Invest., 48:1615-1626, 1969.
pubmed

24) Cooper, G. W., Cooper, B., Chong, C.:Demonstration of a circulating factor regulating blood platelet production using 35S-sulfate in rats and mice. Proc. Soc. Exp. Biol. Med., 134:1123-1127, 1970.

25) Erslev, A. J.:Platelet Kinetics. Platelets and thrombosis. (Sherry, S. & Scriabine, A., eds.), Baltimore:University Park Press, 1972. p. 126-137.

26) De Gabriele, G. and Penington, D. S.:Regulation of platelet production:"Thrombopoietin". Brit. J. Haemat., 13:202-209, 1967.

27) Aster, R. H.:Studies of the fate of platelets in rats and man. Blood, 34:117-128, 1969.
pubmed

28) Aster, R. H. and Jandl, J. H.:Platelet sequestration in man. II. Immunological and clinical studies. J. Clin. Invest., 43:856-869, 1964.
pubmed

29) Ebbe, S.:Origin, production, and life-span of blood platelets in the circulating platelet (Johnson, S. A, ed.), New York:Academic Press, 1971. p. 19-43.

30) Aser, R. H.:Pooling of platelets in the spleen, role in the pathogenesis of "hypersplenic" thrombocytopenia. J. Clin. Invest., 45:645-657, 1966.

31) Aster, R. H.:Studies of the mechanism of hypersplenic thrombocytopenia in rats. J. Lab. Clin. Med., 70:736-751, 1967.
pubmed

32) Matter, M., Hartmann, J. R., Kautz, J., Demarsh, Q. B, and Finch, C. A.:Astudy of thrombopoiesis in induced acute thrombocytopenia. Blood, 15:174-185, 1960.

33) Shulman, N. R., Watkins, S, P., Itscoitz, S. B. & Student, A. B.:Evidence that the spleen will change the youngest and homostatically most effective platelets. Trans. Ass. Amer. Phys., 81:302-313, 1968.

P.226 掲載の参考文献

1) Rebuck, J. W.:Blood platelets. Transfusion, 3:1-5, 1963.
pubmed

2) Johnson, S. A., et al.:The function of platelets, a review. Transfusion, 6:3-17, 1966.

3) Van Horn, D. L. and Johnson, S. A.:The mechanism of thrombocytopenic bleeding. Amer. J. Clin. Path., 46:204-213, 1966.

4) Morrison, F. S. and Baldini, M. G.:Antigenic relationship between blood platelets and vascular endothelium. Blood, 33:46-56, 1969.
pubmed

5) Johnson, S. A.:Endothelial supporting function of platelets. The Circulating Platelets (Johnson, S. A., ed.), New York:Academic Press, 1971. p. 283.

6) Harker, L. A. and Finch, C. A.:Thrombokinetics in man. J. Clin. Invest., 48:963-974, 1969.

7) Baumgartner, H. R. and Haudenschild, C.:Adhesion of platelets to subendothelium. Ann. N. Y. Acad. Sci., 201:22-36, 1972.
pubmed

8) Caen, J. P., et al:Platelet.collagen interactions. Thromb. Diath. Haemorrh., Suppl. 40:181-197, 1970.

9) Wilner, G. D., et al:Aggregation of platelets by collagen. J. Clin. Invest., 47:2616-2621, 1968.
pubmed

10) Wilner, G. D., et al:Activation of Hageman factor by collagen. J. Clin. Invest., 47:2608-2615, 1968.
pubmed

11) Gould, B. S.:Collagen biosynthesis, Treatise on Collagen (Gould, B, S., ed.), Vol. 2, Biology of Collagen, Part A, London:Academic Press, 1968, p. 139.

12) Jamieson, G. A., Urban, C., et al.:An enzymatic basis for platelet.collagen adhesion. ll. Congr. Interv. Soc. on Thrombosis and Haemostasis. Oslo. 1971. p. 220 (Abstr.).

13) Roseman, S.:The synthesis of complex carbohydrates by multiglycosyltransferase system and their potential function in intercellular adhesion. Chem. Phys. Lipids, 5:270-297, 1970.
pubmed

14) Bosmann, H. B.:Platelet adhesiveness and aggregation:The collagen:glycosyl, polypeptide:N-acetylgalactosamynyl and glycoprotein:galactosyl Biochem. Biophys. Res. Comm., 43:1118-1125, 1971.
pubmed

15) Puett, D., et al.:Collagen-induced platelet aggregation. J. Clin, Invest., 52:2495-2506, 1973.
pubmed

16) Kang, A. H., et al:Interaction of an active glycopeptide from chick skin collagen ( al.CBS) with human platelets, J. Biol. Chem., 249:1054-1059, 1974.

17) Chesney, C. McI., Harper, E., et al.:Critical role of the carbohydrate side chains of collagen in platelet aggregation. J. CIin. Invest., 51:2693-2701, 1972.

18) Jaffe, R. and Deykin, D.:Evidence for a structural requirement for the aggregation of platelets by collagen. J. Clin. Invest., 53:875-883, 1974.
pubmed

19) 青木延雄:コラゲン分子内リジン残基周辺構造に近似せる諸種合成化学物質による血小板凝集の抑制について(第1報). 昭和49年第36回日血総会抄録, 1974. p.137.

20) 山中學. 他:血小板機能について, 臨床血液, 16:387-394, 1975.

21) Holmsen, H., et al.:The blood platelet release reaction. Scand. J. Haemat., Suppl. 8:1-26, 1969.

22) Stormorken, H.:The release reaction of secretion. Scand. J. Haemat., 5:401-414, 1968.

23) White, J. G.:Platelet morphology. The Circulating Platelet (Johnson, S. A., ed.), New York:Academic Press, 1971. p. 45.

24) MUrer, E. H.:Thrombin-induced release of calcium from blood platelets. Science, 168:623, 1969.

25) Mills, D. C. B., et al.:The release of nucleotides 5-hydroxy-tryptamine and enzymes from hu. man blood platelets during aggregation. J. Physiol., 193:443-453, 1967.

26) Holmsen, H, and Day, H. J.:The selectivity of the thrombin-induced platelet release reac. tion:subcellular localization of released and retained constituents. J. Lab. Clin. Med., 75:840-855, 1970.

27) Davey, M. G. and LUscher, E. F.:Release reactions of human platelets induced by thrombin and other agents. Biochim. Biophys. Acta, 165:490-506, 1968.
pubmed

28) Niewiarowski, S., et al.:The release of platelet clotting factors during aggregation and viscous metamorphosis, Platelets in Hemostasis (Hagen, E., Wechsler, W., Zilliken, F. eds), Experimental Biology and Medicine, Vol 3, New York, 1968. p. 121-128.

29) Hovig, T.:Release of a platelet-aggregating substance (adenosine diphosphate) from rabbit blood platelets induced by saline" extract" of tendons. Thromb. Diath. Haemorrh., 9:264-278, 1963.

30) Grette, K.:Relaxing factor in extracts of blood platelets and its function in the cells. Nature, 198:488-489, 1963.
pubmed

31) Mills, D. C. B., et al:Release of nucleotides 5-hydroxytryptamnine and enzymes from human blood platelets during aggregation. J. Physiol., 195:715-729, 1968.

32) Benke, O. and Zellander, T.:Substructure in negatively stained microtubules of mammalian blood platelets. Exper. Cell Res., 43:236-239, 1966.

33) Benke, O.:Further studies on microtubules. A marginal bundle in human and rat thrombocytes. J. Ultrastruct. Res., 13:469-477, 1965.

34) Zucker, M. B. and Borrelli, J.:Resersible alteration in platelet morphology produced by an. ticoagulants and by cold. Blood, 9:602-608, 1954.
pubmed

35) White, J. G.:Effects of colchicine and vinca alkaloids of human platelets. 1, Influence on platelet microtubules and contracti (e function. Amer. J. Path., 53:281-289, 1968.

36) White, J. G.:Platelet microtubules and microfilaments. Effects of cytochalasin B on structure and function. Platelet Aggregation (Caen, J., ed.), Paris:Masson, 1971. p. 15.

37) White, J. G.:Electron microscopic studies of platelet-secretion. Progress in Hemostasis and Thrombosis (Space, T. H., ed.), New York:Grune and Stratton, 1974. p. 49.

38) Haslam, R. J.:Biochemical aspects of platelet function. In Proc. XII Congr. Intern. Soc. Haemat., New York, 1968. p. 198.

39) Gaarder, A., et al.:Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets, Nature, 192:531-532, 1961.
pubmed

40) Born, G. V. R.:Aggregation of blood platelets by adenosine diphosphate and its reversal Nature, 194:927-929, 1962.

41) 0:Brien, S. R.:Platelet aggregation, Part II. Some results from a new method of study. J. Clin. Path., 15:452-455, 1962.

42) MacMillan, D. C. and Oliver, H. F.:The initial changes in platelet morphology following the addition of adenosine diphosphate. J. Atheroscler. Res., 5:440-444, 1965.

43) 0:Brien, J. R. and Heywood, J. B.:Effect of aggregating agents and their inhibitors on the mean platelet shape. J. Clin. Path., 19:148-153, 1966.

44) Bull, B. S. and Zucker, M. B.:Changes in platelet volume produced by temperature, metabolic inhibitors and aggregating agents. Proc. Soc. Exp. Biol Med., 120:296-301, 1965.
pubmed

45) Born, G. V. R.:Observations on the change in shape of blood platelets brought about by adenosine diphosphate. J. Physiol., 209:487-511, 1970.

46) MacMillan, D. C.:Secondary clumping effect in human citrated platelet-rich plasma produced by adenosine diphosphate and adrenaline. Nature, 211:140-144, 1966.
pubmed

47) O'Brien, J. R,:Effect of adenosine diphosphate and adrenaline on mean platelet shape.Nature, 207:306-307, 1965.
pubmed

48) O'Brien, J. R.:Changes in platelet membranes possibly associated with platelet stickness. Nature, 212:1057-1058, 1966.

49) Marquis, N. R., et al:Platelet aggregation III. An epinephrine induced decrease in cyclic AMP synthesis. Biocheln. Biophys. Res. Comm., 39:783-789, 1970.

50) Hovig, T.:The effect of calcium and magnesium on rabbit blood platelet aggregation in vitro. Thromb. Diath. Haemorrh., 12:179-200, 1964.
pubmed

51) Cross, M. J.:Effect of fibrjnogen on the aggregation of platelets by adenosine diphosphate. Throm. Diath. Haemorrh., 12:524-527, 1964.

52) Mustard, J. F. and Packham, M. A.:Factors influencing platelet function-adhesion, release and aggregation. Pharmacol Rev., 22:97-187, 1970.
pubmed

53) Inceman, S., Caen, J. and Bernard, J.:Aggregation, adhesion and viscous metamorphosis of platelets in congenital fibrinogen deficiencies. J. Lab. Clin. Med., 68:21-32, 1966.
pubmed

54) Sharp, A. A., et al:Anticoagulant therapy with a purified fraction of Malayan pit viper venom. Lancet, i:493-499, 1968.
pubmed

55) Hellem, A. J:Platelet adhesiveness. Series Haemat., 1:99-145, 1968.

56) Gokeen, M. and Yunis, E.:Fibrinogen as a part of platelet structure. Nature, 200:590-591, 1963.

57) Cooper, I. A. and Firkin, B. G.:Amino acid transport into human platelets and subsequent in. corporation into protein. Thromb. Diath. Haemorrh., 23:140-147, 1970.

58) Nachman, R. L. and Marcus, A. J.:Immunological studies of proteins associated with subcellular fractions of thrombasthenic and a fibrinogenemic platelets. Brit. J. Haemat., 15:181-189, 1968.

59) Ardlie, N. G. and Han, P.:Enzymatic basis for platelet atomosphere and the relationship between platelet function and blood coagulation. Brit. J. Haemat., 26:331-356, 1974.

60) Han, P. and Ardlie, N. G.:Platelet aggregation and release by ADP and thrombin. Evidence for two separate effects of ADP on platelets, involvement of fibrinogen in release and me. chanism of inhibitory action of acetylsalicylic acid. Brit. J. Haemat., 26:357-372, 1974.

61) Haslam, R. J.:Role of adenosine diphosphate in the aggregation of human blood platelets by thrombin and by fatty acids. Nature, 202:765-768, 1964.
pubmed

62) Ireland, D. M.:Effect of thrombin on radioactive nucleotides of human washed platelets. Biochem. J., 105:857-867, 1967.
pubmed

63) Haslam, R. J.:Mechanisms of blood platelet aggregation. Physiology of Hemostasis and Thrombosis (Johnson, S. A. and Seegers, W. H., Eds.), Springfield, I11.:Charles C. Thomas, 1967. p. 88.

64) Born, G. V. R.:The platelet membrane and its functions. Plenary Session, XII Congr. Int. Soc. Hemat., New York, 1968. p. 95.

65) Born, G. V. R. and Gillson, R. E.:Studies on the uptake of 5.hydroxytryptamine by blood platelets. J. Physiol., 146:472-491, 1959.

66) Born, G. V. R. and Brickness, J.:The uptake of 5-hydroxytryptamine by platelets in the cold. J. Physiol., 147:153-161, 1959.

67) Baumgartner, H. R. and Born, G. V. R.:Effects of 5-hydroxytryptamine on platelet aggrega. tion. Nature, 218:137-141, 1968.

68) 0:Brien, J. R.:Some effects of adrenaline and anti.adrenaline compounds on platelets in vitro and in vivo. Nature, 200:763-764, 1963.

69) Salzman, E. W. and Neri, L. L:Profiles of activity in rodents of some narcotic and narcotic antagonist drugs. Nature, 224:610-612, 1969.

70) Ardlie, N. G., et al.:Influence of catecholamines on nucleotide-induced platelet aggregation. Nature, 212:415-417, 1966.
pubmed

71) Mills, D. C. B. and Roberts, G. C.:Effects of adrenaline on human blood platelets. J. Physiol., 193:443-453, 1967.

72) Kerr, J. W., et al:Platelet aggregation by phospholipids and free fatty acids. Lancet, i:1296-1299, 1965.
pubmed

73) Schulz, H. and Landgraber, E.:Elektronen-microskopische Untersuchungen Uber die Absorption und Phagocytose von Influenza Viren durch Thrombocyten. Klin. Wschr., 44:998-1006, 1966.

74) Movat, H. Z., et al.:Platelet phagocytosis and aggregation. J. Cell Biol., 27:531-543, 1965.
pubmed

75) Lewis, N. and Majerus, P. W.:Lipid matebolism in human platelets. II. De novo phospholipid synthesis and the effect of thrombin on the patterns of synthesis. J. Clin. Invest., 48:2114-2123, 1969.

76) Booyse, F. M. and Rafelson, M. E., Jr.:Studies on human platelets. I. Synthesis of platelet protein in a cell-free system. Biochim. Biophys. Acta, 166:689-697, 1968.

77) Majerus, P. W., et al.:Lipid metabolism in human platelets. Evidence for a complete fatty acid synthesizing system. J. Clin. Invest., 48:156-164, 1969.
pubmed

78) Vainer, H. and Wattiaux, R.:Glycogen synthetase activity in blood platelets. Nature, 217:951-952, 1968.

79) Pletscher, A.:Metabolism, transfer and storage of 5-hydroxytryptamine in blood platelets. Brit. J. Pharmacol. Chemother., 32:1-16, 1968.
pubmed

80) Gorstein, F., et al.:Electrolyte concentration, potassium flux.Kinetics and the metabolic depen. dence of potassium transport in human platelets. J. Lab. Clin. Med., 70:938-950, 1967.

81) MUrer, E. H.:Release reaction and energy metabolism in blood platelets with special reference to the burst in oxygen uptake. Biochim. Biophys. Acta, 162:320-326, 1968.

82) MUrer, E. H., et al.:Energy metabolism and platelet function. Scand. J. Clin. Lab. Invest., 19:280-282, 1967.

83) Kinlough.Rathbone, R. L., et al.:The effect of glucose on adenosine diphosphate induced platelet aggregation. J. Lab. Clin. Med., 75:780-787, 1970.
pubmed

84) Kuramoto, A., et al.:Metabolic basis of platelet phagocytosis. Biochim. Biophys. Acta, 201:471-478, 1970.
pubmed

85) Bettex-Galland, M. and Lifschor, E. F::Studies on the metabolism of human blood platelets in relation to clot retraction. Thromb. Diath. Haemorrh., 4:178-195, 1960.

86) Mttrer, E. H.:Clot retraction and energy metabolism of platelets. Effect and mechanism of inhibitors. Biochim. Biophys. Acta, 172:266-276, 1969.

87) Doery, J. C. G., et al::Energy metabolism in human platelets:Interrelationship between glycolysis and oxidative metabolism. Blood, 36:159-168, 1970.

88) Scott, R. B.:Activation of glycogen phosphorylase in blood platelets. Blood, 30:321-330, 1967.
pubmed

89) Hovig, T.:The ultrastructure of blood platelets in normal and abnormal states. Series Haemat., 1:3-64, 1968.

90) Rosenweig, A. and Ways, P.:The oxidation of long chain fatty acids by the formed elements of human blood. Blood, 27:57-64, 1966.

91) Holmsen, H., et al.:Adenine nucleotide metabolism of blood platelets. VI Subcellular localiza. tion of nucleotide pools with different functions in the platelet release reaction. Biochim. Biophys. Acta, 186:254-266, 1969.

92) Holmsen, H. and Weiss, H. J.:Hereditary defect in the platelet release reaction caused by a deficiency in the storage pool of platelet adenine nucleotides. Brit. J. Haemat., 19:643-649, 1970.

93) Logan, L. J., et al.:Albinism and abnormal platelet function. New Engl. J. Med., 284:1340-1345, 1971.
pubmed

94) Holmsen, H.:Compartmentation of adenine nucleotides in platelets. Erythrocytes, Thrombo. cytes, Leukocytes. Recent advances in membrane and metabolic research (Gerlach, E., Moser, K., Deutsch, E., Wilmanns, W., eds.), Stuttgart:Georg Thieme, 1973. p. 321.

95) Weiss, H. J. and Ames, R. P.:UItrastructural findings in storage pool disease and aspirin. like defects of platelets. (J. Clin. Invest., 51:102A, 1972) ; Am. J. Pathol., 71:447-466, 1973.

96) Karpatkin, S. and Langer, R, H.:Biochemical energetics of simulated platelet formation. Effect of thrombin, adenosine diphosphate, and epinephrine on intra-and extracellular adenine nucleotide kinetics. J. Clin. Invest., 47:2158-2168, 1968.

97) Loder, P. B., et al:The effect of collagen on platelet glycolysis and nucleotide metabolism. Brit. J. Haemat., 14:563-573, 1968.
pubmed

98) Karpatkin, S. and Siskind, G. W.:Effect of antibody binding and agglutination on human platelet glycolysis. Comparison with thrombin and epinephrine. Blood, 30:617-624, 1968.

99) Detwiler, T. C.:Failure of thrombin to affect platelet respiration. Arch. Biochem. Biophys., 120:721-722, 1967,

100) Kitchens, G. S. and Newcomb, T. F.:Human platelet respiration. J. Appl Physiol., 25:581-585, 1968.

101) Budtz-Olsen, O. E.:Clot retraction. Oxford:Blackwell, Scientific Publications, 1951.

102) LUscher, E. F.:Glukose als Cofaktor.bei der Retraktion des Blutgerinnsels. Experimentia, 12:294, 1956.

103) Bettex-Galland, M. and LUscher, E. F.:Thrombosthenin.a contractile protein from thrombocytes. Extraction from human blood platelets and some of its properties. Biochim. Biopllys. Acta, 49:536-547, 1961.

104) Born, G. V. R.:Changes in the distribution of phosphorus in platelet rich plasma during clotting. Biochem. J., 68:695-704, 1958.

105) Cohen, I., et al.:Thrombosthenin M, purification and interaction with thrombin. Eur. J. Biochem., 10:388-394, 1969.
pubmed

106) Booyse, F. M. and Raphelson, M. E., Jr.:In vitro incorporation of amino acids into contractile protein of human blood platelets. Nature, 215:283-284, 1967.

107) Johnson, S. A.:Platelets in hemostasis and thrombosis. The Circulating PIatelet (Johnson, S. A., ed.), New York:Academic Press, 1971. p. 355.

108) Marcus, A, J. and Zucker, M. B.:The physiology of blood platelets. New York:Grune and Stratton, 1965. p. 53.

109) Ardlie, N. G., et al:Inhibition and reversal of platelet aggregation by methyl xanthines. Thromb. Diath. Haemorrh., 18:670-673, 1967.
pubmed

110) Marquis, N. R, et al:Platelet aggregation. I. Regulation by cyclic AMP and prostaglandin E, . Biochem. Biophys. Res. Comm., 36:965-972, 1969.

111) Wolfe, S. H. and Schulman, N. R.:Adenyl cyclase activity in human platelets. Biochem. Biophys. Res. Comm., 35:265-272, 1969.

112) Salzman, E. W.:Inhibition of platelet aggregation by cyclic AMP and dibutyryl cyclic AMP. Fed. Proc., 29:316, 1970.

113) Marquis, N. R., et al.:Cyclic AMP dependent platelet protein kinase. Fed. Proc., 30:423 (Abs), 1971.

114) Guccione, M. A., et al:Reaction of i4C.APP and 14C-ATP with washed platelets from rabbits. Blood, 37:542-555, 1971.

115) Robinson, G. A., et al:Divergent effect of epinephrine and prostaglandin El on the level of cyclic AMP in human blood platelets. Pharmacol. Res. Comm., 1:325-332, 1969.

116) Zieve, P, D. and Greenough, W. B.:Adenyl cyclase in human platelets:Activity and responsiveness. Biochem. Biophys. Res. Comm., 35:462-466, 1969.
pubmed

117) Emmons, P. R., et al:Effect of prostaglandin E, on platelet behaviour in vitro and in vivo. Brit. Med. J., 2:468-472, 1967.

118) Kinlough.Rathbone, R. L., et al:The effect of prostaglandin EI on platelet function in vitro and in vivo. Brit. J. Haemat., 19:559-571, 1970.

119) Carlson, L A., et al.:Effect of infusion of prostaglandin El on the aggregation of blood platelets in man. Life Sci., 7:85-90, 1968.

120) Ferreira, S. H. and Vane, J. R.:Prostaglandins:Their disappearance from and release into the circulation. Nature, 216:868-873, 1967.
pubmed

121) Salzman, E. W.:Cyclic AMP and platelet function. New Engl. J. Med., 286:358-363, 1972.
pubmed

122) Weisenberger, H.:Cyclic AMP and Platelet function. Erythrocytes, Thrombocytes, Leuko. cytes. Recent advances in membrane and metabolic research. (Gerlach, E., Moser, K., Deutsch, E., Wilmanns, W., eds.), Stuttgart:Georg Thieme, 1973. p. 327.

123) Smith, J. B. and Willis, A. L.:Aspirin selectively inhibits prostaglandin production in human platelets. Nature, New Biol., 231:235-237, 1971.
pubmed

124) Hidaka, H., et al:Cyclic GMP phosphodiesterase of human blood platelets and its inhibitors. Thromb. Diath. Haemorrh., Suppl. 60:321-327, 1974.

125) Born, G. V. R. and Mills, D. C. B.:Potentiation of the inhibitory effect of adenosine on platelet aggregation by drugs that prevent its uptake. J. Physiol., 202:41-42, 1969.

126) Salzman, E. W. and Levine, L.:Cyclic 3:, 5:-adenosine monophosphate in human blood platelets. II. Effect of N6.2'o-dibutyryl cyclic 3':, 5'-adenosine monophosphate on platelet function. J. Clin. Invest., 50:131-141, 1971.
pubmed

127) Haslam, R. J. and Taylor, A.:Effect of catecholamines on the formation of adenosine 3t, 5:-cyclic monophosphate in human blood platelets. Biochem. J., 125:377-379, 1971.

128) Detwiller, T. C., et al.:Platelet size, ATP content and clot retraction in related to platelet age. Amer. J. Physiol., 203:107-110, 1962.

129) McDonald, T. P., et al:Platelet size in relation to platelet age. Proc. Soc. Exp. Biol Med., 115:684-689, 1964.
pubmed

130) Webber, A. S. and Firkin, B. G.:Two population of platelets. Nature, 205:1332, 1965.

131) Mannucci, P. H. and Sharp, A. A.:Platelet volumes and shape in rabbit to aggregation and adhesion. Brit. J. Haemat., 13:604-617, 1967.

132) Karpatkin, S.:Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J. Clin. Invest., 48:1083-1087, 1969.

133) Hirsh, J., et al:The effect of platelet age on platelet adherence to collagen. J. Clin. Invest., 47:466-473, 1968.
pubmed

134) Booyse, F. M., et al:Studies on human platelets. H. Protein synthetic activity of various platelet populations. Bioch. Biophys. Acta, 157:660-663, 1968.

135) Steiner, M. and Baldini, M.:Protein synthesis in aging blood platelets. Blood, 33:628-633, 1969.
pubmed

136) Karpatkin, S.:Heterogeneity of human platelets. I. Metabolic and kinetic evidence suggestive of young and old platelets. J. Clin. Invest., 48:1073-1083, 1969.

137) Minter, F, M. and Ingram, M.:Density distribution of platelets (abstract). Blood, 30:551, 1967.

138) Minter, F. M. and Ingram, M.:Platelet volume:density relationships in normal and acutely bled dogs. Brit. J. Haemat., 20:55-68, 1971.
pubmed

139) Karpatkin, S. and Charmatz, A.:Heterogeneity of human platelets. III. Glycogen metabolism in platelets of different sizes. Brit. J. Haemat., 19:135-143, 1970.

140) Booyse, F. M., et al:Studies on human platelets. W. Protein synthesis in maturing human platelets. Thromb. Diath. Haemorrh., 26:167-176, 1971.

141) Karpatkin, S. and Strick, N.:Heterogeneity of human platelets. V. Differences in glycolytic and related enzymes with possible relation to platelet age. J. Clin. Invest., 51:1235-1243, 1972.

142) Brewer, S. and Clark, J.:Physiologic function as related to age in platelets (abstract). Blood, 30:550, 1967.

143) Vainer, H.:The platelet populations, Platelet Function and Thrombosis. A Review of Methods (Hannucci, P. H., and Gorini, S., ed.), New York:Plenum Press. 1972. p. 191.

144) 磯部淳一. 山中學:新生血小板性状に関する検討 (III), アルブミン濃度勾配法による検討. 昭和50年第37回日血総会抄録集, 1975. p. 129.

145) Okuma, M., et al.:Lipid peroxidation in aging platelets. Blood, 34:712-716, 1969.
pubmed

146) Yamanaka, M. and Isobe, J.:Inhibitory effect of aspirin on aggregation of newly produced platelets in rabbits. Thromb. Diath. Haemorrh., Suppl. 60:355-362, 1974.

147) Karpatkin, S. and Strick, N.:Heterogeneity of carbohydrate enzymes in platelets. Clin. Res., 18:407, 1970.

148) Gross, R., et al.:Genetic defects in platelet metabo lism as a cause of thrombocytopathias. Biochemistry of Blood Platelets, Colloquium Fed. Europ. Biochem. Soc., Warsaw, London:Academic Press, 1966. p. 161.

149) Caen, J., et al:Congental bleeding disorders with long bleeding time and normal platelet count. 1. Glanzman:sthrombosthenia (report of 15 patients). Amer. J. Med., 41:4-26, 1966.

150) Moser, K., et al:Ahitherto not described enzyme defect in thrombasthenia:Gluthatione redu. ctase deficiency. Thromb. Diath. Haemorrh., 19:46-52, 1968.

151) Kim, B. K., et al:Platelet glycolysis in the Wiskott-Aldrich syndrome. Blood, 34:542-543, 1969.

152) Doery, J. C. G., et al:Erythrocyte and platelet glucose-6-phosphate dehydrogenase in normal and mutant caucasians. Scand. J. Haemat., 6:5-9, 1969.

153) Wurzel, H., et al:Glucose-6.phosphate dehydrogenase activity in platelets. Blood, 17:314-318, 1961.
pubmed

154) Linneweh, F., et al:Glycogenosen aus der glucose-6-phosphatase. Aktivitat und dem Gly:cogengehalt der Thrombozyten. Enzym. Biol CIin., 2:188-195, 1963.

155) Caen, J. P., et al:Platelet-collagen interactions. Thromb. Diath. Haemorrh., Suppl. 40:181-197, 1970.

156) Hirsk, J., et al:Spontaneous bruising associated with a defect in the interaction of platelets with connective tissue. Lancet, ii:18-21, 1967.

157) Vigliano, E. M. and Horowitz, H, 1.:Bleeding syndrome in a patient with IgA myeloma; interaction of protein and connective tissue. Blood, 29:823-836, 1967.

158) Hardisty, R, M, and Hutton, R. A.:Bleeding tendency associated with thew" abnormality of behaviour. Lancet, i:983-985, 1967.

159) Weiss, H. J.:Platelet aggregation, adhesion and adenosine diphosphate release in thrombopathia (platelet factor 3 deficiency):Acomparison with Glanzmann:sthrombasthenia and von Willebrand:s disease. Amer. J. Med., 43:570-578, 1967.

160) Weiss, H. J. and Holmsen, H.:Abnormal platelet release reaction an hereditary defect in the storage pool of platelet adenine nucleotides, Proc. XIII. Congr. Int. Soc. Hemat. Munnich:J. L. Lehmanns Verlag, 1970. p. 31.

161) Mills, D. C B. and Hardisty, R, M.:The nature of the platelet defect in a albinos with a bleeding tendency. Proc. XIII. Congr. Int. Soc. Hemat., Munnich:J. F. Lehmanns Verlag, 1970. P. 31.

162) Zucker, M., et al.:Platelet function in a patients with thrombasthenia. Blood, 28:524-534, 1966.

163) Weiss, H. J. and Kochwa, S.:Studies of platelet function and proteins in three patients with Glanzmann:sthrombasthenia. J. Lab. Clin. Med., 71:153-165, 1968.

164) Al.Mondhiry, H., et al.:Acetylation of human platelets by aspirin. Fed. Proc., 28:576, 1969.

165) Hawkins, D., et al:Acetylation of human serum albumin by acetylsalicylic acid. Science, 160:780-781, 1968.
pubmed

166) Doery, J. C. G., et al,:Aspirin, its effect on platelet glycolysis and release of adenosine diphosphate. Science, 165:65-67, 1969.

167) Doery, J. C. G. and Hirsh, J.:Aspirin and salicylate:Divergent effects on platelet glucose metabolism and function. Experimentia, 27:533-534, 1971.

168) Ball, G., et al:Effect of some inhibitors of platelet aggregation on platelet nucleotides. Biochem. J., 114:669-671, 1969,
pubmed

169) Day, H. J. & Holmsen, H.:Concepts of blood platelet release reaction. Ser. Haemat., 4:3-27, 1971.

170) 鹿取信:アラキドン酸代謝を中心とした血小板の脂質代謝. 医学のあゆみ, 114:577-584, 1980.

171) Hamberg, M., et al,:Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc. Nat. Acad. Sci., 71:345-349, 1974.
pubmed

172) Smith, J. B., et al.:Formation of an intermediate in prostaglandin biosynthesis and its associa. tion with the platelet release reaction. J. Clin. Invest., 53:1468-1472, 1974.

173) Willis, A. L., et al.:An endoperoxide aggregator (LASS) formed in platelets in response to thrombotic stimuli purification, identification and unique biological significance. Prostaglandins, 8:453-507, 1974.
pubmed

174) Rittenhouse-Simmons, S. & Deykin, D.:The metabolism of arachidonic acid in platelets exposed to thrombin or ionophore A23187. J. Clin. Invest., 60:495-498, 1977.
pubmed

175) Bell, R, L, et al.:Digliceride lipase:apathway for arachidonate release from human platelets. Proc. Natl. Acad. Sci. USA, 76:3238-3241, 1979.

176) Moncada, S., et al.:An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Lancet, i:18-20, 1977.

177) Weiss, H. J., et al.:Prostaglandin E2, potentiation of platelet aggregation induced by LASS endoperoxide:absent in storage pool disease, normal after aspirin ingestion. Brit. J. Haemat., 32:257-272, 1976.
pubmed

178) 青木延雄.コラゲンの血小板反応. 臨床科学, 12:324-331,1976.

179) Weiss, H. J. & Rogers, J.:Thrombocytopathies due to abnormalities in platelet release reaction studies on six unrelated patients. Blood, 39:189-196, 1972.

180) Malmsten, C., et al:Physiological role of an endoperoxide in human platelet-Hemostatic defect due to platelet cyclo.oxygenase deficiency. Proc. Natl. Acad. Sci. USA, 72:1446-1450, 1975.
pubmed

181) Weiss, H. J. & Layers, B. A.:Possible congenital defect in platelet thromboxane synthetase. Lancet, i:766, 1977.

182) Roth. G. J. & Majerus, P. W.:The mechanism of the effect of aspirin on human platelets. L Acetylation of a particle fraction protein. J. Clin. Invest., 56:629-632, 1975.

P.249 掲載の参考文献

1) Baumgartner, H. R.:The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi. Microvasc. Res., 5:167-179, 1973.
pubmed

2) Baumgartner, H, R., Haudenschild, C.:Adhesion of platelets to subendothelium. Ann. N. Y. Acad. Sci., 201:22-36, 1972.
pubmed

3) Baumgartner, H. R., Stemerman, M. B., Spaet, T. H.:Adhesion of blood platelets to subendo. thelial surface:distinct from adhesion to collagen. Experientia, 27:283-285, 1971.

4) Behnke, O.:Further studies on microtubules. A marginal bundle in human and rat thrombo. cytes. J. Ultrastr. Res., 13:469-477, 1965.

5) Behnke, O.:Electron microscopic observations on the membrane systems of the rat blood platelet. Anat, Rec., 158:121-138, 1967.
pubmed

6) Behnke, O.:Some possible practical implications of the lability of blood platelet microtubules. Vox Sang, 13:502-507, 1967.

7) Behnke, O.:Electron microscopical observations on the surface coating of human blood platelets. J. Ultrastr. Res., 24:51-69, 1968.

8) Behnke, O.:An electron microscope study of the megakaryocyte of the rat bone marrow. I. The development of the demarcation membrane system and the platelet surface coat. J. Ultra. str. Res., 24:412-433, 1968,

9) Behnke, O.:Effects of some chemicals on blood platelet microtubules, platelet shape and some platelet functions in vitro. Scand. J. Haemat., 7:123-140, 1970.
pubmed

10) Behnke, O,:Electron microscopical identification of platelet contractile proteins. Platelet Aggregation (J. Caen, eds.), Paris:Masson et Coe, 1971. p. 3-13.

11) Behnke, O., Pederson, N. T,:Ultrastructural aspects of megakaryocyte maturation and platelet release. Platelets; Production, Function, Transfusion, and Storage (Baldini, M. G. and Ebbe, S. eds.) New York:Grune & Stratton, 1974. p. 21-32.

12) Behnke, O., Zelander, T.:Filamentous substructure of microtubules of the marginal bundle of mammalian blood platelets. J. Ultrastr. Res., 19:147-165, 1967. N

13) Booyse, F., Kisieleski, D., Seeler, R., Ra felson, M., Jr.:Possible thrombosthenin defect in Glanzman:sthrombasthenia, BIood, 39:377-381, 1972.

14) Breton-Gorius, J., Daniel, M. T., Flandrin, G., Kinet Denoel, G.:Fine structure and peroxidase activity of circulating micromegakaryoblasts and platelets in a case of acute myelofibrosis. Brit. J. Haematol, 25:331-339, 1973.

15) Breton-Gorius, J.:Development of two distinct membrane systems associated in giant com. plexes in pathological megakaryocytes. Ser. Haematol, 8:49-67, 1975.

16) Breton-Gorius, J., Guichard, J.:Ultrastructural localization of peroxidase activity in human platelets and megakaryocytes. Amer. J. Path., 66:277-286, 1972.
pubmed

17) Cowan, D. H., Graham, R. C., Jr.:Structural functional relationships in platelets in acute leukemia and related disorders. Ser. Haematol., 8:68-100, 1975.
pubmed

18) Day, H. J., Holmsen, H.:Concepts of the blood platelet release reaction. Ser. Haematol., 4:3-27, 1971.
pubmed

19) Epstein, C., Sahud, M. A., Piel, C. F., Goodman, J. R., Bernfield, M. R., Kushner, J. H., Ablin, A. R.:Hereditary macrothrombocytopathia, nephritis and deafness. Amer. J. Med., 52:299-310, 1972.
pubmed

20) Evensen, S. A., Solum, N. O., Grφttum, K. A., Hovig, T.:Familial bleeding disorder with a moderate thrombocytopenia and giant blood platelets. Scand. J. Haematol., 13:203-214, 1974.

21) Falcao, L., Probst, M., Gautier, A., Vainer, H., Michel, H., Caen, J. P.:L:ultrastructure des plaquettes thrombastheniques. (effects de I:ADP et du fibrinogene bovin). Thrombos. Diathes. Haemorrh., 18:691-704, 1967.

22) Falcao, L., Caen, J., Gautier, A.:Etude 6volutive de r ultrastructure des megacaryocytes dans un cas de purpurathrombop enique idiopathique avant, 12 jours et 5 mois apres splenectomie. Blut, 19:156-171, 1969.

23) French, J. E., Macfarlane, R. G., Sanders, A. G.:The structure of haemostatic plugs and experimental thrombi in small arteries. Brit. J. Exp. Pathol., 45:467-474, 1964.

24) Haguenau, F., Hollmann, K., Levy, J., Boiron, M.:Etude au microscope electronique des plaquettes sanguines dans les leucemies humaines. J. Microscopie, 2:529-538, 1963.

25) Hattori, A.:Some observations on the ultrastructure of blood platelets in normal and some clinical conditions, with special references to its abnormality. J. Electron Microscopy, 16:239-258, 1967.
pubmed

26) 服部晃:血小板の電子.顕微鏡像. 血液と脈管, 1:667-703, 1970.

27) 服部晃:血球. 細胞, 3 (13):52-56, 1971.

28) Hattori, A.:Scanning electron microscopy of human peripheral blood cells. Acta Haemat. Jap., 35:457-482, 1972.
pubmed

29) 服部晃:血小板の形態と機能. 医学のあゆみ, 114:552-561, 1980.

30) 服部晃, 伊藤粋子:血小板の構造と機能. 日本臨牀, 32:920-924, 1974.
Medical*Online

31) Hattori, A., Ihzumi, T.:Amorphological study on a familial release mechanism abnormality characterized by defective A 23187.induced aggregation. Acta Haematol. Jpn., 43:1155-1167, 1980.

32) 服部晃, 飯泉俊雄, 神保長三:血小板の形態と機能, とくに粘着と凝集反応について. . 血小板-基礎と臨床-(山中學編), 科学評論社, 1975. p. 93-112.

33) 服部晃, 神保長三, 松岡松三:血小板の電子顕微鏡的研究 (特に各種疾患時の異常血小板について). 日血会誌, 32:999-1000, 1969.

34) 服部晃芦沢健, 飯泉俊雄, 柴田昭:骨髄増殖性疾患における血小板-産生, 形態, 機能, 代謝における最近の知見を中心に-. 臨床血液, 21:1443-1455, 1980.

35) 服部晃, 和泉徹, 飯泉俊雄, 小池正:血小板と止血. 新潟医学会雑誌, 94:1-6, 1980.
Medical*Online

36) Hattori, A., Koike, K., Ito, S., Matsuoka, M.:Static and functional morphology of the pathological platelets in primary myelofibrosis and myeloproliferative syndrome. Ser. Haematol., 8:126-150, 1975.
pubmed

37) Hattori, A., Tokunaga, J., Fujita, T., Matsuoka, M.:Scanning electron microscopic observations on human blood platelets and their alterations induced by thrombin. Arch. Histol. Jap., 31:37-54, 1969.
pubmed

38) Hattori, A., Ito, S., Tsukada, T., Koike, K, Matsuoka, M.:Ultrastructure of platelet aggrega. tion at an early stage. Thrombos, Diathes. Haemorrh., Suppl. 60:147-158, 1974.

39) Hattori, A., Ito, S., Tsukada, T., Koike, K., Matsuoka, M.:Platelet adhesion and aggregation in the glass bead column method (Hellem.ll):Ascanning electron microscope study. Arch. Histol. Jap., 36:323-337, 1974.

40) Hattori, A., Jinbo, C., Iizumi, T., Ito, S., Matsuoka, M.:Ascanning electron microscope study on hemostatic reaction. Early hemostatic plug formation and the effect of aspirin. Arch. Histol Jap., 37:343-364, 1975.

41) Hattori, A., Sanada, M., Kojima, T., Ihzumi, T., Shibata, A.:Spherothrombocytosis in diseases and pregnancy. Lancet, ii:1027-1028, 1979.

42) Hattori, A., Tsukada, T., Ito, S., Koike, K., Matsuoka, M.:Scanning electron microscope study of platelet "adhesiveness" to glass beads (Hellem II Method). Normal subjects, the effect of aspirin and patients with von Willebrand:s disease. Thrombos. Diathes. Haemorrh., Suppl. 60:447-457, 1974.

43) 服部晃, 小島知子, 高橋薫, 真田雅好, 飯泉俊雄, 長山礼三, 高橋芳右, 小林勲, 小池正, 柴田昭:DICにみられた球状血小板症. 医. 学のあゆみ, 115:384-386, 1980.

44) Hoak, J. C.:Freeze-etching studies of human platelets. Blood, 40:514-522, 1972.
pubmed

45) Holme, R., Sixma, J. J., Murer, E. H., Hovig, T.:Demonstration of platelet fibrinogen secretion via the surface connecting system. Thrombos. Res., 4:377-382, 1974.

46) Holmsen, H.:Are platelet shape change, aggregation, and release reaction tangiable mani. festations of one basic platelet function?Platelets:Production, Formation, Transfusion, and Storage (Baldini, M. G., & Ebbe, S, eds.), New York:Grune & Stratton, 1974. p. 207-220.

47) Holmsen, H., Day, H. J.:Adenine nucleotides and platelet function. Ser. Haematol, 4:28-58, 1971.
pubmed

48) Holmsen, H., Weiss, H.:Further evidence for a deficient storage pool of adenosine nucleotides in platelets from some patients with thrombocytopathia"storage pool disease" . Blood, 39:197-209, 1972.
pubmed

49) Hovig, T.:The ultrastructure of blood platelets in normal and abnormal state. Ser. Haematol., 1:3-64, 1968.

50) Hovig, T.:The ultrastructural basis of platelet function. PIatelets:Production, Formation, Transfusion, and Storage (Baldini, M. G. & Ebbe, S. eds.), New York:Grune & Stratton, 1974. p. 221-234.

51) 石原隆雄:血餅退縮過程における血小板の電顕的研究, 特にMicrofilamentsの意義について. 血液と脈管, 4:457-471, 1973.

52) 石原隆雄, 菅原譲:血小板の電顕的組織化学的研究-Lysosomal Enzyme Release Reactionにおける意義について. 日血会誌, 37:93-106, 1974.

53) Jamieson, G. A.:Interaction of platelet and collagen. Platelet:Production, Formation, Transfusion, and Storage (Baldini, M. G. & Ebbe, S. eds.), New York:Grune & Stratton, 1974. p. 171-186.

54) Jean, G.:Thrombocytes et thrombopathies. Experientia, 17:428-429, 1961.

55) Jean, G. Marx, R., Gautier, A.:Applications de le recherche ultrastructurale a l'etude des thrombocythemies. Nouv. Rev. Franc. Hematol., 6:591-610, 1966.

56) Jean, G., Racine, L:Gautier, A., Marx, R.:Granulations denses anormales dansl esthrombo. cytes humains. Thrombos. Diathes. Haemorrh., 10:42-60, 1963.

57) Jean, G., Racine, L, Marx, R., Gautier, A.:Sur la presence de graisses neutres dans les thrombocytes humains normaux et pathologiques. Thrombos. Diathes. Haemorrh., 9:1-11, 1963.

58) Kay, M. M. B., Fudenberg, H. H.:Inhibition and reversal of platelet activation by cytochalasin Bor colcemid. Nature, 244:288-289, 1973.

59) 小出亮, 恒松由記子, 山田兼雄, 渡辺陽之輔, 榎本康弘:特異な巨核球形態を示したPrimary Thrombocythemiaの1幼児例. 臨床血液, 15:1255-1264, 1974.

60) 河野喜一:血小板の微細構造にかんする研究. 日内会誌, 57:607-616, 1968.

61) 神前五郎:血小板の微細構造. 脂質と止血, 新宿書房, 1975.P.10-22.

62) Kosaki, G., Inoshita, K., Okuma, H.:Electron microscopic studies on human thrombocytogenesis. Thrombos. Diathes. Haemorrh., Suppl. 60:97-102, 1974.

63) 神前五郎, 田中健一, 井下勝男, 大熊宏:血小板無力症の血小板電像. 日血会誌, 32:479-480, 1969.

64) Kurstjens, R., Bolt, C., Vossen, M., Haanen, C.:Familial thrombopathic thrombocytopenia. Brit. J. Haemat., 15:305-317, 1968.
pubmed

65) MacPherson, G. G.:Origin and development of the demarcation system in megakaryocytes of rat bone marrow. J. Ultrastruct. Res., 40:167-177, 1972.
pubmed

66) 巻渕隆夫, 伊藤正一, 品田章二, 服部晃, 神保長三, 塚田恒安, 松岡松三:凝血異常を伴った原発性出血性血小板血症の1例. 日内会誌, 60:132-137, 1971.

67) Maldonado, J. E.:The ultrastructure of the platelets in refractory anemia ("preleukemia") and myelomonocytic Ieukemia. Ser. Haematol., 8:101-125, 1975.

68) Maldonado, J. E., Brigden, L. P.:Adistinct anomaly of platelet granules in refractory anemia and myelomonocytic leukemia:Apreliminary communication. Thrombos. Diathes. Haemorrh., Suppl. 60:239-246, 1974.

69) Matsukura, Y.:Immuno-electron microscopical demonstration of ABO blood group antigens in human platelets. Acta Med. Biol., 19:137-146, 1971.
Medical*Online

70) 松岡松三, 大山芳郎, 塚田恒安:先天性心疾患に伴う特異な出血性素因. 日本医事新報, 2251:19-28, 1967.

71) 松岡松三, 服部晃, 伊藤粋子, 桜川信男:再生不良性貧. 血における血小板の微細構造学的研究. 再生不良性貧血III (厚生省研究班記録), 1974. p.231-244.

72) 松岡松三, 塚田恒安, 立川実, 神保長三, 服部晃, 伊藤健一郎:大型血小板を伴う先天性血小板病症 (thrombocytopathia) の1例について. 日血会誌, 32:472-474, 1969.

73) Mauer, H. M., Wolff, J. A., Buckingham, S., Spielvogel, A. S.:"Impotent" platelets in albino with prolonged bleeding times. Blood, 39:490-499, 1972.

74) 宮川捷敏, 河北靖夫:各種血液疾患における血小板の微細構造. 日血会誌, 32:64-71, 1969.

75) 永井清保, 下谷三喜夫, 原宏, 大植更二, 小林司郎, 川越裕也, 阿部裕, 泉口康幸:栓球血症について (自験例を中心にして). 臨床血液, 10:101-109, 1969.

76) Niewiarowski, S., Poplawski, A., Prokopowicz, J., Kanska, B., Lechner K., Stockinger, L:Abnormalities of platelet function and ultrastructure in macrothrombocytic thrombopathia. Scand. J. Haemat., 6:377-385, 1969.
pubmed

77) Paulus, J. M., Breton.Gorius, J., Kinet-Denoel, C., Boniver, J.:Megakaryocyte ultrastructure and ploidy in human macrothrombocytosis. Platelets:Production, Function, Transfusion and Storage (Baldini, M. G, & Ebbe, S. eds.), New York:Grune & Stratton, 1974. p. 131-141.

78) Raccuglia, G, .:Gray platelet syndrome. A viariety of qualitative platelet disorders. Amer. J. Med., 51:818-828, 1971.
pubmed

79) Rafelsen, Jr., M. Booyse, F. M.:Molecular aspects of platelet aggregation. Platelet Aggrega tion (Caen, J. ed.), Paris:Masson, 1971. p. 95-105.

80) 真田雅好, 服部晃, 飯泉俊雄, 伊藤粋子, 渡部透, 和泉徹, 桜川信男, 松岡松三, 黒滝栄子, 田中百合子, 織田島弘子, 関川秀子, 保坂安子:血小板の外形と機能に関する研究 (第2報) 保存と振温における血小板外形と粘着凝集能. 血液と脈管, 9:413-417, 1978.

81) Schulz, H.:Thrombocyten und Thrombose im elektronem mikroskopischen Bild. Berlin:Springer, 1968.

82) Schulz, H., Pottel, A.:Elektronen mikroskopische Untersuchungen der Megakaryozyten und Thrombozyten eines Falles von primar hamorrhagischer Thrombozythaemie. Blut, 19:208-222, 1969.

83) Sheppard, B. L., French, J. E.:Platelet adhesion in the rabbit abdominal aorta following the removal of the endothelium:ascanning and transmission electron microscopical study. Proc. Roy. Soc. Lond. B., 176:427-432, 1971.

84) Shoop, R., Balcerzak, S. P., Larrimer, N. R., Lee, R. E.:Surface morphology of the early hemostatic reaction. Amer. J. Med. Sci., 260:122-129, 1970.
pubmed

85) Sixma, J. J., Molenaar, I.:Microtubules and microfibrils in human platelets. Thrombos. Diathes. Haemorrh., Suppl. 16:153-162, 1966.

86) Stemerman, M., Ross, R.:Experimental arteriosclerosis. L Fibrous plaque formation in primates. An electron microscope study. J. Exp. Med., 136:769-789, 1972.

87) Stermerman, M.:Platelet interaction with intimal connective tissue. Platelets:Production, Function, Transfusion, and Storage (Baldini, M. G. & Ebbe, S. eds.), New York:Grune & Stratton, 1974. p. 157-170.

88) Vossen, M. E. M. H., Stadhounders, A. M., Kurstjens, R., Haanen, C.:Observations on platelet ultrastructure in familial thrombocytopathic thrombocytopenia. Amer. J. Path., 53:1021-1039, 1968.

89) Warren, B. A., Khan, S., Vales, O.:The interaction of platelets, endothelium and fibrin with reference to fibrinolysis. Thrombos. Diathes. Haemorrh., Suppl. 56:35-50, 1973.

90) Weiss, H. J., Ames, R. P.:Ultrastructural findings in storage pool disease and aspirin-1ike defects of platelets. Amer. J. Pathol., 71:447-466, 1973.

91) Weiss, H. J., Witte, L. D., Kaplan K. L., Lages, B. A., Chernoff, A., Nossel, H. L., Goodman, D. S., Baumgartner:H. R.:Heterogeneity in storage pool deficiency:Studies on granule.bound substances in 18 patients including variants deficient in a.granules, platelet Factor 4, β. thromboglobulin, and platelet-derived growth factor. Blood, 54:1296-1319, 1979.

92) White, J. G.:Effects of colchicine and vinca alkaloids on human platelets. I. Influence on platelet microtubules and contractile function. Amer. J. Pathol., 53:281-291, 1968.

93) White, J. G.:Effecs of colchicine and vinca alkaloids on human platelets. n. Changes in the dense tubular system and formation of an unusual inclusion in incubated cells. Amer. J. Pathol., 53:447-461, 1968.

94) White, J. G.:Effects of ethylenediamine tetracetic acid (EDTA) on platelet structure. Scand. J,Haemat., 5:241-254, 1968.
pubmed

95) White, J. G.:Tubular elements in platelet granules. Blood, 32:148-156, 1968.
pubmed

96) White, J. G.:The substructure of human platelet microtubules. Blood, 32:638-648, 1968.
pubmed

97) White, J. G.:The submembrane filaments of blood platelets. Amer. J. Pathol., 56:267-277, 1969.

98) White, J. G.:Interaction of membrane systems in blood platelets. Amer. J. Pathol., 66:295-306, 1972.

99) White, J. G,:Platelet morphology and function. Hematology (Williams, W. J., et al eds.), New York:McGraw-Hill, 1972. p. 1023-1039.

100) White, J. G.:Ultrastructural defects in congenital disorders of platelet function. Ann. New York Acad. Sci., 201:205-233, 1972.

101) White, J. G.:Shape Change. Thrombos. Diathes. Haemorrh., Suppl. 60:159-171, 1974.

102) White, J. G.:Electron microscopic studies of platelet secretion. Progress in Hemostasis and Thrombosis. Vol 2. (Spaet, T. H. eds.), New York:Grune & Stratton, 1974. p. 49-98.

103) White, J. G.:Current concepts of platelet structure. Am. J. Clinical Pathol., 71:363-378, 1979.

104) White, J. G., Krivit, W.:The ultrastructural localization and release of platelet lipids. Blood, 27:167-186, 1966.
pubmed

105) White, J. G., Krivit, W.:An ultrastructural basis for the shape changes induced in platelets by chilling. Blood, 30:625-635, 1967.
pubmed

106) White, J. G. Krumwiede, M.:In fl uence of cytochalasin B on the shape change induced in platelets by cold. Blood, 41:823-832, 1973.

107) White, J. G., Edson, J. R., Desnick, S. J., Witkop, Jr., C. J.:Studies of platelets in a variant of the Hermansky.Pudlak syndrome. Amer. J. Pathol., 63:319-332, 1971.

108) Yamada, E.:The fine structure of the megakaryocyte in the mouse spleen. Acta Anat., 29:267-290, 1957.
pubmed

109) 山中學:血小板の形態と機能. 血液と脈管, 5:445-453, 1974.

110) Zucker-Franklin, D., Nachman, R. L., Marcus, A. J.:Ultrastructure of thrombosthenin, the contractile protein of human blood platelets. Science, 157:945-946, 1967.
pubmed

249

6. 毛細血管

P.269 掲載の参考文献

1) Bennett, H. S., Luft, J, H., Hampton, J. C.:Morphological classification of vertebrate blood capillaries. Amer. J. Physiol., 196:381-390, 1959.
pubmed

2) Bruns, R. R., Palade, G. E.:Studies on blood capillaries. I. General organization of blood capillaries in muscle. J. Cell Biol., 37:244-276, 1968.
pubmed

3) Bruns, R. R., Palade, G. E.:Studies on blood capillaries. II. Transport of ferritin molecules across the wall of muscle capillaries, J. Cell Biol., 37:277-299, 1968.
pubmed

4) Chambers, R., Zweifach, B. W.:Intercellular cement and capillary permeability. Physiol. Rev., 27:436-483, 1947.
pubmed

5) Clementi, F. and Palade, G. E.:Intestinal capillaries. I. Permeability to peroxidase and fer. ritin. J. Cell Biol, 41:33-58, 1969.

6) Clementi, F., Palade, G. E.:Intestinal capillaries. II. Structural effects of EDTA and histamine. J. Cell Biol., 42:706-714, 1969.
pubmed

7) Cotran, R. S., Karnovsky, M. J.:Ultrastructural studies on the permeability of the mesothelium to horseradish peroxidase. J. Cell Biol., 37:123-137, 1968.
pubmed

8) Farqhar, M. G., Palade, G. E.:Junctional complexes in various epithelia. J. Cell Biol., 17:375-412, 1963.

9) Fawcett, D. W.:Surface specialization of absorbing cells. J. Histochem. Cytochem., 13:75-91, 1965.

10) Florey, E. E., Poole, J. C. F., Meek, G. A.:Endothelial cells and ttcement" 1ines. J. Pathol. Bacteriol., 77:625-636, 1959.

11) Fujita, T.:Ascanning electron microscope study of the human spleen. Arch. histol. jap., 37:187-216, 1974.

12) Giacomelli, F., Wiener, J., Spiro, D.:Cross.striated arrays of filaments in endothelium. J. Cel (Biol., 45:188-192, 1970.

13) Herrlinger, H., Anzil, A. P., Blinzinger, K., Kronski, D.:Endothelial microtubular bodies in human brain capillaries and venule J. Anat., 118:205-209, 1974.
pubmed

14) Ito, T., Shibasaki, S.:Electron microscopic study on the hepatic sinusoidal wall and the fat. storing cells in the normal human liver. Arch. histol jap., 29:137-192, 1968.

15) Karnovsky, M. J.:The ultrastructural basis of capillary permeability studied with peroxidase as a tracer. J. Cell Biol., 35:213-236, 1967.
pubmed

16) Kobayashi, S.:Some observations on the capillary vesicles and the pores. J. Electron Microsc., 17:322-326, 1968.

17) Kobayashi, S.:Occurrence of unique colloidal particles in snake blood and their transport across the capillary wall A proposal of a new hypothesis on the permeability of the blood capillaries. Arch. histol. jap., 31:511-528, 1970.

18) Kobayashi, S.:Ferritin labeling in the fixed muscle capillary. A doubt on the tracer.experiments as the basis for the vesicular transport theory. Arch. histol. jap., 32:81-86, 1970.
pubmed

19) 小林繁:毛細血管内皮層における物質の通路. 医学のあゆみ, 75:469-474, 1970.

20) Luft, J, H.:Fine structure of capillary and endocapillary layer as revealed by ruthenium red. Fed, Proc., 25:1773-1783, 1966.
pubmed

21) Majno, G.:Ultrastructure of the vascular membrane. Handbook of Physiology. 2. Circulation III (Hamilton, W. F. and Dow, P. eds.), Amer. Physiol. Soc., 1965. p. 2293-2375.

22) Muto, M.:Ascanning electron microscopic study on endothelial cells and Kupffer cells in rat liver sinusoids. Arch. histol. jap., 37:369-386, 1975.

23) Palade, G. E.:Fine structure of blood capillaries. J. appl. Physics, 24:1424, 1953.

24) Palade, G. E., Bruns, R. R.:Structural modulations of plasmalemmal vesicles. J. Cell Biol., 37:633-649, 1968.
pubmed

25) Reese, T. S., Karnovsky, M. J.:Fine structural localization of a blood-brain barrier to exogenous peroxidase. J. Cell Biol., 34:207-217, 1967.
pubmed

26) Rhodin, J. A. G.:The diaphragm of capillary endothelial fenestrations. J. Ultrastr. Res., 6:171-185, 1962.

27) Sengel, A., Stoebner, P.:Golgi origin of tubular inclusions in endothelial cells. J. Cell Biol., 44:223-226, 1970.
pubmed

28) Stehbens, W. E.:Endothelial vesicles and protein transport. Nature, 207:197-198, 1965.
pubmed

29) Tabuchi, H., Yamamoto, T.:Specific granules in the endothelia of blood and lymphatic vessels in the cardiac valves of dogs. Arch. histol. jap., 37:217-224, 1974.
pubmed

30) Tokunaga, J., Edanaga, M., Fujita, T., Adachi, K.:Freeze cracking of scanning electron microscope specimens. A study of the kidney and spleen. Arch. histol. jap., 37:165-182, 1974,
pubmed

31) Weibel, E. R.:Neue Cytoplasmatische Componente von Endothelzellen. Acta anat., 59:390, 1964.

32) Weibel, E. R., Palade, G. E.:New cytoplasmic components in arterial endothelia. J. Cell Biol., 23:101-112, 1964.
pubmed

33) Wolff, J.:Elektronen mikroskopische Untersuchungen ifber die Vesikulation im Kapillarendothel. Lokalization, Variation und Fusion der Vesikel. Z. Zellforsch., 73:143-164, 1966.

34) Wolff, J., Merker, H. .J.:Ultrastruktur und Bildung von Poren im Endothel von porcsen und geschlossenen Kapillaren. Z. Zellforsch., 73:174-191, 1966.
pubmed

35) 山田英智:血管内皮の構造と機能. 血液と脈管, 3:511-521, 1972.

36) 山元寅男:内皮細胞と基底膜との関係 (電顕方面). 最新医学, 19:2843-2852, 1964.

37) 山元寅男:毛細血管の電子顕微鏡的形態学. 生体の科学, 17:112-133, 1966.

38) Yohro, T., Burnstock, G.:Filament bundles and contractility of endothelial cells in coronary arteries. Z. Zellforsch., 138:85-95, 1973.
pubmed

a) Simionescu, N., Simionescu, M., Palade, G. E.:Permeability of muscle capillaries to small hemepeptides. Evidence for the existence of patent transendothelial channels. J. Cell Biol., 64:585-607, 1975.

b) Palade, G. E., Simionescu, M., Simionescu, N.:Structural aspects of the permeability of the microvascular endothelium. Acta Physiol Scand. Suppl., 463:11-32, 1979.

c) Wagner, R. C., Casley-Smith, R.:Endothelial vesicles. Microvasc. Res., 21:267-298, 1981.

P.286 掲載の参考文献

1) Zweifach, B. W.:Functional Behavior of the Microcirculation. Springfield, Ill.:Thomas, 1961.

2) Starling, E. H.:On the absorption of fluids from connective tissue space. J. Physiol. (London), 19:312, 1896.

3) Sevitt, S.:Local blood flow changes in experimental burns. J. Path. Bact., 61:427, 1949.

4) Landis, E. M.:Micro-injection studies of capillary permeability. Am. J. Physiol., 81:124, 1927.

5) Landis, E. M., Jonas, L., Angevine, M., Erb, W.:The passage of fluid and protein through the human capillary wall during venous congestion. J. Clin. Invest., 11:717, 1932.
pubmed

6) Rowley, D. A.:Venous constriction as the cause of increased vascular permeability produced by 5-hydroxy tryptamine, histamine, bladykinin, and 4880 in the rat. Brit. J. Exp. Path., 45:56, 1964.
pubmed

7) Majano, G., Gilmour, P., Leventhal, M.:On the mechanism of vascular leakage caused by histaminelike mediators. A microscopic study. Circulation Res., 21:833, 1967.

8) Sevitt, S.:Early and delayed and edema and increase in capillary permeability after burns of the skin. J. Path. Bact., 75:27, 1958,
pubmed

9) Wilhelm, D. L., Masson, B.:Vascular permeability changes in inflammation:The role of endogenous permeability factors in mild thermal injury. Brit. J. Exp. Path., 41:487, 1960.

10) Spector, W. G., Willoughby, D. A.:Experimentat suppression of the acute inflammatory changes of thermal injury. J. Path. Bact., 78:121, 1959.

11) Logan, G., Wilhelm, D. C.:Ultraviolet injury as an experimental model of the inflammatory reaction. Nature, 198:968, 1963.

12) Uriuhara, T., Movat, H. Z.:The role of PMN-1eukocytes in tissue injury, inflammation and hypersensitivity. V. Partial suppression in leukopenic rabbits of vascular hyperpermeability due to thermal injury. Proc. Soc. Exp. Biol. Med., 124:279, 1967.

13) Taichman, N. S., Movat, H. Z.:Do polymorphonuclear leukocytes play a role in passive cutaneous anaphylaxis in the guinea pig?. Int. Arch. Allerg., 30:97, 1966.
pubmed

14) 畔柳武雄:新しい血管透過性因子. 臨床血液, 15:904, 1974.

15) Udaka, K., Takeuchi, Y., Movat, H. Z.:Simple method for quantitation of enhanced vas-cular permeability. Proc. Soc. Exp. Biol. Med., 133:1384, 1970.

16) 畔柳武雄:血管透過性因子. 医学のあゆみ, 78:259-263, 1971.

17) Majano, G., Palade, C. E.:Studies on inflammation. I. The effect of histamine and serotonin on vascular permeability:An electron microscopic study. J. Biophys. Biochem. Cytol., 11:57, 1961.

18) Marchesi, V. T.:The passage of colloidal carbon through inflammed endothelium. Proc. Roy. Soc. (B), 156:550, 1962.

19) Movat, H. Z., Fernando, N. V. P.:Acute inflammation. I. The earliest fine structural changes at the blood tissue barrier. Lab. Invest., 12:895, 1963.

20) Peterson, R. D. A., Good, R. A.:Morphology of vascular permeability. I. Passive cutaneous anaphylaxis. Lab. Invest., 11:507, 1962.

21) Movat, H. S., Fernando, N. V. P.:Allergic inflammation. I. The earliest fine structural changes at the blood tissue barrier during antigen.antibody interaction. Arn. J. Path., 42:41, 1963.

22) Pappas, C. D., Tennyson, V. M.:An electron microscopic study of the passage of colloidal particles from the blood vessels of the capillary processes and choroid plexus of the rabbit. J. Ceil Biol., 15:227, 1962.

23) Majno, G.:Mechanism of abnormal vascular permeability in akute inflammation. Injury, Inflammation and Immunity (Thomas, C., Uhr, J. W., Grant, L., eds.), Baltimore:Williams and Wilkins, 1964.

24) Majno, G., Shea, S. M., Leventhal, M.:Endothelial contraction induced by histamine type mediators. J. Cell Biol., 42:647, 1969.
pubmed

25) Wells, F. R., Miles, A. A.:Site of the vascular response to thermal injury. Nature, 200:1015, 1963.
pubmed

26) Cotran, R. S., Majno, G.:The delayed and prolonged vascular leakage in inflammation.I. Topography of the leaking vessels after thermal injury. Am. J. Path., 45:261, 1964.
pubmed

27) Movat, H. Z., Uriuhara, T.:Akute inflammation. II. The fine structural changes at the blood tissue barrier during advanced phase of increased permeability (Abstract). Am. J.Path., 44:la, 1964.

28) Cotran, R. S.:The delayed and prolonged vascular leakage in inflammation. ll. An electron microscopic study of the vascular response after thermal injury. Am. J. Path., 46:589, 1965.

29) Miles, A. A., Wilhelm, D. L.:The activation of endogenous substances including Pathologi. cal increase of in capillary permeability. The Biochemical Response to Injury (Stoner, H.B., eds.), Oxford:Blackwell, 1960.

30) Wilhelm, D. L.:Chemical mediators. The Inflammatory Process (Zweifach, B. V. V., Grant, L., McClusky, R. T., eds.), New York:Academic Press, 1965.

31) Riley J. F.:The Mast Cell. Edinburgh:Livingstone, 1959.

32) Rocha e Silva, M.:Histamine release by naturally accuring substances. Ciba Foundation Symposio on histamine (Wolstenholme, G. E. W., O:Connor, C. M. eds.), London:Churchill, 1956.

33) Paton, W. D. M.:Histamine release by compounds of simple chemical structure. Phamacol Res., 9:269, 1957.

34) Schayer, R. W.:Induced symthesis of histamine, microcirculation regulation and the mechanism of action of the adrenal glucocorticoid hormones. Prog. Allergy, 7:187, 1963.

35) Ogoin, T. A., Shegel, S. M.:Changes in the skin blood flow and capillary permeability in man and animals following serotonin injections. Arch. Int. Pharmacodyn., 153:226, 1965.

36) Rowley, D. A., Benllitt, E. P.:5.hydroxy tryptamine and histamine as mediators of vascular injury produced by agents which damage mast cells in rats. J. Exp. Med., 103:399, 1956.

37) Parrat, J. R., West, G. B.:5.hydroxy tryptamine and anaphylactord reaction in the rat. J. Physiol., 139:27, 1957.

38) Mota, T.:The mechanism of anaphylaxis. I. Production and biological properties of marst cell sensitizing antibody, Immunolog., 7:681, 1964.

39) Halpern, B. N., Neveu, T., Spector, S.:On the nature of the chemical mediators involved in anaphylactic reactions in mice. Brit. J. Pharmacol. Exp. Ther., 20:389, 1963.

40) Werle, E., Gotze, Keppler, A.:Uber die Wirkung des Kallikreins auf den isolierten Dam und Uber eine neue dormkoutraktiereucte Substanz. Bioch. Z., 289:217, 1937.

41) Hamberg, U., Rocha e Silva, M.:On the release of bradykinin by trypsin and snake venom. Arch. Int. Pharmacodyn., 110:222, 1957.

42) Elliot, D. F., Horton, E. W., Lewis, G. P.:Actions of pure bradykinin. J. Physiol., 153:473, 1960.

43) Pierce, J. V., Webster, M. E.:The purification and some properties of two different kal. 1iclinogens from human plasma. Hypotensive Peptides (Frdos, E. G., Back, N., Sicuteri, F., eds.), New York:Springer, 1961.

44) Webster, M. E., Prirce, J. V,:The nature of the kalliclins released from human plasma by kallikrein and other enzymes. Ann. N. Y. Acad. Sci., 104:91, 1963.

45) Elliot, D. F., Lewis, G. P.:Methionyl.lysyl.bradykinin, a new kinin from ox blood. Biochem. J., 95:437, 1965.

46) Lewis, G. P.:Plasma kinins and other vaso.active compounds in acute inflammation, Ann. N. Y. Acad. Sci., 116:847, 1964.

47) Rocha e Silva, M., Rosenthal, S. R.:Release of pharmacologically active substances from rat skin in vivo following thermal injury. J. Pharmacodyn. Exp. Ther., 132:110, 1961.

48) Melmon, K. L., Webster, M. E., Goldfinger, S. E., Seegmiller, J. E.:The presence of a kinin in in flammatory synovial effusion from arthritides of varying etiology. Arthritis Rheum., 10:13, 1967.

49) Margolis, J.:Activation of plasma by contact with glass:Evidence for a common reaction which release plasma kinin and initiates coagulation. J. Physiol., 144:1, 1958.
pubmed

50) Webster, M. E., Ratnoff, O. D.:Role of Hageman factor in the activation of vasodilator activity in human plasma. Nature, 192:180, 1961.

51) Movat, H. Z., Dilorenzo, N, L.:Activation of the plasma kinin system by antigen.antibody aggregates. 1. Generation of permeability factor in guinea pig serum. Lab. Invest., 19:187, 1968.

52) Ratnoff, O. D., Rosenblum, J. M.:Role of Hageman factor in the intiation of clotting by glass, evidence that glass frees Hageman factor from inhibitors. Am. J. Med., 25:260, 1958.

53) Mackay, M. E., Mills, A. A., Schachter, H., Wilhelm, D. C.:Susceptibility of the guinea pig to pharmacological factors from its own serum. Nature, 172:714, 1953.

54) Miles, A. A., Wilhelm, D. C.:Enzyme like globu|in from serum producing the vascular phenomenon of inflammation. 1. An active permeability factor and its inhibitor in guinea pig serum, Brit. J. Exp. Path., 36:71, 1955.

55) Kagan, L. J., Leddy, J. P., Becket, E. L.:The presence of two permeability globulins in human serum. J. Clin. Invest., 42:353, 1963.

56) Werle, E., Forrel, M. M., Maier, L.:Zur Kentnisse der blutdrucksenkenden Wirkung des trypsins. Naunyn.Schmiedberg Arch. Pharrn. Exp. Path., 225:369, 1955.

57) Werle, E., Vogel, R., Kaliampetsos, G.:Uber das Darm wand und scine Beziehring zum Blutkallikreingehalt bei Sorung der Parmbuktionen. In I. Wld Congr. Gastroenterology Munnich, Barsel:S, Kagel, 2:778, 1963.

58) Sherry, S., Colman, R. W.:Observations on the plasma kallikreinogen.kallikrein enzyme system. Trans. Ass. Am. Physicians, 81:40, 1968.

59) Frey, E. K., Krnat, H., Werle, E.:Kallikrein, Enke, Stuttgart, 1950.

60) Werle, E., Trantschold, J.:Kallikrein, Kallidin, kallikrein inhibitor. Ann. N. Y. Acad. Sci., 104:117, 1963.

61) Colman, R. W., Mattler, L., Sherry, S.:Studies on the kallikreinogen kallikrein system. I. Isolation and purification of plasma kallikrein. J. Clin. Invest., 48:11, 1969.
pubmed

62) Donaldson, V. H., Evans, R. R.:A biochemical abnormality in hereditary angioneurotic edema. Absence of serum inhibitor of CI esterase. Am. J. Med., 35:35, 1963.

63) Landerman, N. S., Webster, M. E., Becker, E. L., Ratcliiffe, H. D.:Hereditary angioneurotic, edema. ll. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J. Allergy, 33:330, 1962.
pubmed

64) Pensky, J., Schwick, H. G.:Human serum inhibitor of CI esterase. Identity with al-neuraminic glycoprotein. Science, 163:698, 1969.

65) Ratnoff, O. D.:Increased vascular permeability induced by human plasmin. J. Exp. Med., 122:905, 1965.
pubmed

66) 鈴木友二:キニン生成系におけるブラスミン. 抗ブラスミン療法, 第一製薬, 1968. p. 96.

67) Back, N., Stegger, B.:Activation of bovine bradykininogen by human plasmin. Life Sci. . 4:153, 1965.

68) Vogt, W.:Kinin formation by plasmin:An indirect process med輌ated by activation of kallikrein. J. Physiol., 170:153, 1964.

69) Pierce, G. V., Webster, M. E.:The purification and some properties of two different kal. lidinogens from human plasma. Hypotensive peptides (Erdos, E. G., Back, N., Sicuteri, F., eds.), New York:Springer, 1966.

70) Endos, E. G., Yang, H. Y. F.:Kininase. Handbook of Experimental Pharmacology Vol. XXV. Bradykinin, kallidin and kallikrein, New York:Springer, 1970.

71) Colman, R. W., Girey, G. J. D., Zaset, R., Talamo, R. C.:The human plasma kallikrein-kinin system. Prog. in Hemotology, 7:255, 1971.

72) Movat, H. Z.:The acute inflammatory reaction. Inflammation, immunity and hypersensitivity. (Movat, H. Z., eds.), New York:Harper & Row, 1971.

73) 林秀男:炎症性血管透過性因子vasoexinの作用特異性, その意義について. 第18回日本医学会総会学術講演集. 1971. p. 507.

74) Menkin, V.:Biochemical Mechanism in Inflammation. Springfield:Thomas, 1956. 75) 畔柳武雄:新らしい血管透過性因子IgG-PF. 臨床血液, 15:904, 1974.

76) Cochrane, C. G., Mifller.Eberhard, H. J.:The derivation of two distinct anaphylatoxin activities from the third and fifth component of human complement. J. Exp. Med., 127:371, 1968.

77) Shin, H. S., Snydel.man, R., et al:Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement. Science, 162:361, 1968.

78) Mota, T.:The mechanism of action of anaphylatoxin. Its effect on guinea pig mast cells. . Immunology, 2:403, 1959.

79) Clark, R. A. F., Dvorak, H. F. and Colrin, R. B.:Fibronectin in delayed.type hypersensitivity:skin reactions. J. Immunology, 128 (2):787, 1981.

80) Heimark, R. L., Kwachi, K., Fujikawa, K. and Davie, E. W.:Surface activation of blood coagulation, fibinolysis and kinin formation. Nature, 286 (31):456, 1980.

81) Meier, H. L., Pierce, J. V., Coleman, R. W. and Kaplan, A. P.:Activation and function of Hageman factor. The role of high molecular weight kininogen and prekallikrein. J. Clin. Invest. . 60:18, 1977.

82) Mandel, R. and Kaplan, A. P.:Hageman factor sabstrates. Human plasma prekallikrein me. chanism of Hageman factor and participaticn in Hageman factor-dependent fibrinolysis. J. Biol Chem., 252:6097, 1977.

83) Saito, H., Ratnoff, O. D., Waldman, R. and Abraham, J. P.:Fitzgerald trait. Deficiency of a hitherto unrecognized agent. Fitzgerald factor, participating in surface.mediated reactions of clotting, fibrinolysis, generation of kinins, and the property of diluted plasma enhancing vas. cular permeability (PF/Dil). J. Clin. Invest., 55:1082, 1975.

84) Wuepper, K. D., Miller, D. R. and Lacombe, M. J.:Flaujeac trait. Deficieney of haman plasma kininogen. J. Clin. Invest., 56:1663, 1975.

85) Mandel, R. J., Coleman, R. W. and Kaplan, A. P.:Identification of prekallikrein and high molecular weight kininogen as a complex in human plasma. Proc. Natl. Acad. Sci. U. S. A., 73:4197, 1976.

86) Williams, T. J. and Jose, P. J.:Mediation of increased vascular permeability after complement activation. Histamine.independent action of rabbit C5a. J. Exp. Med., 153:136, 1981.
pubmed

87) Vallota, E. H. and Muller.Eberhard, H. J.:Formation of C3a and C5a anaphylatoxins in whole human serum after inhibition of the anaphylatoxin inactivator. J. Exp. Med., 137:1109, 1973.
pubmed

88) Hugli, T. E. and Muller.Eberhard, H. J.:A naphylatoxins:C3a and C5a. Adv. Immunol, 26:1, 1978.
pubmed

89) Jose, P. J., Peck, M. J., Robinson, C. and Williams, T. J.:Characterization of a histamine-indepevdent vascular permeability:increasing factor generated on exposure of rabbit plasma to zymosan. J. Physiol., 28:13, 1978.

はじめての方へ

個人／法人会員登録のご案内